

HEALTH ANNUAL STATEMENT

FOR THE YEAR ENDED DECEMBER 31, 2022 OF THE CONDITION AND AFFAIRS OF THE

Anthem Health Plans of Maine, Inc.

NAIC G	roup Code <u>0671</u> <u>0671</u> NAI (Current) (Prior)	C Company Code <u>52618</u> Emp	oloyer's ID Number3	1-1705652
Organized under the Laws of	Maine	, State of Domicile or F	Port of Entry	ME
Country of Domicile		United States of America		
Licensed as business type:		Life, Accident & Health		
Is HMO Federally Qualified? Ye	es[]No[X]			
Incorporated/Organized	03/10/2000	Commenced Busi	ness	06/05/2000
Statutory Home Office	2 Gannett Drive	j	South Portland, ME, US	S 04106-6911
	(Street and Number)		(City or Town, State, Coun	try and Zip Code)
Main Administrative Office		2 Gannett Drive		
South	Portland, ME, US 04106-6911	(Street and Number)	866-583-618	32
	own, State, Country and Zip Code)		(Area Code) (Telepho	
Mail Address	2 Gannett Drive	,	South Portland, ME, US	S 04106-6911
	(Street and Number or P.O. Box)		(City or Town, State, Coun	try and Zip Code)
Primary Location of Books and F	Records	220 Virginia Avenue		
lı	ndianapolis, IN, US 46204	(Street and Number)	800-331-14	76
	own, State, Country and Zip Code)	,,	(Area Code) (Telepho	ne Number)
Internet Website Address		www.elevancehealth.com		
Statutory Statement Contact	Leigh Barrett	,	317-43	2-6988
-	(Name)		, , ,	ephone Number)
eign	.barrett@elevancehealth.com (E-mail Address)	,	317-488-62 (FAX Number	
		OFFICERS		
President and Chairperson	Denise Finn McDonough		surer Vir	ncent Edward Scher
Secretary	Kathleen Susan Kiefer	Assistant Trea	surer E	ric Kenneth Noble
		OTHER		
Laura Sanborn, Ass	sistant Secretary			
Desire Fire N		RECTORS OR TRUSTEES	12	all land Organization
Denise Finn M Ronald Williar		Laurie Helm Benintendi Vincent Edward Scher		athleen Susan Kiefer John Edward Gallina
Heather Chockle	y Steinmeyer			
State of	Indiana			
County of	Indiana SS Johnson			
all of the herein described asses tatement, together with related condition and affairs of the said in accordance with the NAIC An rules or regulations require diffrespectively. Furthermore, the second	ty being duly sworn, each depose and say ts were the absolute property of the said exhibits, schedules and explanations there reporting entity as of the reporting period sinual Statement Instructions and Accountiferences in reporting not related to accope of this attestation by the described	reporting entity, free and clear from ein contained, annexed or referred to, tated above, and of its income and de ing Practices and Procedures manual punting practices and procedures, a officers also includes the related corru	any liens or claims thereon, is a full and true statement of ductions therefrom for the pexcept to the extent that: (1 ccording to the best of the seponding electronic filing was provided to the second the second that the second the second that the second that the second that the seco	except as herein stated, and that this fall the assets and liabilities and of the eriod ended, and have been completed) state law may differ; or, (2) that state ir information, knowledge and belief, ith the NAIC, when required, that is an
exact copy (except for formatting to the enclosed statem@ntuSigne	g differences due to electronic filing) of the d by:	enclosed statement. The electronic f DocuSigned by:	iling may be requested by va	
Dennice	Finn McDonough	katly kiefer		Vincent E. Scher
1FA874CC6	58104C8	D85175EE05784B1		A85A33722D4143E
Denise Finn McDor President	nough	Kathleen Susan Kiefer Secretary		Vincent Edward Scher Treasurer
Subscribed and sworn to before day of	me this February 2023	b. If no, 1. State the	ginal filing?	Yes [X] No []
Rita F. Gentry		3. Number o	f pages attached	
Executive Assistant 1/17/2029				

Riss E Gentry
Notary Public
SEAL
Johnson County, State of Indiana
My Commission Expires. Survays 17, 2029
Commission No. NP0641321

ASSETS

			Current Year		Prior Year
		1 Assets	2 Nonadmitted Assets	3 Net Admitted Assets (Cols. 1 - 2)	4 Net Admitted Assets
1.	Bonds (Schedule D)			389,337,511	358,721,043
2.	Stocks (Schedule D):				
	2.1 Preferred stocks			0	0
	2.2 Common stocks			0	0
3.	Mortgage loans on real estate (Schedule B):				
	3.1 First liens			0	0
	3.2 Other than first liens			0	0
	Real estate (Schedule A):				
	4.1 Properties occupied by the company (less \$0				
	encumbrances)	11,926		11,926	34,075
	4.2 Properties held for the production of income (less				
	\$0 encumbrances)			0	0
	4.3 Properties held for sale (less \$0			0	
_	encumbrances)				0
5.	Cash (\$				
	investments (\$2,710,049 , Schedule E - Part 2) and snort-term	6 001 795		6 001 705	9 177 559
6.	Contract loans, (including \$ premium notes)				
	Derivatives (Schedule DB)				
	Other invested assets (Schedule BA)				
9.	Receivables for securities				
10.	Securities lending reinvested collateral assets (Schedule DL)				
11.	Aggregate write-ins for invested assets				
	Subtotals, cash and invested assets (Lines 1 to 11)				
13.	Title plants less \$ charged off (for Title insurers				
	only)			0	0
14.	Investment income due and accrued	2,389,561		2,389,561	1,849,395
	Premiums and considerations:				
	15.1 Uncollected premiums and agents' balances in the course of collection	31,433,872	1,498,849	29,935,023	29,283,547
	15.2 Deferred premiums, agents' balances and installments booked but				
	deferred and not yet due (including \$36,844,345				40 550 000
	earned but unbilled premiums)				
	15.3 Accrued retrospective premiums (\$	0 004 505		0 004 505	4 050 074
40	contracts subject to redetermination (\$2,376,747)	3,201,383		3,201,383	1,853,971
	Reinsurance: 16.1 Amounts recoverable from reinsurers			0	3 281 522
	16.2 Funds held by or deposited with reinsured companies				
	16.3 Other amounts receivable under reinsurance contracts				
	Amounts receivable relating to uninsured plans				
	Current federal and foreign income tax recoverable and interest thereon				
	Net deferred tax asset				
19.	Guaranty funds receivable or on deposit	86,765		86,765	120, 194
20.	Electronic data processing equipment and software			0	0
21.	Furniture and equipment, including health care delivery assets				
	(\$)				
	Net adjustment in assets and liabilities due to foreign exchange rates				
	Receivables from parent, subsidiaries and affiliates				
	Health care (\$				
	Aggregate write-ins for other than invested assets	59,906,573	1,908,535	57,998,038	47,469,017
26.	Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)	791,084,563	50,576,611	740,507,952	683,378,987
27.	From Separate Accounts, Segregated Accounts and Protected Cell				
	Accounts				
28.	Total (Lines 26 and 27)	791,084,563	50,576,611	740,507,952	683,378,987
	DETAILS OF WRITE-INS				
1101.					
1102.					
1103. 1198.	Summary of remaining write-ins for Line 11 from overflow page				
		0			
	Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above) Federal Employee Program assets held by agent				_
	State income tax receivable				
	Miscellaneous receivables			91,513	
	Summary of remaining write-ins for Line 25 from overflow page	· ·	,	· ·	,
	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)				
_000.	. State (Entro Edo) tilla Edda piad Edda/Lillo Ed above)	00,000,070	1,000,000	01,000,000	T1,700,011

LIABILITIES, CAPITAL AND SURPLUS

			Current Year		Prior Year
		1	2	3	4
		0		T. (.)	Tatal
	007.000	Covered	Uncovered	Total	Total
1.	Claims unpaid (less \$				
2.	Accrued medical incentive pool and bonus amounts			1,287,677	
3.	Unpaid claims adjustment expenses	3,566,155		3,566,155	3,525,589
4.	Aggregate health policy reserves, including the liability of				
	\$3,536,682 for medical loss ratio rebate per the Public				
	Health Service Act	136,272,333		136,272,333	134,764,755
5.	Aggregate life policy reserves			0	0
6.	Property/casualty unearned premium reserves			0	0
7.	Aggregate health claim reserves			0	0
8.	Premiums received in advance				
9.	General expenses due or accrued				
10.1					
10.1	(including \$ on realized capital gains (losses))			0	A 577 203
40.0	Net deferred tax liability				
11.	Ceded reinsurance premiums payable				
12.	Amounts withheld or retained for the account of others				
13.	Remittances and items not allocated	16,645,942		16,645,942	22,755,894
14.	Borrowed money (including \$ current) and				
	interest thereon \$ (including				
	\$current)			0	0
15.	Amounts due to parent, subsidiaries and affiliates	130 , 122 , 304		130 , 122 , 304	0
16.	Derivatives				
17.	Payable for securities				
18.	Payable for securities lending				
		10,004,442		10,004,442	13,000,002
19.	Funds held under reinsurance treaties (with \$				
	authorized reinsurers, \$0 unauthorized				
	reinsurers and \$0 certified reinsurers)			0	0
20.	Reinsurance in unauthorized and certified (\$				
	companies				
21.	Net adjustments in assets and liabilities due to foreign exchange rates			0	0
22.	Liability for amounts held under uninsured plans	72,692,007		72,692,007	109,378,750
23.	Aggregate write-ins for other liabilities (including \$				
	current)	5,808,418	0	5,808,418	13,939,698
24.		585,852,297			
25.	Aggregate write-ins for special surplus funds				
26.	Common capital stock				
	Preferred capital stock				
27.	·				
28.	Gross paid in and contributed surplus				
29.	Surplus notes				
30.	Aggregate write-ins for other than special surplus funds				
31.	Unassigned funds (surplus)	XXX	XXX	24,570,630	15,944,519
32.	Less treasury stock, at cost:				
	32.1 shares common (value included in Line 26				
	\$	xxx	XXX		
	32.2 shares preferred (value included in Line 27				
	\$	XXX	XXX		
33.	Total capital and surplus (Lines 25 to 31 minus Line 32)				
34.	Total liabilities, capital and surplus (Lines 24 and 33)	XXX	XXX	740,507,952	683,378,987
54.			***	740,307,332	000,070,907
	DETAILS OF WRITE-INS	4 050 400		4 050 400	0 500 050
	Escheat liability	· · ·			
2302.	·			1,681,311	
2303.	Other liabilities	1,660,629		1,660,629	1,453,684
2398.	Summary of remaining write-ins for Line 23 from overflow page	513,295	0	513,295	8,408,613
2399.	Totals (Lines 2301 thru 2303 plus 2398)(Line 23 above)	5,808,418	0	5,808,418	13,939,698
2501.	Deferred gain on sale-leaseback transaction		xxx	5,903,698	7, 192,533
2502.					
2503.					
2598.	Summary of remaining write-ins for Line 25 from overflow page				
2599.	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above)	XXX	XXX	5,903,698	7,192,533
3001		XXX			
		1			
3002.					
		xxx	XXX		
3002.		xxx	XXX		

STATEMENT OF REVENUE AND EXPENSES

1 Duncovered Total 1. Member Months	01,954	otal 4,864,236 4,864,236 4,864,236 31,726,413 34,698,998
1. Member Months	18,984	4,864,236 131,726,413 34,698,998
Net premium income (including \$ non-health premium income)	01,954	131,726,413 34,698,998
Change in unearned premium reserves and reserve for rate credits	37,893)34,698, 0	34,698,998
Change in unearned premium reserves and reserve for rate credits	37,893)34,698, 0	34,698,998
4. Fee-for-service (net of \$	0	
Risk revenue	0	
6. Aggregate write-ins for other health care related revenues	0	
	0	
7. Aggregate write-ins for other non-health revenues		
	14 001 1 100 405	
8. Total revenues (Lines 2 to 7)	4,001 1,100,423,	166,425,411
Hospital and Medical:		
9. Hospital/medical benefits		
10. Other professional services		
11. Outside referrals		
12. Emergency room and out-of-area	31, 168 68, 404,	68,404,778
13. Prescription drugs	34,477176,420,	176,420,722
14. Aggregate write-ins for other hospital and medical0	0	0
15. Incentive pool, withhold adjustments and bonus amounts	90,6316,480,	6,480,899
16. Subtotal (Lines 9 to 15)	² ,4701,046,749,	046,749,086
Less:		
17. Net reinsurance recoveries	i6,86121,431,	21,431,584
18. Total hospital and medical (Lines 16 minus 17)	15,609 1,025,317,	025,317,502
19. Non-health claims (net)		
20. Claims adjustment expenses, including \$	37,64435,679,	35,679,930
21. General administrative expenses	68,667,	68,667,646
22. Increase in reserves for life and accident and health contracts (including \$		
increase in reserves for life only)	0	0
23. Total underwriting deductions (Lines 18 through 22)		
24. Net underwriting gain or (loss) (Lines 8 minus 23)		.36.760.333
25. Net investment income earned (Exhibit of Net Investment Income, Line 17)		
26. Net realized capital gains (losses) less capital gains tax of \$(75,954)		
27. Net investment gains (losses) (Lines 25 plus 26)		
28. Net gain or (loss) from agents' or premium balances charged off [(amount recovered	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	0,201,022
\$	25 280) (874	(87/ 255)
	19,004	505,557
30. Net income or (loss) after capital gains tax and before all other federal income taxes (Lines 24 plus 27 plus 28 plus 29)	57,36744,656,	44,656,237
31. Federal and foreign income taxes incurred		15,431,114
		29,225,123
DETAILS OF WRITE-INS		-, -, -
0601		
0602 XXX		
0603 XXX		
0698. Summary of remaining write-ins for Line 6 from overflow page		
0699. Totals (Lines 0601 thru 0603 plus 0698)(Line 6 above)	0	0
0701XXX		
0702		
0703		
0798. Summary of remaining write-ins for Line 7 from overflow page	0	0
0799. Totals (Lines 0701 thru 0703 plus 0798)(Line 7 above)	0	0
1401.		
1402.		
1403.		
1498. Summary of remaining write-ins for Line 14 from overflow page	0	0
1499. Totals (Lines 1401 thru 1403 plus 1498)(Line 14 above)	0	0
2901. Miscellaneous income	39,834565,	565,337
2902.		
2903		
2998. Summary of remaining write-ins for Line 29 from overflow page	0	0
2999. Totals (Lines 2901 thru 2903 plus 2998)(Line 29 above) 0 73	39,834 565,	565,337

STATEMENT OF REVENUE AND EXPENSES (Continued)

OTATEMENT OF REVENUE AND EXITENCES	Oonanaoa	/
	1 Current Year	2 Prior Year
CAPITAL AND SURPLUS ACCOUNT		
Capital and surplus prior reporting year	146,289,952	155,707,822
Net income or (loss) from Line 32	55,351,002	29,225,123
Change in valuation basis of aggregate policy and claim reserves		
-		
-		
44.2 Transferred from surplus (Stock Dividend)	0	0
44.3 Transferred to surplus.		
Surplus adjustments:		
45.1 Paid in	0	0
45.2 Transferred to capital (Stock Dividend)		
45.3 Transferred from capital		
Dividends to stockholders	(29,200,000)	(35,000,000
Aggregate write-ins for gains or (losses) in surplus	(1,288,835)	(1,288,835
Net change in capital and surplus (Lines 34 to 47)		(9,417,870
Capital and surplus end of reporting period (Line 33 plus 48)	153,627,228	146,289,952
DETAILS OF WRITE-INS		
Deferred gain on sale-leaseback transaction	(1,288,835)	(1,288,835
Summary of remaining write-ins for Line 47 from overflow page	0	0
Totals (Lines 4701 thru 4703 plus 4798)(Line 47 above)	(1,288,835)	(1,288,835
	Capital and surplus prior reporting year	Capital and surplus prior reporting year

CASH FLOW

	CASITILOW	1	2
		1	
		Current Year	Prior Year
	Cash from Operations		
	Premiums collected net of reinsurance		1,148,849,140
	let investment income	_	
	Aiscellaneous income		0
	otal (Lines 1 through 3)		1,158,609,726
	Senefit and loss related payments		
	Net transfers to Separate Accounts, Segregated Accounts and Protected Cell Accounts		
7. C	Commissions, expenses paid and aggregate write-ins for deductions	188,886,843	61,472,671
	Dividends paid to policyholders		
	Gederal and foreign income taxes paid (recovered) net of \$(75,954) tax on capital gains (losses)		10,439,152
10. T	otal (Lines 5 through 9)	1,268,218,161	1,043,515,999
11. N	Net cash from operations (Line 4 minus Line 10)	(66,198,638)	115,093,727
	Cash from Investments		
12. F	Proceeds from investments sold, matured or repaid:		
1	2.1 Bonds	61,553,822	170,722,669
1	2.2 Stocks	0	0
1	2.3 Mortgage loans	0	0
	2.4 Real estate		
	2.5 Other invested assets		
	2.6 Net gains or (losses) on cash, cash equivalents and short-term investments		
	2.7 Miscellaneous proceeds		3,199,977
	2.8 Total investment proceeds (Lines 12.1 to 12.7)		
	Cost of investments acquired (long-term only):	33,733,133	
	3.1 Bonds	94 150 206	184 689 679
	3.2 Stocks		
	3.3 Mortgage loans		0
	3.4 Real estate		
	3.5 Other invested assets		
	3.6 Miscellaneous applications		3,678,771
			188,368,450
	3.7 Total investments acquired (Lines 13.1 to 13.6)		, ,
	Net increase (decrease) in contract loans and premium notes		0 (44 444 550)
15. N	Net cash from investments (Line 12.8 minus Line 13.7 minus Line 14)	(32,113,650)	(14,444,559)
	Cash from Financing and Miscellaneous Sources		
	Cash provided (applied):		
	6.1 Surplus notes, capital notes		
	6.2 Capital and paid in surplus, less treasury stock		
	6.3 Borrowed funds		
1	6.4 Net deposits on deposit-type contracts and other insurance liabilities	0	0
1	6.5 Dividends to stockholders	29,200,000	35,000,000
1	6.6 Other cash provided (applied)	126,236,521	(54,018,539)
17. N	Net cash from financing and miscellaneous sources (Lines 16.1 to 16.4 minus Line 16.5 plus Line 16.6)	97,036,521	(89,018,539)
	RECONCILIATION OF CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS		
18. N	Net change in cash, cash equivalents and short-term investments (Line 11, plus Lines 15 and 17)	(1,275,767)	11,630,629
19. C	Cash, cash equivalents and short-term investments:		
1	9.1 Beginning of year	8 , 177 , 552	(3,453,077)
1	9.2 End of year (Line 18 plus Line 19.1)	6,901,785	8,177,552

Note: Supplemental disclosures of cash flow information for non-cash transactions:		

ANALYSIS OF OPERATIONS BY LINES OF BUSINESS

		1	2 Comprehensive	3 Madiaana	4 Dontol	5	6 Federal Employees	7 Title XVIII	8 Title XIX	9	10
		Total	(Hospital & Medical)	Medicare Supplement	Dental Onlv	Vision Onlv	Health Benefits Plan	Medicare	XIX Medicaid	Other Health	Other Non-Health
1.	Net premium income	1,207,401,954		58,566,490	10,149,646	8,089,057	257,584,948	(94,289)	iviculcalu	10,233,623	NOIT-I ICAILII
	Change in unearned premium reserves and reserve for	1,207,401,334	002,072,479		10, 143,040	,009,001	237,304,340	(34,203)		10,200,020	
۷.	rate credit	(5,387,893)	3.773.407	(563)	614.729		(9.783.453)	7 987			
3	Fee-for-service (net of \$	(0,007,000)		(000)			(0,700,400)				
J.	medical expenses)	0									XXX
4.	Risk revenue	٥	•••••							•••••	XXX
	Aggregate write-ins for other health care related										
0.	revenues	0	0	0	0	0	0	0	0	0	XXX
6.	Aggregate write-ins for other non-health care related										
	revenues	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	0
7.	Total revenues (Lines 1 to 6)	1,202,014,061	866,645,886	58,565,927	10,764,375	8,089,057	247,801,495	(86, 302)	0	10,233,623	0
8.	Hospital/medical benefits	706,311,763	494,524,124	40,351,356	6,124		161,497,465	(118,048)		10,050,742	XXX
9.	Other professional services	71,816,385	42,409,270	7, 102, 169	3,319,611	5,329,479	13,664,998	(9, 142)			XXX
10.	Outside referrals	13,788,046	9,451,281	30,234	4,279,170	27,361					XXX
11.	Emergency room and out-of-area	71,831,168	70,594,477					(4,506)			XXX
12.	Prescription drugs		130,458,933	(1, 118, 570)			54,405,651	(11,537)			XXX
13.	Aggregate write-ins for other hospital and medical	0	0	0	0	0	0	0	0	0	XXX
14.	Incentive pool, withhold adjustments and bonus amounts	6,590,631	5,637,363				953,719	(451)			XXX
15.	Subtotal (Lines 8 to 14)	1,054,072,470	753,075,448	47,606,386	7,604,905	5,356,840	230,521,833	(143,684)	0	10,050,742	XXX
16.	Net reinsurance recoveries	156,861	138,555							18,306	XXX
17.	Total medical and hospital (Lines 15 minus 16)	1,053,915,609	752,936,893	47,606,386	7,604,905	5,356,840	230,521,833	(143,684)	0	10,032,436	XXX
18.	Non-health claims (net)	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
19.	Claims adjustment expenses including										
	•	38,087,644	28, 172, 819	3,741,555	753,963	415,441	5,325,583	(55,020)		(266,697)	
20.	General administrative expenses		53,280,372	7,076,021	1,425,894	785,682	10,071,731	(104,053)		(5,879,505)	
21.	Increase in reserves for accident and health contracts	0									XXX
22.	Increase in reserves for life contracts	0	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
23.	Total underwriting deductions (Lines 17 to 22)	1, 158, 659, 395	834,390,084	58,423,962	9,784,762	6,557,963	245,919,147	(302,757)	0	3,886,234	0
24.	Total underwriting gain or (loss) (Line 7 minus Line 23)	43,354,666	32,255,802	141,965	979,613	1,531,094	1,882,348	216,455	0	6,347,389	0
	DETAILS OF WRITE-INS										
0501.											XXX
0502.											XXX
0503.											XXX
0598.	Summary of remaining write-ins for Line 5 from overflow	_	_		_	_	_			_	
	page	0	0	0	0	0	0	0	0	0	XXX
	Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above)	0	0	0	0	0	0	0	0	0	XXX
0601.			XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
0602.			XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
0603.			XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	
0698.	Summary of remaining write-ins for Line 6 from overflow	٥	xxx	xxx	XXX	XXX	xxx	XXX	XXX	xxx	0
0699.	page	۰۰	XXX	XXX	XXX	XXX	XXX	XXX	XXX	XXX	۷
	Totals (Lines 0601 thru 0603 plus 0696) (Line 6 above)	U	***	***	***	***	^^^	***	***	***	XXX
1301. 1302.							······				XXX
1302. 1303.							·····				XXXXXX
	Summary of remaining write-ins for Line 13 from						······			•	
1390.	overflow page	n	n	n	۸۱	n	n	n	n	n	XXX
1300	Totals (Lines 1301 thru 1303 plus 1398) (Line 13 above)	n	n	n	n	n	n	n	n	n	XXX
1000.	rotais (Lines 1901 tilla 1909 plus 1990) (Line 19 above)	0	0	0	0	0	0	0 1	0	U	////

m

ANNUAL STATEMENT FOR THE YEAR 2022 OF THE Anthem Health Plans of Maine, Inc.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 1 - PREMILIMS

PART 1 - PREMIUMS	1	2	3	1
	'	2	3	4
				Net Premium
Line of Duninger	Direct	Reinsurance	Reinsurance	Income
Line of Business	Business	Assumed	Ceded	(Cols. 1 + 2 - 3)
Comprehensive (hospital and medical) individual	133,925,113		1,760,022	132,165,091
Comprehensive (hospital and medical) group	730 , 707 , 388			730,707,388
3. Medicare Supplement	58,566,490			58,566,490
4. Dental only	10,149,646			10,149,646
5. Vision only	8,089,057			8,089,057
6. Federal Employees Health Benefits Plan	257,584,948			257,584,948
7. Title XVIII - Medicare	(94,289)			(94,289)
8. Title XIX - Medicaid	0			0
9. Credit A&H				0
10. Disability Income				0
11. Long-Term Care				0
12. Other health	10,272,551		38,928	10,233,623
13. Health subtotal (Lines 1 through 12)	1,209,200,904	0	1,798,950	1,207,401,954
14. Life	0			0
15. Property/casualty	0			0
16. Totals (Lines 13 to 15)	1,209,200,904	0	1,798,950	1,207,401,954

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2 - CLAIMS INCURRED DURING THE YEAR

		1	Compre	hensive	4	5	6	7	8	9	10	11	12	13	14
		•		& Medical)				,	Ŭ	Ŭ	10		1-	10	
		Total	2 Individual	3 Group	Medicare Supplement	Dental Only	Vision Only	Federal Employees Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Credit A&H	Disability Income	Long-Term Care	Other Health	Other Non-Health
1.	Payments during the year:														
	1.1 Direct	1,057,998,491	106,377,973	646,965,144	47,487,224	7,665,585	5,390,306	234,090,281	(155,972)					10, 177, 950	
	1.2 Reinsurance assumed	0													
	1.3 Reinsurance ceded	6,986,399	6,982,724											3,675	
	1.4 Net	1,051,012,092	99,395,249	646,965,144	47,487,224	7,665,585	5,390,306	234,090,281	(155,972)	0	0	0	0	10, 174, 275	0
2.	Paid medical incentive pools and														
	bonuses	7 , 170 , 493	1,331,300	4,666,525				1,223,306	64					(50,702)	
	Claim liability December 31, current year from Part 2A:														
	3.1 Direct	171,060,778	15 , 196 ,683	109,104,916	6,102,854	592,809	405 , 189	37,479,659		0	0	0	0	2,173,061	0
	3.2 Reinsurance assumed	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	3.3 Reinsurance ceded	227,228	201,763	0	0	0	0	0	0	0	0	0	0	25,465	0
	3.4 Net	170 , 833 , 550	14,994,920	109,104,916	6,102,854	592,809	405 , 189	37,479,659	5,607	0	0	0	0	2,147,596	0
4.	Claim reserve December 31, current year from Part 2D: 4.1 Direct	0													
	4.2 Reinsurance assumed														
	4.3 Reinsurance ceded														
	4.4 Net		 N	0		0	Λ							Λ	
	Accrued medical incentive pools and		0		0					0	0	0		0	
	bonuses, current year	1,287,677	285,472	798,549				195,510						8,146	
	Net health care receivables (a)	1,565,777	209,874	1,173,541	233 , 169	(1,385)		(174,680)	(18,479)					143,737	
7.	Amounts recoverable from reinsurers December 31, current year	0													
8.	Claim liability December 31, prior year from Part 2A:							40 450 505							
	8.1 Direct	180,011,653	16,633,390	112,189,827	5,750,523	654,875	438,654	42,176,505	, -	0				2, 156, 532	0
	8.2 Reinsurance assumed	0			0	0	0	0	0	0				0	0
	8.3 Reinsurance ceded	3,775,245	3,764,410		0	0	0	0	0	0				10,835	0
	8.4 Net	176,236,408	12,868,980	112,189,827	5,750,523	654,875	438,654	42,176,505	11,347	0	0	0	0	2,145,697	0
	Claim reserve December 31, prior year from Part 2D:	_			_		_	_	_						_
	9.1 Direct	0			0	0	0	0	0	<u>0</u>				0	0
	9.2 Reinsurance assumed	0								0					
	9.3 Reinsurance ceded	0			0	0	0	J0	0	0				0	0
	9.4 Net	0	0	0	0	0	0	J0	0	0	0	0	0	0	0
	Accrued medical incentive pools and bonuses, prior year	1,867,540	556,161	888,321	0	0	0	465,099	515	0				(42,556)	0
11.	Amounts recoverable from reinsurers	0 004 500	0.004.500					1		_					_
	December 31, prior year	3,281,522	3,281,522		0	0	0	0	0	0	1		-	0	0
12.	Incurred Benefits:									_	_	_	_	40.050	_
	12.1 Direct	1,047,481,839	104,731,392	642,706,692	47,606,386	7,604,904	5,356,841	229,568,115		0	0	0	0	10,050,742	0
	12.2 Reinsurance assumed	0	0	0	0	0	0	0		0	0	0		0	0
	12.3 Reinsurance ceded	156,860	138,555	0	0	0	0	0	0	0	0	0		18,305	0
	12.4 Net	1,047,324,979	104,592,837	642,706,692	47,606,386	7,604,904	5,356,841	229,568,115	(143,233)	0	0	0	0	10,032,437	0
13.	Incurred medical incentive pools and bonuses	6,590,630	1,060,611	4,576,753	0	0	0	953,717	(451)	0	0	0	0	0	0

⁽a) Excludes \$64,443,518 loans or advances to providers not yet expensed.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2A - CLAIMS LIABILITY FND OF CURRENT YEAR

				PAR	I ZA - CLAINS	LIABILITY EN	D OF CURREN	I TEAR						
	1	Compre	hensive	4	5	6	7	8	9	10	11	12	13	14
		(Hospital 8	, , ,											
		2	3				Federal Employees							
				Medicare			Health	Title XVIII	Title XIX		Disability	Long-Term		Other
	Total	Individual	Group	Supplement	Dental Only	Vision Only	Benefits Plan	Medicare	Medicaid	Credit A&H	Income	Care	Other Health	Non-Health
Reported in Process of Adjustment:			·	••	•	•								
'													(005)	
1.1 Direct	71,119,739	2,943,384	57,885,161	1,056,927	293,590	140,763	8 , 795 , 138	5,601					(825)	
1.2 Reinsurance assumed														
1.3 Reinsurance ceded	0													
1.4 Net	71,119,739	2,943,384	57,885,161	1,056,927	293,590	140,763	8,795,138	5,601	0	0	0	0	(825)	0
Incurred but Unreported:														
'	00 044 000	40.050.000	54 040 755	5 045 007	200 240	004 400	00 004 504						0 470 000	
2.1 Direct	99,941,039	12,253,299	51,219,755	5,045,927	299,219	264,426	28,684,521	6					2, 173,886	
2.2 Reinsurance assumed	0													
2.3 Reinsurance ceded		201,763											25,465	
2.4 Net	99,713,811	12,051,536	51,219,755	5,045,927	299,219	264,426	28,684,521	6	0	0	0	0	2,148,421	0
Amounts Withheld from Paid Claims and Capitations:														
3.1 Direct														
3.2 Reinsurance assumed														
3.3 Reinsurance ceded														
3.4 Net			0		0	0	0	0	0	0	0	0	0	0
3.4 Net		0		0		U	u				0	0	u	
4. TOTALS:														
4.1 Direct	171,060,778	15 , 196 , 683	109, 104, 916	6, 102,854	592,809	405,189	37,479,659	5,607	0	0	0	0	2,173,061	0
4.2 Reinsurance assumed	0	0	0	0	0	0	0	0		0	0	0	0	0
4.3 Reinsurance ceded		201,763	0			0	0	0	0	0	0	0	25,465	0
4.4 Net	170,833,550	14,994,920	109,104,916	6,102,854	592.809	405,189	37,479,659	5.607	0	0	0	0	2,147,596	0
4.4 Net	170,000,000	14,334,320	109, 104, 910	0, 102,034	392,009	405, 105	31,419,039	3,007	0	U	U	U	2, 147, 390	U

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2B - ANALYSIS OF CLAIMS UNPAID - PRIOR YEAR - NET OF REINSURANCE

	Claims Paid D		Claim Reserve a December 31 o		5	6
	1	2	3	4		Estimated Claim Reserve and Claim
Line of Business	On Claims Incurred Prior to January 1 of Current Year	On Claims Incurred During the Year	On Claims Unpaid December 31 of Prior Year	On Claims Incurred During the Year	Claims Incurred In Prior Years (Columns 1 + 3)	Liability December 31 of Prior Year
Comprehensive (hospital and medical) individual	8,184,865	95,840,078	1,094,830	13,900,091	9,279,695	12,868,979
Comprehensive (hospital and medical) group		556,794,685	7,370,762	101,734,153	106, 148, 949	112,189,826
3. Medicare Supplement	5, 163, 513	42,854,779	6,829	6,096,025	5,170,342	5,750,524
4. Dental Only		7,218,049	21,091	571,718	471,487	654,875
5. Vision Only		5, 121,416	88	405, 101	268,978	438,654
6. Federal Employees Health Benefits Plan		196,832,866	385 , 106	37,094,553	37,842,425	42,176,505
7. Title XVIII - Medicare	(145,886)	0	5,474	133	(140,412)	11,347
8 Title XIX - Medicaid	0	0	0	0	0	0
9. Credit A&H	0	0	0	0	0	0
10. Disability Income	0	0	0	0	0	0
11. Long-Term Care	0	0	0	0	0	0
12. Other health	2,964,847	7,209,428	448,532	1,699,064	3,413,379	2,145,698
13. Health subtotal (Lines 1 to 12)	153, 122, 131	911,871,301	9,332,712	161,500,838	162,454,843	176,236,408
14. Health care receivables (a)	2,665,925	9,599,670	0	0	2,665,925	0
15. Other non-health	0	0	0	0	0	0
16. Medical incentive pools and bonus amounts	683, 161	6,487,332	416,578		1,099,739	1,867,540
17. Totals (Lines 13 - 14 + 15 + 16)	151,139,367	908,758,963	9,749,290	162,371,937	160,888,657	178,103,948

⁽a) Excludes \$64,443,518 loans or advances to providers not yet expensed.

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Comprehensive (Hospital & Medical)

		•	Cur	mulative Net Amounts F	Paid	
		1	2	3	4	5
	Year in Which Losses Were Incurred	2018	2019	2020	2021	2022
1.	Prior	97,413	94,563	94,219	94,248	94,248
2.	2018	544,874	597,263	597,595	597,696	598,850
3.	2019	XXX	652,969	721,237	721,985	722,461
4.	2020	XXX	XXX	559,762	633,321	635,407
5.	2021	XXX	XXX	XXX	609, 140	710,466
6.	2022	XXX	XXX	XXX	XXX	649,216

Section B - Incurred Health Claims - Comprehensive (Hospital & Medical)

	Sum of Cumulative Net A		Liability, Claim Rese standing at End of Ye		ve Pool and Bonuses
	1	2	3	4	5
Year in Which Losses Were Incurred	2018	2019	2020	2021	2022
1. Prior	97,812	94,568	94,450	94,279	94,248
2. 2018	612,871	597,936	597,631	597,902	599,709
3. 2019	XXX	723,846	722,797	722,594	722,791
4. 2020	XXX	XXX	645,015	637,810	636,833
5. 2021	XXX	XXX	XXX	730,308	716,641
6. 2022	XXX	XXX	XXX	XXX	765,610

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Comprehensive (Hospital & Medical)

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2018	708,821	598,850	21,286	3.6	620 , 136	87.5	859	29	621,024	87.6
2.	2019		722,461	28,250	3.9	750,711	86.6	330	3	751,044	86.6
3.	2020		635,407	30,877	4.9		83.4	1,426	12	667,722	83.6
4.	2021	824,542	710,466	30,925	4.4	741,391	89.9	6, 175	137	747,703	90.7
5.	2022	866,646	649,216	23,738	3.7	672,954	77.7	116,394	2,293	791,641	91.3

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Medicare Supplement

		Cumulative Net Amounts Paid					
		1	2	3	4	5	
	Year in Which Losses Were Incurred	2018	2019	2020	2021	2022	
1.	Prior	7,206	7,191	7,414	7,400	7,400	
2.	2018	35,294	39,657	40,249	40,238	40,233	
3.	2019	XXX	37,601	41,343	41,362	41,320	
4.	2020	XXX	XXX	33,581	40,668	40,675	
5.	2021	XXX	XXX	XXX	41,886	47,039	
6.	2022	XXX	XXX	XXX	XXX	42,141	

Section B - Incurred Health Claims - Medicare Supplement

		Sum of Cumulative N	et Amount Paid and Clair Out	m Liability, Claim Resetstanding at End of Ye	erve and Medical Incenti ar	ve Pool and Bonuses
	Year in Which Losses Were Incurred	1 2018	2 2019	3 2020	4 2021	5 2022
1.	Prior	7,319	7,191	7,551	7,540	7,400
2.	2018	40,418	40,033	40,274	40,261	40,233
3.	2019	XXX	43,240	42,182	42,145	41,320
4.	2020	XXX	XXX	41,910	40,680	40,676
5.	2021	XXX	XXX	XXX	46,679	47,045
6.	2022	XXX	XXX	XXX	XXX	48,237

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Medicare Supplement

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2018		40,233	2,548	6.3	42,781	90.3	0	0	42,781	90.3
2.	2019		41,320	3,461	8.4	44,781	87.9	0	0	44,781	87.9
3.	2020		40,675	3,335	8.2	44,010	78.1	1	0	44,011	78.1
4.	2021		47,039	3,811	8.1	50,850	86.6	6	0	50,856	86.6
5.	2022	58,566	42,141	3,201	7.6	45,342	77.4	6,096	156	51,594	88.1

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Dental Only

		Cumulative Net Amounts Paid					
		1	2	3	4	5	
	Year in Which Losses Were Incurred	2018	2019	2020	2021	2022	
1.	Prior	283	290	293	294	294	
2.	2018	5,611	5,918	5,920	5,921	5,921	
3.	2019	XXX	6,442	6,798	6,807	6,807	
4.	2020	XXX	XXX	5,225	5,724	5,734	
5.	2021	XXX	XXX	XXX	7,015	7,455	
6.	2022	XXX	XXX	XXX	XXX	7,217	

Section B - Incurred Health Claims - Dental Only

-	Sum of Cumulative Net A	Amount Paid and Claim Outs	Liability, Claim Resetanding at End of Yea	erve and Medical Incention	ve Pool and Bonuses
	1	2	3	4	5
Year in Which Losses Were Incurred	2018	2019	2020	2021	2022
1. Prior		291	294	294	294
2. 2018	5,993	5,925	5,921	5,921	5,921
3. 2019	XXX	6,933	6,807	6,808	6,807
4. 2020	XXX	XXX	5,788	5,740	5,736
5. 2021	XXX	XXX	XXX	7,653	7,474
6. 2022	XXX	XXX	XXX	XXX	7,789

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Dental Only

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2018	8,588	5,921	644	10.9	6,565	76.4	0	0	6,565	76.4
2.	2019	9,161	6,807	687	10.1	7,494	81.8	0	0	7,494	81.8
3.	2020	8.928	5.734	619	10.8	6.353	71.2	2	0	6.355	71.2
4.	2021		7,455		9.9	8.193	75.4	19	0	8.212	75.6
5.	2022	10,764	7,217	660	9.1	7,877	73.2	572	13	8,462	78.6

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Vision Only

	,	Cumulative Net Amounts Paid						
		1	2	3	4	5		
	Year in Which Losses Were Incurred	2018	2019	2020	2021	2022		
1.	Prior	276	276	276	276	276		
2.	2018	5,009	5,253	5,253	5,253	5,253		
3.	2019	XXX	5,527	5,867	5,859	5,858		
4.	2020	XXX	XXX	4,666	4,920	4,915		
5.	2021	XXX	XXX	XXX	5,446	5,720		
6.	2022	XXX	XXX	XXX	XXX	5,121		

Section B - Incurred Health Claims - Vision Only

	Coulon B mountain claims violen city						
		Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Outstanding at End of Year					
		1	2	3	4	5	
	Year in Which Losses Were Incurred	2018	2019	2020	2021	2022	
1.	Prior	278	276	276	276	276	
2.	2018	5,278	5,250	5,253	5,253	5,253	
3.	2019	XXX	5,945	5,867	5,859	5,858	
4.	2020	XXX	XXX	5 , 130	4,920	4,915	
5.	2021	xxx	XXX	XXX	5,885	5,720	
6.	2022	XXX	XXX	XXX	XXX	5.526	

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Vision Only

			1	2	3	4	5	6	7	8	9	10
		Years in which			Olaina Adinatas ant	(0-1, 2/0)	Claim and Claim Adjustment Expense	(0-1, 5(4))		Unpaid Claims	Total Claims and Claims Adjustment	(0-1,0/4)
		Premiums were Earned and Claims were Incurred	Premiums Earned	Claims Payment	Claim Adjustment Expense Payments	(Col. 3/2) Percent	Payments (Col. 2 + 3)	(Col. 5/1) Percent	Claims Unpaid	Adjustment Expenses	Expense Incurred (Col. 5+7+8)	(Col. 9/1) Percent
Ī	1.	2018	7,539	5,253	455	8.7	5,708	75.7	0	0	5,708	75.7
	2.	2019	7,893	5,858	447	7.6	6,305	79.9	0	0	6,305	79.9
	3.	2020	7.606	4.915	392	8.0	5.307	69.8	0	0	5.307	69.8
	4.	2021	8,078	5,720	510	8.9	6,230	77.1	0	0	6,230	77.1
	5.	2022	8,089	5,121	366	7.1	5,487	67.8	405	11	5,903	73.0

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Federal Employees Health Benefits Plan Premium

			Cumi	ulative Net Amounts F	Paid	
		1	2	3	4	5
	Year in Which Losses Were Incurred	2018	2019	2020	2021	2022
1.	Prior	19,678	18,642	18,288	18,338	18,338
2.	2018	172,367	191,368	191,511	191,629	191,574
3.	2019	XXX	189,259	208,694	209, 149	209,022
4.	2020	XXX	XXX	177,987	199,890	200, 126
5.	2021	XXX	xxx	XXX	193,087	230,597
6.	2022	XXX	XXX	XXX	XXX	197,925

Section B - Incurred Health Claims - Federal Employees Health Benefits Plan Premium

	Sum of Cumulative N	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Poo Outstanding at End of Year						
Voc. S. Mil'S. L. L More Learner	1	5						
Year in Which Losses Were Incurred	2018	2019	2020	2021	2022			
1. Prior	19,742	18,356	18,272	18,346	18,338			
2. 2018	190,942	190,952	191,406	191,659	191,574			
3. 2019	XXX	210,476	208,615	209,272	209,011			
4. 2020	xxx	XXX	203,666	200,433	200, 158			
5. 2021	XXX	XXX	XXX	235,025	231,051			
6. 2022	xxx	XXX	XXX	XXX	235, 125			

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Federal Employees Health Benefits Plan Premium

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2018		191,574	5,280	2.8	196,854	94.0	0	0		94.0
2.	2019	223.242		4.835	2.3	213.857	95.8	(11)	0	213.846	95.8
3.	2020	223,756	200 , 126	5,197	2.6	205,323	91.8	32	0		91.8
4.	2021	249,576	230,597	5,499	2.4	236,096	94.6	454	9		94.8
5.	2022	247,801	197,925	4,456	2.3	202,381	81.7	37,200	845	240,426	97.0

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Title XVIII

			Cur	mulative Net Amounts F	Paid	
		1	2	3	4	5
	Year in Which Losses Were Incurred	2018	2019	2020	2021	2022
1.	Prior	3,970	3,584	3,350	3,336	3,336
2.	2018	3,176	3,338	3,337	3,337	3,340
3.	2019	XXX	895	945	946	944
4.	2020	XXX	XXX	883	1,829	1,690
5.	2021	XXX	XXX	XXX	266	267
6.	2022	XXX	XXX	XXX	XXX	0

Section B - Incurred Health Claims - Title XVIII

	Sum of Cumulative Net A	mount Paid and Claim Outs	Liability, Claim Resestanding at End of Yea	rve and Medical Incention	e Pool and Bonuses
	1	2	3	4	5
Year in Which Losses Were Incurred	2018	2019	2020	2021	2022
1. Prior	3,891	3,460	3,352	3,336	3,336
2. 2018	3,357	3,347	3,337	3,337	3,346
3. 2019	XXX	975	946	944	944
4. 2020	XXX	XXX	1,908	1,828	1,689
5. 2021	XXX	XXX	XXX	280	267
6. 2022	XXX	XXX	XXX	XXX	0

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Title XVIII

		1	2	3	4	5	6	7	8	9	10	
						Claim and Claim				Total Claims and		
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment		
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)	
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent	
1.	2018	1,067	3,340		10.1	3,679	344.8	6	0	3,685	345.4	
2.	2019	612	944	546	57.8	1.490	243.5	0	0	1.490	243.5	
3.	2020	1.170	1.690	153	9.1	1.843	157.5	(1)	0	1.842	157.4	
4.	2021	(34)	267	9	3.4	276	(811.8)	0	0	276	(811.8)	
5.	2022	(86)	0	(28)	0.0	(28)	32.6	0	0	(28)	32.6	

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted) Section A - Paid Health Claims - Other

			Cun	nulative Net Amounts F	Paid	
		1	2	3	4	5
	Year in Which Losses Were Incurred	2018	2019	2020	2021	2022
1.	Prior	591	758 .	757	757	757
2.	2018	8,862	9,239	9,241	9,241	9,241
3.	2019	XXX	6,316	6,820	6,821	6,919
4.	2020	XXX	XXX	8,266	9,410	9,889
5.	2021	XXX	XXX	XXX	9,023	11,287
6.	2022	XXX	XXX	XXX	XXX	7,139

Section B - Incurred Health Claims - Other

	Sum of Cumulative Ne	t Amount Paid and Clain Out	n Liability, Claim Rese standing at End of Ye	erve and Medical Incenti ar	ve Pool and Bonuses
Year in Which Losses Were Incurred	1 2018	2 2019	3 2020	4 2021	5 2022
1. Prior	570	793	758	757	757
2. 2018	9,846	9,144	9,239	9,241	9,241
3. 2019	XXX	7,780	6,925	6,822	6,919
4. 2020	XXX	XXX	9,736	9,525	10,156
5. 2021	XXX	XXX	XXX	11,011	11,471
6. 2022	XXX	XXX	XXX	XXX	8,844

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Other

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1	. 2018	9,022	9,241	(2,128)	(23.0)	7,113	78.8	0	0	7,113	78.8
2	2019	10 , 157	6,919	548	7.9	7,467	73.5	0	1	7,468	73.5
3	2020		9,889	375	3.8	10,264	76.7	267	3	10,534	78.7
4	2021	14,653	11,287	170	1.5	11,457	78.2	184	13	11,654	79.5
5	. 2022	10,234	7,139	(210)	(2.9)	6,929	67.7	1,705	41	8,675	84.8

PART 2C - DEVELOPMENT OF PAID AND INCURRED HEALTH CLAIMS (\$000 Omitted)

Section A - Paid Health Claims - Grand Total

			Cun	nulative Net Amounts P	Paid	
		1	2	3	4	5
	Year in Which Losses Were Incurred	2018	2019	2020	2021	2022
1.	Prior	129,417	125,304	124,597	124,649	124,649
2.	2018	775 , 193	852,036	853, 106	853,315	854,412
3.	2019	XXX	899,009	991,704	992,929	993,331
4.	2020	XXX	XXX	790,370	895,762	898,436
5.	2021	XXX	XXX	XXX	865,863	1,012,831
6.	2022	XXX	XXX	XXX	XXX	908,759

Section B - Incurred Health Claims - Grand Total

	Sum of Cumulative Net Amount Paid and Claim Liability, Claim Reserve and Medical Incentive Pool and Bonu						
	Outstanding at End of Year						
	1	2	3	4	5		
Year in Which Losses Were Incurred	2018	2019	2020	2021	2022		
1. Prior	129,910	124,935	124,953	124,828	124,649		
2. 2018	868,705	852,587	853,061	853,574	855,277		
3. 2019	XXX	999 , 195	994 , 139	994,444			
4. 2020	XXX	XXX	913, 153	900,936	900 , 163		
5. 2021	XXX	XXX	XXX	1,036,841	1,019,669		
6. 2022	XXX	XXX	XXX	XXX	1,071,131		

Section C - Incurred Year Health Claims and Claims Adjustment Expense Ratio - Grand Total

		1	2	3	4	5	6	7	8	9	10
						Claim and Claim				Total Claims and	
	Years in which					Adjustment Expense			Unpaid Claims	Claims Adjustment	
	Premiums were Earned and Claims			Claim Adjustment	(Col. 3/2)	Payments	(Col. 5/1)		Adjustment	Expense Incurred	(Col. 9/1)
	were Incurred	Premiums Earned	Claims Payment	Expense Payments	Percent	(Col. 2 + 3)	Percent	Claims Unpaid	Expenses	(Col. 5+7+8)	Percent
1.	2018		854,412	28,424	3.3		89.0	865	29	883,730	89.1
2.	2019	1,169,038	993,331	38,774	3.9	1,032,105	88.3	319	4	1,032,428	88.3
3.	2020	1,109,881	898,436	40,948	4.6	939,384	84.6	1,727	15	941,126	84.8
4.	2021	1,166,425	1,012,831	41,662	4.1	1,054,493	90.4	6,838	159	1,061,490	91.0
5.	2022	1,202,014	908,759	32, 183	3.5	940,942	78.3	162,372	3,359	1,106,673	92.1

UNDERWRITING AND INVESTMENT EXHIBIT

PART 2D - AGGREGATE RESERVE FOR ACCIDENT AND HEALTH CONTRACTS ONLY

	PART 2D - AGGREGATE RESERVE FOR ACCIDENT AND HEALTH CONTRACTS ONLY													
		1	Compreh		4	5	6	7	8	9	10	11	12	13
			(Hospital &	3				Federal						ļ
			_	· ·				Employees					_	ļ
		Total	Individual	Group	Medicare Supplement	Dental Only	Vision Only	Health Benefits Plan	Title XVIII Medicare	Title XIX Medicaid	Credit A&H	Disability Income	Long-Term Care	Other
1.	Unearned premium reserves	4,288	986	(284)		2,810	(4)			Modificato	0.00.00.0		ou.o	0 11.01
2.	Additional policy reserves (a)	0		, ,		,	, ,							ļ
3.	Reserve for future contingent benefits	0												
4.	Reserve for rate credits or experience rating refunds													
	(including \$ for investment income)	122,737,158	3,536,682	63,761,333	563			55,438,580						
5.	Aggregate write-ins for other policy reserves	13,530,887	12,891,701	540,369	0	0	0	0	98,817	0	0	0	0	0
6.	Totals (gross)	136,272,333	16,429,369	64,301,418	1,343	2,810	(4)	55,438,580	98,817	0	0	0	0	0
7.	Reinsurance ceded													
8.	Totals (Net)(Page 3, Line 4)	136,272,333	16,429,369	64,301,418	1,343	2,810	(4)	55,438,580	98,817	0	0	0	0	0
9.	Present value of amounts not yet due on claims	0												
10.	Reserve for future contingent benefits	0												
11.	Aggregate write-ins for other claim reserves	0	0	0	0	0	0	0	0	0	0	0	0	0
12.	Totals (gross)	0	0 .	0	0	0	0	0	0	0	0	0	0	0
13.	Reinsurance ceded	0												
14.	Totals (Net)(Page 3, Line 7)	0	0	0	0	0	0	0	0	0	0	0	0	0
	DETAILS OF WRITE-INS													
0501.	Risk Adjustment Redetermination	13,530,887	12,891,701	540,369					98,817					
0502.														
0503.														
0598.	Summary of remaining write-ins for Line 5 from overflow page	0	0 .	0	0	0	0	0	0	0	0	0	0	0
0599.	Totals (Lines 0501 thru 0503 plus 0598) (Line 5 above)	13,530,887	12,891,701	540,369	0	0	0	0	98,817	0	0	0	0	0
1101.														
1102.														
1103.														
1198.	Summary of remaining write-ins for Line 11 from overflow page	0	0 .	0	0	0	0	0	0	0	0	0	0	0
1199.	Totals (Lines 1101 thru 1103 plus 1198) (Line 11 above)	0	0	0	0	0	0	0	0	0	0	0	0	0

(a) Includes \$ _____ premium deficiency reserve.

UNDERWRITING AND INVESTMENT EXHIBIT

PART 3 - ANALYSIS OF EXPENSES

		S				
		Claim Adjustme	ent Expenses	3	4	5
		Cost Containment Expenses	Other Claim Adjustment Expenses	General Administrative Expenses	Investment Expenses	Total
1.	Rent (\$ for occupancy of					
	own building)	168,548	332,619	428,714	0	929,881
2.	Salary, wages and other benefits	9,424,267	7,477,285	37,306,290	0	54,207,842
3.	Commissions (less \$					
	ceded plus \$assumed)	0	0	15 .283 .598	0	15.283.598
4.	Legal fees and expenses			278,302		
5.	Certifications and accreditation fees					
6.	Auditing, actuarial and other consulting services					
7.	Traveling expenses			250,429		
8.	Marketing and advertising			1,565,261		
9.	Postage, express and telephone		153,800	2,438,049		
10.	Printing and office supplies		,	272,266		
	Occupancy, depreciation and amortization			0		0
11.	Equipment			198,591		200 , 107
12.		102	1,304	190,591	0	200, 107
13.	Cost or depreciation of EDP equipment and software	38 , 185	73,465	7,420,994	0	7,532,644
14.	Outsourced services including EDP, claims, and				_	
	other services					
15.	Boards, bureaus and association fees			359,501		
16.	Insurance, except on real estate					
17.	Collection and bank service charges					
18.	Group service and administration fees					
19.	Reimbursements by uninsured plans	0	0	(43,656,917)	0	(43,656,917)
20.	Reimbursements from fiscal intermediaries	0	0	0	0	0
21.	Real estate expenses	33,734	3,675	719,872	0	757,281
22.	Real estate taxes	0	0	69,075	0	69,075
23.	Taxes, licenses and fees:					
	23.1 State and local insurance taxes	54	0	8,099,508	0	8,099,562
	23.2 State premium taxes	0	0	8,321,978	0	8,321,978
	23.3 Regulatory authority licenses and fees	13,822	4,653	172, 189	0	190,664
	23.4 Payroll taxes	533,430	462,620	2,266,798	0	3,262,848
	23.5 Other (excluding federal income and real estate taxes)	0	0	4,929,210	0	4,929,210
24.	Investment expenses not included elsewhere	0	0	0	303,014	303,014
25.	Aggregate write-ins for expenses	3,903,131	4,670,101	(916,596)	0	7,656,636
26.	Total expenses incurred (Lines 1 to 25)	20,472,512	17,615,132	66,656,142	303,014	(a) 105,046,800
27.	Less expenses unpaid December 31, current year	0	3,566,155	15,461,209	0	19,027,364
28.	Add expenses unpaid December 31, prior year		3,525,589	22,151,470		25,677,059
29.	Amounts receivable relating to uninsured plans, prior year			107,596,060		107,596,060
30.	Amounts receivable relating to uninsured plans, current year			148,984,274		148,984,274
31.	Total expenses paid (Lines 26 minus 27 plus 28 minus 29 plus 30)	20,472,512	17,574,566	114,734,617	303,014	153,084,709
	DETAILS OF WRITE-INS					
2501.	Miscellaneous expense	3,903,131	4,670,101	(916,596)	0	7,656,636
2502.						
2503.						
2598.	Summary of remaining write-ins for Line 25 from overflow page	0	0	0	0	0
	Totals (Lines 2501 thru 2503 plus 2598)(Line 25 above) des management fees of \$ 100 193 348 three terms are the second at the s	3,903,131 o affiliates and \$	4,670,101	(916,596) n-affiliates.	0	7,656,636

(a) Includes management fees of \$100, 193, 348 to affiliates and \$ to non-affiliates.

EXHIBIT OF NET INVESTMENT INCOME

		1	2
		Collected During Year	Earned During Year
1.	U.S. government bonds	(a)738,513	737,963
1.1	Bonds exempt from U.S. tax	(a)	
1.2	Other bonds (unaffiliated)	(a)9,237,407	9,778,452
1.3	Bonds of affiliates	(a)	
2.1	Preferred stocks (unaffiliated)	(b)	
2.11	Preferred stocks of affiliates	(b)	
2.2	Common stocks (unaffiliated)		
2.21	Common stocks of affiliates		
3.	Mortgage loans	(c)	
4.	Real estate		
5	Contract Loans		
6	Cash, cash equivalents and short-term investments	(e)313,906	313,906
7	Derivative instruments		
8.	Other invested assets		
9.	Aggregate write-ins for investment income	64 ,015	63,686
10.	Total gross investment income	10,353,841	
11.	Investment expenses		(g)303,014
12.	Investment taxes, licenses and fees, excluding federal income taxes		(g)0
13.	Interest expense		
14.	Depreciation on real estate and other invested assets		(i)
15.	Aggregate write-ins for deductions from investment income		0
16.	Total deductions (Lines 11 through 15)		303,014
17.	Net investment income (Line 10 minus Line 16)		10,590,993
	DETAILS OF WRITE-INS		
0901.	Miscellaneous income	7,880	7,880
0902.	Securities lending	56, 135	55,806
0903.			
0998.	Summary of remaining write-ins for Line 9 from overflow page	0	0
0999.	Totals (Lines 0901 thru 0903 plus 0998) (Line 9, above)	64,015	
1501.			
1502.			
1503.			
1598.	Summary of remaining write-ins for Line 15 from overflow page		0
1599.	Totals (Lines 1501 thru 1503 plus 1598) (Line 15, above)		0

(a) Includes \$	589,811	accrual of discount less \$	1,361,241	amortization of premium and less \$	3182,900	paid for accrued interest on purchases.
(b) Includes \$	0	accrual of discount less \$	0	amortization of premium and less \$	30	paid for accrued dividends on purchases.
(c) Includes \$	0	accrual of discount less \$	0	amortization of premium and less \$	\$	paid for accrued interest on purchases.
(d) Includes \$		for company's occupancy	of its own building	s; and excludes \$	interest on encu	mbrances.
(e) Includes \$	123,691	accrual of discount less \$		amortization of premium and less \$	\$	paid for accrued interest on purchases.
(f) Includes \$		accrual of discount less \$		amortization of premium.		
	and Separate Acco		\$	investment taxes, licenses and	fees, excluding fede	eral income taxes, attributable to
(h) Includes \$		interest on surplus notes a	nd \$	interest on capital notes.		
(i) Includes \$	0	depreciation on real estate	e and \$	depreciation on other inve	sted assets.	

EXHIBIT OF CAPITAL GAINS (LOSSES)

						1
		1	2	3	4	5
				Total Realized Capital	Change in	Change in Unrealized
		Realized Gain (Loss)	Other Realized	Gain (Loss)	Unrealized Capital	Foreign Exchange
		On Sales or Maturity	Adjustments	(Columns 1 + 2)	Gain (Loss)	Capital Gain (Loss)
1.	U.S. Government bonds	(48,307)	0	(48,307)	0	0
1.1	Bonds exempt from U.S. tax			0		
1.2	Other bonds (unaffiliated)	(563,058)	(849,396)	(1,412,454)	252,275	0
1.3	Bonds of affiliates				0	0
2.1	Preferred stocks (unaffiliated)	0	0	0	0	0
2.11	Preferred stocks of affiliates				0	0
2.2	Common stocks (unaffiliated)				0	0
2.21	Common stocks of affiliates	0	0	0	0	0
3.	Mortgage loans			0	0	0
4.	Real estate		0	0	v	0
5.	Contract loans			0		
	Cash, cash equivalents and short-term investments	(6 974)		(6.074)		
6.				(0,074)		
7.	Derivative instruments			0		
8.	Other invested assets		0		0	0
9.	Aggregate write-ins for capital gains (losses)				0	0
10.	Total capital gains (losses)	670,596	(849,396)	(178,800)	252,275	0
	DETAILS OF WRITE-INS					
0901.	Deferred gain on sale-leaseback transaction	1,288,835		1,288,835		
0902.	-					
0903.						
0998.	Summary of remaining write-ins for Line 9 from					
	overflow page	0	0	0	0	0
0999.	Totals (Lines 0901 thru 0903 plus 0998) (Line 9,					
5000.	above)	1,288,835	0	1,288,835	0	0
	,	, ,		, ,		

EXHIBIT OF NON-ADMITTED ASSETS

		1 Current Year Total Nonadmitted Assets	2 Prior Year Total Nonadmitted Assets	3 Change in Total Nonadmitted Assets (Col. 2 - Col. 1)
1.	Bonds (Schedule D)		Norlaumilled Assets	(COI. 2 - COI. 1)
	Stocks (Schedule D):			
۷.	2.1 Preferred stocks			0
	2.2 Common stocks			
3.	Mortgage loans on real estate (Schedule B):			
J.	3.1 First liens			0
	3.2 Other than first liens.			
4.	Real estate (Schedule A):			
4.	4.1 Properties occupied by the company			0
	4.2 Properties held for the production of income			
	4.3 Properties held for sale			
_	Cash (Schedule E - Part 1), cash equivalents (Schedule E - Part 2) and short-term investments			
5.	(Schedule DA)			0
6.	Contract loans			0
7.	Derivatives (Schedule DB)			0
8.	Other invested assets (Schedule BA)			0
9.	Receivables for securities			0
10.	Securities lending reinvested collateral assets (Schedule DL)			0
11.	Aggregate write-ins for invested assets			
12.	Subtotals, cash and invested assets (Lines 1 to 11)			
13.	Title plants (for Title insurers only)			
14.	Investment income due and accrued			
15.	Premiums and considerations:			
	15.1 Uncollected premiums and agents' balances in the course of collection	1.498.849	2.284.801	
	15.2 Deferred premiums, agents' balances and installments booked but deferred and not yet due			
	15.3 Accrued retrospective premiums and contracts subject to redetermination			
16.	Reinsurance:			
	16.1 Amounts recoverable from reinsurers			0
	16.2 Funds held by or deposited with reinsured companies			
	16.3 Other amounts receivable under reinsurance contracts			
17	Amounts receivable relating to uninsured plans			
	Current federal and foreign income tax recoverable and interest thereon		20,017,000	0
	Net deferred tax asset			
19.	Guaranty funds receivable or on deposit			
20.	Electronic data processing equipment and software			
21.	Furniture and equipment, including health care delivery assets			
22.	Net adjustment in assets and liabilities due to foreign exchange rates			
23.	Receivable from parent, subsidiaries and affiliates			
24.	Health care and other amounts receivable			
25.	Aggregate write-ins for other than invested assets	1,908,535	1,240,300	(007,949
26.	Total assets excluding Separate Accounts, Segregated Accounts and Protected Cell Accounts (Lines 12 to 25)	50,576,611	42,590,794	(7,985,817
27.	From Separate Accounts, Segregated Accounts and Protected Cell Accounts			
28.	Total (Lines 26 and 27)	50,576,611	42,590,794	
	DETAILS OF WRITE-INS	, , ,	, , .	, , , , , ,
1101.	527/1125 01 7/1/12 11/15			
1102.				
1103.				
1198.	Summary of remaining write-ins for Line 11 from overflow page		0	
		0	0	0
1199.	Totals (Lines 1101 thru 1103 plus 1198)(Line 11 above) Prepaid expenses			-
2501.				
2502.	Miscellaneous receivables	, ,	,	,
2503.				
2598.	Summary of remaining write-ins for Line 25 from overflow page	J0	0	0

EXHIBIT 1 - ENROLLMENT BY PRODUCT TYPE FOR HEALTH BUSINESS ONLY

				Total Members at End of			6
	Source of Enrollment	1 Prior Year	2 First Quarter	3 Second Quarter	4 Third Quarter	5 Current Year	Current Year Member Months
	Course of Empliment	Thor roa	1 not Quartor	CCCONG Quartor	Time Quartor	Guiront Tour	Womber World
1	. Health Maintenance Organizations	23,281	33,350	32,747	31,902	31,522	390,521
2	Provider Service Organizations						
3	Preferred Provider Organizations	270,700	256,050	253,205	252,672	250,281	3,044,910
4	Point of Service	62,971	45 , 133	44,857	44,340	44,076	537,775
5	Indemnity Only	24,652	24,023	23,866	23,709	23,257	286, 182
6	Aggregate write-ins for other lines of business	25,936	21,986	21,918	21,509	20,758	259,596
7	. Total	407,540	380,542	376,593	374,132	369,894	4,518,984
	DETAILS OF WRITE-INS						
0601	Consumer Driven Health Products	25,619	21,260	21,131	20,674	20,067	250, 162
0602	Disability and Accident	317	726	787	835	691	9,434
0603							
0698	. Summary of remaining write-ins for Line 6 from overflow page	0	0	0	0	0	0
0699	. Totals (Lines 0601 thru 0603 plus 0698) (Line 6 above)	25,936	21,986	21,918	21,509	20,758	259,596

1. Summary of Significant Accounting Policies and Going Concern

A. Accounting Practices

The accompanying financial statements of Anthem Health Plans of Maine, Inc. (the "Company") have been prepared in conformity with the National Association of Insurance Commissioners' ("NAIC") *Annual Statement Instructions* and in accordance with accounting practices prescribed by the NAIC *Accounting Practices and Procedures Manual* ("NAIC SAP"), subject to any deviations prescribed or permitted by the Maine Bureau of Insurance ("Bureau").

A reconciliation of the Company's net income (loss) and capital and surplus between NAIC SAP and practices prescribed and permitted by the Bureau is shown below:

		SSAP#	F/S Page	F/S Line#	2022	2021
Net	<u>Income</u>					
(1)	Anthem Health Plans of Maine, Inc. state basis (Page 4, Line 32, Columns 2 & 3)	XXX	XXX	XXX	\$ 55,351,002	\$ 29,225,123
(2)	State Prescribed Practices that is an increase/(decrease) from NAIC SAP:					
(3)	State Permitted Practices that is an increase/(decrease) from NAIC SAP:					
(4)	NAIC SAP (1-2-3=4)	XXX	XXX	XXX	\$ 55,351,002	\$ 29,225,123
Sur	<u>plus</u>					
(5)	Anthem Health Plans of Maine, Inc. state basis (Page 3, Line 33, Columns 3 & 4)	XXX	XXX	XXX	\$153,627,228	\$146,289,952
(6)	State Prescribed Practices that is an increase/(decrease) from NAIC SAP:					
(7)	State Permitted Practices that is an increase/(decrease) from NAIC SAP:					
(8)	NAIC SAP (5-6-7=8)	XXX	XXX	XXX	\$153,627,228	\$146,289,952

B. Use of Estimates in the Preparation of the Financial Statements

Preparation of financial statements requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

C. Accounting Policies

Health premiums are earned over the term of the related insurance policies and reinsurance contracts. Premiums written are reported net of excess loss reinsurance ceded and experience rating refunds. Unearned premium reserves are established to cover the unexpired portion of premiums written and are computed by pro rata methods for direct business and based on reports received from ceding companies for reinsurance. Premiums paid by subscribers prior to the effective date are recorded on the balance sheet as premiums received in advance and are subsequently credited to income as earned during the coverage period. Premium rates for certain lines of business are subject to approval by the Bureau. Expenses incurred in connection with acquiring new insurance business, including acquisition costs such as sales commissions, are charged to operations as incurred. All other costs, including underwriting expenses, are charged to operations as incurred.

In addition, the Company uses the following accounting policies:

- (1) Short-term investments include investments with maturities of less than one year and more than three months at the date of acquisition and are reported at amortized cost, which approximates fair value. Non-investment grade short-term investments are stated at the lower of amortized cost or fair value.
- (2) Investment grade bonds not backed by other loans are stated at amortized cost, with amortization calculated based on the modified scientific method, using lower of yield to call or yield to maturity. Non-investment grade bonds are stated at the lower of amortized cost or fair value as determined by various third-party pricing sources.
- (3) The Company has no investments in common stocks of unaffiliated companies.
- (4) The Company has no investments in preferred stocks.
- (5) The Company has no mortgage loans real estate.
- (6) Loan-backed securities are stated at amortized cost. Prepayment assumptions for loan-backed securities and structured securities were obtained from broker-dealer survey values or internal estimates. These assumptions are consistent with the current interest rate and economic environment. The retrospective adjustment method is used to value all loan-backed securities. Non-investment grade loan-backed securities are stated at the lower of amortized cost or fair value.
- (7) The Company has no investments in subsidiaries, controlled and affiliated companies.
- (8) The Company has no investments in joint ventures, partnerships or limited liability companies.
- (9) The Company has no derivative instruments.
- (10) The Company recognizes losses from other-than-temporary impairments ("OTTI") of investments in accordance with Statements of Standard Accounting Practice ("SSAP") No. 26R, *Bonds*; and SSAP No. 30, *Common Stock*; and SSAP No. 32R, *Preferred Stock*.
- (11) The Company does not anticipate investment income as a factor in premium deficiency calculations.
- (12) Unpaid claims and claims adjustment expenses include management's best estimate of amounts based on historical claim development patterns and certain individual case estimates. The established liability considers health benefit provisions, business practices, economic conditions and other factors that may materially affect the cost, frequency and severity of claims. Liabilities for unpaid claims and claim adjustment expenses are based on assumptions and estimates, and while management believes such estimates are reasonable, the ultimate liability may be in excess of or less than the amount provided. The methods for making such estimates and for establishing the resulting liabilities are continually reviewed and changes in estimates are incorporated into current period estimates.
- (13) The Company has not modified its capitalization policy from the prior period.
- (14) Pharmacy rebate receivables are recorded when earned based upon actual rebate receivables billed and an estimate of receivables based upon current utilization of specific pharmaceuticals and provider contract terms.
- (15) Service fees earned from providing administrative services to self-insured customers are deducted from operating expenses, and related claim payments and subsequent reimbursements of those claim payments are excluded from net income.
- (16) Premium under the Federal Employee Program ("FEP") is earned when chargeable benefit costs, allowable expenses and retentions are incurred. Deferred premiums are recorded to offset the FEP liabilities for incurred claims but not reported and claims adjustment expenses that are due from the Office of Personnel Management ("OPM"), when the claims are ultimately paid.
- (17) A discount rate is applied to guaranty fund liabilities and assets related to assessments from insolvencies of entities that wrote long-term care contracts.

D. Going Concern

Not applicable.

2. Accounting Changes and Corrections of Errors

There were no accounting changes or corrections of errors during the years ended December 31, 2022 and 2021.

3. Business Combinations and Goodwill

A. Statutory Purchase Method

Not applicable.

B. Statutory Merger

Not applicable.

C. Assumption Reinsurance

Not applicable.

D. Impairment Loss

Not applicable.

E. Subcomponents and Calculation of Adjusted Surplus and Total Admitted Goodwill

Not applicable.

4. Discontinued Operations

The Company had no operations that were discontinued during 2022 or 2021.

5. Investments

A. Mortgage Loans, including Mezzanine Real Estate Loans

The Company did not have investments in mortgage loans at December 31, 2022 or 2021.

B. Debt Restructuring

The Company did not have invested assets that were restructured debt at December 31, 2022 or 2021.

C. Reverse Mortgages

The Company did not have investments in reverse mortgages at December 31, 2022 or 2021.

D. Loan-Backed Securities

(1) Prepayment assumptions for single-class and multi-class mortgage-backed and asset-backed securities were obtained from broker-dealer survey values or internal estimates. The Company used various third-party pricing sources in determining the market value of its loan-backed securities.

(2) The following OTTI were recognized during the year on loan-backed securities:

		(1)		(2)	(3)
		ortized Cost asis Before OTTI	R	OTTI Recognized in Loss	Fair Value 1 - 2
OTT	Trecognized 1st Quarter				
a.	Intent to sell	\$ _	\$	_	\$ _
b.	Inability or lack of intent to retain the investment in the security for a period of time sufficient to recover the amortized cost basis	\$ _	\$	_	\$ _
c.	Total 1st Quarter	\$ _	\$	_	\$
ОТТ	T recognized 2nd Quarter				
d.	Intent to sell	\$ _	\$	_	\$ _
e.	Inability or lack of intent to retain the investment in the security for a period of time sufficient to recover the amortized cost basis	\$ 3,637,507	\$	598,710	\$ 3,038,797
f.	Total 2nd Quarter	\$ 3,637,507	\$	598,710	\$ 3,038,797
OTT	Trecognized 3rd Quarter				
g.	Intent to sell	\$ _	\$	_	\$ _
h.	Inability or lack of intent to retain the investment in the security for a period of time sufficient to recover the amortized cost basis	\$ _	\$	_	\$ _
i.	Total 3rd Quarter	\$ _	\$	_	\$
ОТТ	T recognized 4th Quarter				
j.	Intent to sell	\$ _	\$	_	\$ _
k.	Inability or lack of intent to retain the investment in the security for a period of time sufficient to recover the amortized cost basis	\$ 2,962,942	\$	250,686	\$ 2,712,256
1.	Total 4th Quarter	\$ 2,962,942	\$	250,686	\$ 2,712,256
m.	Annual aggregate total		\$	849,396	

(3) The table below illustrates, by security and in the aggregate, the effects of OTTI on the Company's loan-backed securities for the year ended December 31, 2022. All the loan-backed securities where OTTI was recognized are categorized such that the present value of cash flows expected to be collected is less than the amortized cost basis of the security.

1 CUSIP	2 Book/Adjusted Carrying Value Amortized Cost Before Current Period OTTI	Projected	4 Recognized OTTI	5 Amortized Cost After OTTI	6 Fair Value at time of OTTI	7 Date of Financial Statement Where Reported
3622EBAB4	\$ 1,684,869	\$1,494,383	\$ 190,486	\$1,494,383	\$1,284,661	6/30/2022
2254W0NZ4	1,952,638	1,544,414	408,224	1,544,414	1,357,156	6/30/2022
2254W0NZ4	1,488,697	1,355,993	132,705	1,355,992	1,144,679	12/31/2022
3622EBAB4	1,474,245	1,356,264	117,981	1,356,264	1,133,193	12/31/2022
Total			\$ 849,396	:		

(4) All impaired securities (fair value is less than cost or amortized cost) for which an other-than-temporary impairment has not been recognized in earnings as a realized loss (including securities with a recognized other-than-temporary impairment for non-interest related declines when a non-recognized interest related impairment remains):

a. The aggregate amount of unrealized losses:

The aggregate related fair value of securities with unrealized losses:

1. 2.	Less than 12 Months 12 Months or Longer	*	(3,570,113) (5,133,506)
1.	Less than 12 Months	*	66,066,878
2.	12 Months or Longer	\$	41,859,741

(5) The Company's bond portfolio is sensitive to interest rate fluctuations, which impact the fair value of individual securities. Unrealized losses on bonds were primarily caused by the effects of the interest rate environment and the widening of credit spreads on certain securities. The Company currently has the ability and intent to hold these securities until their full cost can be recovered. Therefore, the Company does not believe the unrealized losses represent an OTTI at December 31, 2022 or 2021.

E. Dollar Repurchase Agreements and/or Securities Lending Transactions

- (1) The Company did not enter into repurchase agreements at December 31, 2022 or 2021.
- (2) The Company participates in a securities lending program whereby marketable securities in its investment portfolio are transferred to independent brokers or dealers based on, among other things, their creditworthiness in exchange for collateral initially equal to at least 102% of the market value of the loaned securities. The Company receives the collateral in cash or securities, and if cash is received the cash collateral is thereafter invested according to guidelines of the Company's Investment Policy.

(3) Collateral Received

b.

a. Aggregate amount collateral received

			Fair Value
1.	Secu	rrities Lending	
	(a)	Open	\$ 14,362,120
	(b)	30 days or less	
	(c)	31 to 60 days	
	(d)	61 to 90 days	
	(e)	Greater than 90 days	 <u> </u>
	(f)	Sub-total	\$ 14,362,120
	(g)	Securities received	 1,305,589
	(h)	Total collateral received	\$ 15,667,709

- 2. Dollar repurchase agreement Not applicable.
- b. The fair value of that collateral and of the portion of that collateral that it has sold or repledged \$ 15,667,709
- c. The Company receives cash collateral in an amount in excess of fair value of the securities lent. The Company reinvests the cash collateral according to guidelines of the Company's Investment Policy.
- (4) The Company does not have any securities lending transactions administered by an affiliated agent.

(5) Collateral Reinvestment

a. Aggregate amount collateral reinvested

			Amortized Cost		<u>Fair Value</u>	
1.	Secu	rities Lending				
	(a)	Open	\$	_	\$	_
	(b)	30 days or less		4,536,444		4,537,822
	(c)	31 to 60 days		5,352,846		5,353,007
	(d)	61 to 90 days		1,437,577		1,437,869
	(e)	91 to 120 days		846,887		847,347
	(f)	121 to 180 days		1,150,733		1,150,947
	(g)	181 to 365 days		1,034,366		1,035,128
	(h)	1 to 2 years		_		_
	(i)	2 to 3 years				_
	(j)	Greater than 3 years				<u> </u>
	(k)	Sub-total	\$	14,358,853	\$	14,362,120
	(1)	Securities received		1,305,589		1,305,589
	(m)	Total collateral reinvested	\$	15,664,442	\$	15,667,709

- 2. Dollar repurchase agreement Not applicable.
- b. Not applicable.
- (6) Not applicable.
- (7) Not applicable.

F. Repurchase Agreements Transactions Accounted for as Secured Borrowing

The Company did not enter into repurchase agreement transactions accounted for as secured borrowing at December 31, 2022 or 2021.

G. Reverse Repurchase Agreements Transactions Accounted for as Secured Borrowing

The Company did not enter into reverse repurchase agreement transactions accounted for as a secured borrowing at December 31, 2022 or 2021.

H. Repurchase Agreements Transactions Accounted for as a Sale

The Company did not enter into repurchase agreement transactions accounted for as a sale at December 31, 2022 or 2021.

I. Reverse Repurchase Agreements Transactions Accounted for as a Sale

The Company did not enter into reverse repurchase agreement transactions accounted for as a sale at December 31, 2022 or 2021.

J. Real Estate

- (1) The Company recognized an impairment loss on its investment in real estate of \$22,149 at December 31, 2022 and did not recognize any impairment losses at December 31, 2021.
- (1) On July 30, 2015, the Company sold its real estate investment in its office building located at 2 Gannett Drive in South Portland, Maine to WPME001, LLC, a Maine limited liability company, for \$25,800,000. Concurrently, the Company leased back the 2 Gannett Drive in South Portland, Maine office building under a 12 year year lease agreement with four optional 5-year renewal periods. In accordance with

statutory accounting principles, the Company accounted for the transaction as a sale-leaseback settled entirely in cash, and recognized the entire gain directly to special surplus funds. The recognized gain to special surplus funds of \$15,466,022 is being amortized to unassigned surplus on a straight-line basis over the 12 year life of the lease. This amount will be reported as a realized capital gain in each year in the statements of revenue and expenses. The amount of realized gain in the statements of revenue and expenses recognized was \$1,288,835 and \$1,288,835 in 2022 and 2021, respectively.

- (2) Not applicable.
- (3) The Company did not engage in retail land sales operations during 2022 or 2021.
- (4) Not applicable.

K. Investments in Low-Income Housing Tax Credits

The Company did not invest in properties generating low-income housing tax credits during 2022 or 2021.

L. Restricted Assets

(1) Restricted assets (including pledged)

		1	2	3	4	5	6	7
Res	stricted Asset Category	Total Gross (Admitted & Nonadmitted) Restricted from Current Year	Total Gross (Admitted & Nonadmitted) Restricted from Prior Year	Increase/ (Decrease) (1 minus 2)	Total Current Year Nonadmitted Restricted	Total Current Year Admitted Restricted (1 minus 4)	Gross Admitted and Nonadmitted Restricted to Total Assets (a)	Admitted Restricted to Total Admitted Assets (b)
a.	Subject to contractual obligation for which liability is not shown	\$ —	\$ —	\$ —	s —	s —	0.00 %	0.00 %
b.	Collateral held under security lending agreements	15,664,442	19,853,982	(4,189,540)	_	\$15,664,442	1.98 %	2.12 %
c.	Subject to repurchase agreements	_	_	_	_	s —	0.00 %	0.00 %
d.	Subject to reverse repurchase agreements	_	_	_	_	s —	0.00 %	0.00 %
e.	Subject to dollar repurchase agreements	_	_	_	_	s —	0.00 %	0.00 %
f.	Subject to dollar reverse repurchase agreements	_	_	_	_	s —	0.00 %	0.00 %
g.	Placed under option contracts	_	_	_	_	\$ —	0.00 %	0.00 %
h.	Letter stock or securities restricted as to sale-excluding FHLB capital stock	_	_	_	_	\$ —	0.00 %	0.00 %
i.	FHLB capital stock	_	_	_	_	\$ —	0.00 %	0.00 %
j.	On deposit with states	830,197	850,725	(20,528)	_	\$ 830,197	0.10 %	0.11 %
k.	On deposit with other regulatory bodies	_	_	_	_	s —	0.00 %	0.00 %
1.	Pledged as collateral to FHLB (including assets backing funding agreements)	_	_	_	_	\$ —	0.00 %	0.00 %
m.	Pledged as collateral not captured in other categories	_	_	_	_	\$ —	0.00 %	0.00 %
n.	Other restricted assets	_	_	_	_	\$ —	0.00 %	0.00 %
0.	Total Restricted Assets	\$ 16,494,639	\$ 20,704,707	\$(4,210,068)	\$ —	\$16,494,639	2.08 %	2.23 %

- (a) Column 1 divided by Asset Page, Column 1, Line 28
- (b) Column 5 divided by Asset Page, Column 3, Line 28
- (2) Not applicable.
- (3) Not applicable.

(4) Collateral Received and Reflected as Assets Within the Reporting Entity's Financial Statements

		1	2	3	4	
	Collateral Assets	Book/ Adjusted Carrying Value (BACV)	Fair Value	% of BACV to Total Assets (Admitted and Nonadmitted*)	% of BACV to Total Admitted Assets **	
a.	Cash	\$ —	\$ —	— %	— %	
b.	Schedule D, Part 1	_			_	
c.	Schedule D, Part 2 Section 1	_	_		_	
d.	Schedule D, Part 2 Section 2			_	_	
e.	Schedule B	_	_		_	
f.	Schedule A	_			_	
g.	Schedule BA, Part 1	_	_	_	_	
h.	Schedule DL, Part 1	15,664,442	15,667,709	1.98	2.12	
i.	Other		<u> </u>		<u> </u>	
j.	Total Collateral Assets (a+b+c+d+e+f+g+h+i)	\$ 15,664,442	\$15,667,709	1.98 %	2.12 %	

^{*} Column 1 divided by Asset Page, Line 26 (Column 1)

^{**} Column 1 divided by Asset Page, Line 26 (Column 3)

		<u>1</u>	<u>2</u>
		Amount	% of Liability to Total Liabilities *
k.	Recognized Obligation to Return Collateral Asset	\$ 15,664,442	2.7 %

^{*} Column 1 divided by Liability Page, Line 24 (Column 3)

M. Working Capital Finance Investments

The Company did not have any working capital finance investments at December 31, 2022 and 2021.

N. Offsetting and Netting of Assets and Liabilities

The Company did not have any offsetting or netting of assets and liabilities at December 31, 2022 and 2021.

O. 5GI Securities

The Company has no 5GI Securities as of December 31, 2022 and 2021.

P. Short Sales

The Company did not have any short sales at December 31, 2022 and 2021.

Q. Prepayment Penalty and Acceleration Fees

	General Account		
(1) Number of CUSIPs		3	
(2) Aggregate Amount of Investment Income	\$	36,818	

R. Reporting Entity's Share of Cash Pool by Asset Type

The Company did not participate in a cash pool at December 31, 2022 or 2021.

6. Joint Ventures, Partnerships and Limited Liability Companies

- **A.** The Company has no investments in joint ventures, partnerships or LLCs.
- **B.** Not applicable.

7. Investment Income

- **A.** All investment income due and accrued with amounts that are over 90 days past due is non-admitted.
- **B.** At December 31, 2022 and 2021 there was no nonadmitted accrued investment income.

8. Derivative Instruments

The Company has no derivative instruments.

9. Income Taxes

A. The components of net deferred tax assets (liabilities):

(g) Net Admitted Deferred Tax Asset/(Net Deferred Tax

Liability) (1e - 1f)

(1) The components of net deferred tax asset (liabilities) are as follows:

The components of net deferred tax asset (liabilities) are as follows:							
			12/31/2022				
		(1)	(2)	(3)			
		Ordinary	Capital	(Col 1+2) Total			
(a) (b)	Gross Deferred Tax Assets	\$ 24,009,237	\$ 250,894	\$ 24,260,131			
(c)	Statutory Valuation Allowance Adjustments Adjusted Gross Deferred Tax Assets (1a - 1b)	24,009,237	250,894	24,260,131			
(d)	Deferred Tax Assets Nonadmitted	24,009,237	230,694	24,200,131			
(e)	Subtotal Net Admitted Deferred Tax Asset (1c - 1d)	24,009,237	250,894	24,260,131			
(f)	Deferred Tax Liabilities	25,252,062	271,601	25,523,663			
(g)	Net Admitted Deferred Tax Asset/(Net Deferred Tax Liability) (1e - 1f)	\$ (1,242,825)	\$ (20,707)	\$ (1,263,532)			
			12/31/2021				
		(4)	(5)	(6)			
		Ordinary	Capital	(Col 4+5) Total			
(a)	Gross Deferred Tax Assets	\$ 20,424,449	\$ 136,487	\$ 20,560,936			
(b)	Statutory Valuation Allowance Adjustments						
(c)	Adjusted Gross Deferred Tax Assets (1a - 1b)	20,424,449	136,487	20,560,936			
(d)	Deferred Tax Assets Nonadmitted			<u> </u>			
(e)	Subtotal Net Admitted Deferred Tax Asset (1c - 1d)	20,424,449	136,487	20,560,936			
(f)	Deferred Tax Liabilities	11,934,222	98,897	12,033,119			

\$ 8,490,227 \$ 37,590 \$ 8,527,817

	Change	
(7)	(8)	(9)
(Col 1-4) Ordinary	(Col 2-5) Capital	(Col 7+8) Total

- (a) Gross Deferred Tax Assets
- (b) Statutory Valuation Allowance Adjustments
- (c) Adjusted Gross Deferred Tax Assets (1a 1b)
- (d) Deferred Tax Assets Nonadmitted
- (e) Subtotal Net Admitted Deferred Tax Asset (1c 1d)
- (f) Deferred Tax Liabilities
- (g) Net Admitted Deferred Tax Asset/(Net Deferred Tax Liability) (1e 1f)

\$ 3,584,788	\$ 114,407	3,699,195
3,584,788	114,407	3,699,195
_	_	_
3,584,788	114,407	3,699,195
13,317,840	172,704	13,490,544
\$ (9,733,052)	\$ (58,297) \$	5 (9,791,349)

(2) The amount of admitted adjusted gross deferred tax assets under each component of SSAP No. 101, *Income Taxes* ("SSAP No. 101") are as follows:

		12/31/2022		
		(1)	(2)	(3)
		Ordinary	Capital	(Col 1+2) Total
Adr	nission Calculation Components SSAP No. 101		·	
(a) (b)	Federal Income Taxes Paid in Prior Years Recoverable Through Loss Carrybacks. Adjusted Gross Deferred Tax Assets Expected To Be Realized	\$ 13,695,873	\$ 83,631	\$ 13,779,504
	(Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 Below) 1. Adjusted Gross Deferred Tax Assets Expected To Be	8,987,608	167,263	9,154,871
	Realized Following the Balance Sheet Date.	8,987,608	167,263	9,154,871
	Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold.	XXX	XXX	23,044,084
(c)	Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Liabilities.	1,325,756	_	1,325,756
(d)	Deferred Tax Assets Admitted as the result of application of SSAP No. 101. Total $(2(a) + 2(b) + 2(c))$	\$ 24,009,237	\$ 250,894	\$ 24,260,131
			12/21/2021	
		(4)	(5)	(6)
				(Col 4+5)
Adr	nission Calculation Components SSAP No. 101	Ordinary	Capital	Total
(a)	Federal Income Taxes Paid in Prior Years Recoverable Through Loss Carrybacks. Adjusted Gross Deferred Tax Assets Expected To Be Realized	\$ 18,927,713	\$ 77,993	\$ 19,005,706
	(Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 Below) 1. Adjusted Gross Deferred Tax Assets Expected To Be	288,617	38,996	327,613
	Realized Following the Balance Sheet Date. 2. Adjusted Gross Deferred Tax Assets Allowed per	288,617	38,996	327,613
(2)	Limitation Threshold.	XXX	XXX	20,664,320
(c)	Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Liabilities.	1,208,119	19,498	1,227,617
(u)	Deferred Tax Assets Admitted as the result of application of SSAP No. 101. Total $(2(a) + 2(b) + 2(c))$	\$ 20,424,449	\$ 136,487	\$ 20,560,936
			Change	
		(7)	(8)	(9)
		(Col 1-4) Ordinary	(Col 2-5) Capital	(Col 7+8) Total
Adr	nission Calculation Components SSAP No. 101		·	
(a) (b)	Federal Income Taxes Paid in Prior Years Recoverable Through Loss Carrybacks. Adjusted Gross Deferred Tax Assets Expected To Be Realized	\$ (5,231,840)	\$ 5,638	\$ (5,226,202)
	(Excluding The Amount Of Deferred Tax Assets From 2(a) above) After Application of the Threshold Limitation. (The Lesser of 2(b)1 and 2(b)2 Below)	8,698,991	128,267	8,827,258
	Adjusted Gross Deferred Tax Assets Expected To Be Realized Following the Balance Sheet Date. Defending the Balance Sheet Date.	8,698,991	128,267	8,827,258
, .	Adjusted Gross Deferred Tax Assets Allowed per Limitation Threshold.	XXX	XXX	2,379,764
(c)	Adjusted Gross Deferred Tax Assets (Excluding The Amount Of Deferred Tax Assets From 2(a) and 2(b) above) Offset by Gross Deferred Tax Liabilities.	117,637	(19,498)	98,139
(d)	Deferred Tax Assets Admitted as the result of application of SSAP No. 101. Total $(2(a) + 2(b) + 2(c))$	\$ 3,584,788	\$ 114,407	\$ 3,699,195

(3) 2022 2021 (a) Ratio Percentage Used To Determine Recovery Period And Threshold Limitation Amount. 687.18 % 611.94 % (b) Amount Of Adjusted Capital And Surplus Used To Determine Recovery Period And Threshold Limitation In 2(b)2 Above. 153,627,228 \$ 137,762,135 (4) 12/31/2022 12/31/2021 Change (1) **(4)** (2) (3) (5) (6)(Col 1-3) Ordinary (Col 2-4) **Ordinary Ordinary** Capital Capital Capital Impact of Tax-Planning Strategies Determination of Adjusted Gross Deferred Tax Assets and Net Admitted Deferred Tax Assets, By Tax Character As A Percentage. Adjusted Gross DTAs Amount From Note 9A1(c) \$24,009,237 \$250,894 \$20,424,449 \$136,487 \$ 3,584,788 \$114,407 Percentage of Adjusted Gross DTAs By Tax Character Attributable To The Impact Of Tax Planning Strategies 0.00 % 0.00~%0.00%0.00~%0.00~%0.00~%Net Admitted Adjusted Gross DTAs Amount From Note 9A1(e) \$24,009,237 \$250,894 \$20,424,449 \$136,487 \$ 3,584,788 Percentage of Net Admitted Adjusted Gross DTAs By Tax Character Admitted Because Of The Impact Of Tax 0.00 % 0.00 % 0.00 % 0.00 % 0.00 % 0.00 % Planning Strategies (b) Does the Company's tax-planning strategies include the use of reinsurance? Yes No

B. The Company has no unrecognized deferred tax liabilities at December 31, 2022 and 2021.

C. Current income taxes incurred consist of the following major components:

					(1)		(2)	г	(2)
					(1)		(2)		(3)
					12/31/2022	1	2/31/2021		(Col 1-2) Change
(1)	Cur	rent Iı	ncome Tax	_					
		Fede Fore		\$	(993,635)	\$	15,431,114	\$	(16,424,749)
		Subt	-		(993,635)		15,431,114		(16,424,749)
			eral income tax expense on net capital gains		(75,954)		(59,529)		(16,425)
	(e)		zation of capital loss carry-forwards		_		_		_
	(f)	Othe	· · · · · · · · · · · · · · · · · · ·		_		_		_
	(g)	Fede	eral and foreign income taxes incurred	\$	(1,069,589)	\$	15,371,585	\$	(16,441,174)
(2)			Tax Assets:						
	(a)	Ordi	-	\$	200 501	ď	102 505	d.	(112.004)
		(1) (2)	Discounting of unpaid losses Unearned premium reserve	3	290,501 665,410	Э	403,505 849,366	3	(113,004) (183,956)
		(3)	Policyholder reserves		7,639,457		4,989,364		2,650,093
		(4)	Investments		T,037,437		ч, <i>7</i> 0 <i>7</i> , <i>3</i> 0ч		2,030,073
		(5)	Deferred acquisition costs		_		_		_
		(6)	Policyholder dividends accrual		_		_		_
		(7)	Fixed assets		377,752		114,850		262,902
		(8)	Compensation and benefits accrual		426,812		186,278		240,534
		(9)	Pension accrual		_		_		_
			Receivables - nonadmitted		10,025,067		8,758,287		1,266,780
			Net operating loss carry-forward		_		_		_
			Tax credit carry-forward						(520.561)
		(13)	Other (00) S have 1 (2 m = 52 1 d m = 1 2 12)		4,584,238		5,122,799		(538,561)
	(b)	State	(99) Subtotal (sum of 2a1 through 2a13) atory valuation allowance adjustment		24,009,237		20,424,449		3,584,788
	(b) (c)		admitted						
	(d)		nitted ordinary deferred tax assets (2a99 - 2b - 2c)		24,009,237		20,424,449		3,584,788
	(e)	Capi			21,000,207		20,121,119		2,00.,700
		(1)	Investments		250,894		136,487		114,407
		(2)	Net capital loss carry-forward		230,674		130,407		114,407
		(3)	Real estate		_		_		_
		(4)	Other		_		_		_
		()	(99) Subtotal (2e1+2e2+2e3+2e4)	_	250,894		136,487		114,407
	(f)	Statı	utory valuation allowance adjustment		, —		, —		, —
	(g)	Non	admitted		_		_		_
	(h)	Adn	nitted capital deferred tax assets (2e99 - 2f - 2g)		250,894		136,487		114,407
	(i)	Adn	nitted deferred tax assets (2d + 2h)	\$	24,260,131	\$	20,560,936	\$	3,699,195
(3)	Def		Tax Liabilities:						
	(a)	Ordi	nary						
		(1)	Investments	\$	_	\$	_	\$	_
		(2)	Fixed assets		_		_		_
		(3)	Deferred and uncollected premium		_		_		_
		(4)	Policyholder reserves		25 252 062		11.024.222		12 217 040
		(5)	Other (00) Substant (2-1+2-2+2-2+2-4+2-5)		25,252,062		11,934,222		13,317,840
	(L)	C	(99) Subtotal (3a1+3a2+3a3+3a4+3a5)		25,252,062		11,934,222		13,317,840
	(b)	Capi							
		(1)	Investments Real estate		_		_		
		(2) (3)	Other		271,601		98,897		172,704
		(3)	(99) Subtotal (3b1+3b2+3b3)		271,601		98,897		172,704
	(c)	Defe	erred tax liabilities (3a99 + 3b99)		25,523,663		12,033,119		13,490,544
(4)	` /		red tax assets/liabilities (2i - 3c)	\$	(1,263,532)	\$	8,527,817	\$	(9,791,349)
(+)	1401	acici	100 tax assets/11001111105 (21 - 30)	Φ	(1,203,332)	Ψ	0,227,017	ψ	(7,171,377)

D. The Company's income tax expense and change in deferred income taxes differs from the amount obtained by applying the federal statutory income tax rate of 21% for the year ended December 31 as follows:

 2022	2021
\$ 11,399,097 \$	9,365,308
(1,677,022)	(2,380,430)
(287,760)	(254,006)
(638,686)	(132,526)
366,952	_
(493,799)	1,053
\$ 8,668,782 \$	6,599,399
\$ (1,069,589) \$	15,371,585
9,738,371	(8,772,186)
\$ 8,668,782 \$	6,599,399
\$	\$ 11,399,097 \$ (1,677,022) (287,760) (638,686) 366,952 (493,799) \$ 8,668,782 \$ \$ (1,069,589) \$ 9,738,371

E. Operating loss carryforwards:

- (1) The Company has no operating loss carryforwards and no tax credit carryforwards as of December 31, 2022 or 2021.
- (2) The following are income taxes incurred in the current and prior year(s) that will be available for recoupment in the event of future net losses:

	Ordinary	Capital	Total
2022	- \$	— \$	_
2021	13,695,873	_	13,695,873
2020	N/A	661,220	661,220

- (3) The Company has no protective tax deposits reported as admitted assets under Section 6603 of the Internal Revenue Service Code as of December 31, 2022 and 2021.
- F. The following companies will be included in the consolidated federal income tax return with their parent Elevance Health, Inc. ("Elevance Health") as of December 31, 2022 and either are current members of the consolidated tax sharing agreement or are in the process of being added to the consolidated tax sharing agreement. Allocation of federal income taxes with affiliates subject to the tax sharing agreement is based upon separate income tax return calculations with credit for net losses that can be used on a consolidated basis. Pursuant to this agreement, the Company has the enforceable right to recoup federal income taxes paid in prior years in the event of future losses, which it may incur, or to recoup its net losses carried forward as an offset to future net income subject to federal income taxes. Intercompany income tax balances are settled based on the Internal Revenue Service due dates.

Alliance Care Management, LLC DeCare Dental Networks, LLC American Imaging Management, Inc. DeCare Dental, LLC America's 1st Choice of South Carolina, Inc. Designated Agent Company, Inc. AMERIGROUP Community Care of New Mexico, Inc. EHC Benefits Agency, Inc. AMERIGROUP Corporation Elevance Health Inc Amerigroup Delaware, Inc. Empire HealthChoice Assurance, Inc. Amerigroup District of Columbia, Inc. Empire HealthChoice HMO, Inc. Amerigroup Insurance Company Federal Government Solutions, LLC AMERIGROUP Iowa, Inc. FHC Health Systems, Inc. AMERIGROUP Maryland, Inc. Freedom Health, Inc. Amerigroup Mississippi, Inc. Freedom SPV, Inc. AMERIGROUP New Jersey, Inc. Golden West Health Plan, Inc. AMERIGROUP Ohio, Inc. Health Core, Inc. Amerigroup Oklahoma, Inc. Health Management Corporation Healthkeepers, Inc. Amerigroup Pennsylvania, Inc.

AMERIGROUP Tennessee, Inc. HealthLink HMO, Inc. AMERIGROUP Texas. Inc. HealthLink, Inc. HealthPlus HP, LLC AMERIGROUP Washington, Inc. HealthSun Health Plan, Inc. AMGP Georgia Managed Care Company, Inc.

Anthem Blue Cross Life and Health Insurance Company Healthy Alliance Life Insurance Company

HEP AP Holdings, Inc. Anthem Financial, Inc. Anthem Health Plans of Kentucky, Inc. HMO Colorado, Inc. Anthem Health Plans of Maine, Inc. HMO Missouri, Inc.

Anthem Health Plans of New Hampshire, Inc. IEC Group Holdings, Inc. Anthem Health Plans of Virginia, Inc. IEC Group, Inc. d/b/a AmeriBen

Anthem Health Plans, Inc. Imaging Management Holdings, LLC

Anthem Holding Corp. IngenioRx, Inc. Anthem Insurance Companies, Inc. Integra MLTC, Inc.

Anthem Kentucky Managed Care Plan, Inc. Legato Health Technologies U.S., Inc. Anthem Southeast, Inc. Living Complete Technologies, Inc.

Anthem UM Services, Inc. Massachusetts Behavioral Health Partnership

APR. LLC Matthew Thornton Health Plan, Inc.

Arcus Enterprises, Inc. Missouri Care, Incorporated myNEXUS Holdings, Inc. Aspire Health, Inc.

myNEXUS, Inc. Associated Group, Inc.

Beacon Health Financing, LLC myNEXUS Management, Inc. Beacon Health Options Care Services, Inc. Nash Holding Company, LLC Beacon Health Options Holdco, Inc. National Government Services, Inc. Beacon Health Options, Inc. New England Research Institutes, Inc.

Beacon Health Options of California, Inc. Optimum Healthcare, Inc. Beacon Health Options of Pennsylvania, Inc. OPTIONS Health Care, Inc. Beacon Health Vista Parent, Inc. Park Square Holdings, Inc.

BHS IPA LLC Park Square I, Inc. Blue Cross Blue Shield Healthcare Plan of Georgia, Inc. Park Square II, Inc.

Resolution Health, Inc. Blue Cross of California RightCHOICE Managed Care, Inc.

Blue Cross of California Partnership Plan, Inc. Rocky Mountain Hospital and Medical Service, Inc.

Carelon Digital Platforms, Inc. SellCore, Inc.

Blue Cross Blue Shield of Wisconsin

Carelon Holdings, Inc. Simply Healthcare Plans, Inc. Carelon Holdings I, Inc. Southeast Services, Inc. Carelon Insights, Inc. State Sponsored Services, Inc. Carelon PharmacvRx. Inc. The Elevance Health Companies, Inc.

CareMore Health IPA of New York, Inc. The Elevance Health Companies of California, Inc.

CareMore Health of Arizona, Inc. TrustSolutions, LLC

CareMore Health Plan UNICARE Health Plan of West Virginia, Inc.

CareMore Health Plan of Arizona, Inc. UNICARE Illinois Services, Inc.

CareMore Health Plan of Nevada, Inc. UNICARE Life & Health Insurance Company

CareMore Health Plan of Texas, Inc. UNICARE National Services, Inc. CareMore Health System UNICARE Specialty Services, Inc. Cerulean Companies, Inc. ValueOptions Federal Services, Inc. CHCS IPA, Inc. ValueOptions of New Jersey, Inc.

ValueOptions Texas, Inc. Claim Management Services, Inc.

WellPoint California Services Inc. Community Care Health Plan of Kansas, Inc. Community Care Health Plan of Nebraska, Inc. WellPoint Dental Services, Inc. WellPoint Health Solutions, Inc. Community Care Health Plan of Nevada, Inc. Community Insurance Company WellPoint Holding Corporation

WellPoint Information Technology Services, Inc. Compcare Health Services Insurance Corporation

Crossroads Acquisition Corp. WellPoint Insurance Services, Inc. DeCare Analytics, LLC WellPoint Military Care Corporation

DeCare Dental Health International, LLC Wisconsin Collaborative Insurance Company

G. Not applicable.

H. Repatriation Transition Tax (RTT)

Not applicable.

I. Alternative Minimum Tax (AMT) Credit

On August 16, 2022, the U.S. government enacted the Inflation Reduction Act which includes a new corporate alternative minimum tax (the "Corporate AMT") of 15% on the adjusted financial statement of income ("AFSI") of corporations with average AFSI exceeding \$1.0 billion over a three-year period. The Corporate AMT is effective beginning after December 31, 2022. The controlled group of corporations, of which the Company is a member, has determined it is an applicable corporation for purposes of determining if the Corporate AMT exceeds the regular federal income tax payable. The controlled group has determined that it does not expect to be subject to the Corporate AMT in 2023. The Company has determined that it would not be an applicable corporation on a stand-alone basis, therefore it does not expect to be subject to the Corporate AMT in 2023.

10. Information Concerning Parent, Subsidiaries, Affiliates and Other Related Parties

A. Nature of the Relationship

The Company is a Maine domiciled stock insurance company and is a wholly-owned subsidiary of ATH Holding Company, LLC ("ATH Holding") which is a wholly-owned subsidiary of Elevance Health, a publicly traded company. The shareholders of Elevance Health approved a proposal to amend its articles of incorporation to change the name to Elevance Health, Inc. from Anthem, Inc. The name change was effective June 27, 2022.

B. Significant Transactions for Each Period

The following significant transactions took place between the Company and its affiliates:

The Board of Directors of the Company declared an ordinary dividend in the amount of \$29,200,000 on December 15, 2022. The Company paid the dividend to its parent company, ATH Holding, on December 28, 2022.

The Board of Directors of the Company declared an ordinary dividend in the amount of \$35,000,000 on December 15, 2021. The Company paid the dividend to its parent company, ATH Holding, on December 28, 2021.

C. Transactions with Related Parties who are not Reported on Schedule Y

The Company has no transactions with related parties who are not reported on Schedule Y.

D. Amounts Due to or from Related Parties

At December 31, 2022, the Company reported no amounts due from affiliates. At December 31, 2022, the Company reported \$130,122,304 due to affiliates. At December 31, 2021, the Company reported \$54,436,870 due from affiliates. At December 31, 2021, the Company reported no amounts due to affiliates. The receivable and payable balances represent intercompany transactions that will be settled in accordance with the settlement terms of the intercompany agreement.

Following is a summary of transactions between the Company and various affiliates during the years:

	2022		2021	
The Anthem Companies Inc.				
Payroll and Employee Administrative Services	\$	64,008,919	\$ 60,478,841	
Elevance Health, Inc.				
Federal Income Tax Payments		20,182,860	10,439,152	
Corporate Services		25,881,624	19,965,248	
Information Technology Services		3,623,345	4,936,526	
Anthem Insurance Companies, Inc.				
Information Technology Services		622	1,547	
Corporate/Shared Services		497,125	606,801	
WellPoint Information Technology Services, Inc.				
Information Technology Services		4,541,236	4,215,559	
Corporate Services		602,471	188,069	
Blue Cross of California				
Corporate Services		44,992	74,852	
Information Technology Services		56	40	
Anthem Health Plans, Inc.				
Claims Processing		3,305	2,210	
Corporate Services		15,554	14,675	
Anthem Health Plans of New Hampshire, Inc.				
Corporate Services		(2,573)	43,063	
Anthem Health Plans of Virginia, Inc.				
Information Technology Services		2,425	8,746	
Corporate Services		(76,591)	(16,622)	
Costs allocated from other Elevance Health, Inc. affiliates not listed above		1,050,838	1,782,592	
Total Schedule Y, Part 2, Column 8	\$	120,376,208	\$ 102,741,299	

E. Management and Service Contracts and Cost Sharing Arrangements

The Company has entered into administrative services agreements with its affiliated companies. Pursuant to these agreements, various administrative, management and support services are provided to or provided by the Company. The costs and expenses related to these administrative management and support services are allocated to or allocated by the Company in an amount equal to the direct and indirect costs and expenses incurred in providing these services. Costs include expenses such as salaries, employee benefits, information technology, pharmacy benefits administration, communications, advertising, consulting services, rent, utilities, billing, accounting, underwriting, and product development, which support the Company's operations. These costs are allocated based on various utilization statistics.

In addition, the Company is party to the Fair Market Value ("FMV") Services Attachment, to the master administrative services agreement with affiliates, the costs and expenses related to certain services including behavioral health, palliative care, utilization management, payment integrity services, subrogation services as well as health and wellness programs are allocated to or allocated by the Company in an amount equal to the fair market value of the services provided. These costs are allocated based on various utilization statistics.

The Company is party to a cash concentration agreement with its affiliated companies. Under this agreement, any of the Company's affiliates may be designated as a cash manager to handle the collection and/or payment of funds on behalf of the Company. Conversely, the Company may be designated as a cash manager to handle the collection and/or payment of funds on behalf of its affiliates. Cash services covered under this agreement include the collection of premiums and other revenue, the collection of benefit

and administrative expense reimbursements, the payment of policy benefits, payroll expense, general and administrative expense, and accounts payable disbursements.

F. Guarantees or Contingencies for Related Parties

The Company did not enter into guarantees or undertakings for the benefit of an affiliate which would result in a material contingent exposure of the Company's or any affiliated insurer's assets or liabilities.

G. Nature of Control Relationships that Could Affect Operations or Financial Position

ATH Holding owns all outstanding shares of the Company. The Company's ultimate parent is Elevance Health.

H. Amount Deducted for Investment in Upstream Company

The Company does not own shares of upstream intermediate entities or Elevance Health.

I. Detail of Investments in Affiliates Greater than 10% of Admitted Assets

At December 31, 2022 and 2021, the Company did not have investments in affiliates.

J. Write-down for Impairments of Investments in Subsidiaries, Controlled or Affiliated ("SCA") Companies

Not applicable.

K. Investment in a Foreign Insurance Subsidiary

The Company does not have investments in foreign insurance subsidiaries.

L. Investment in Downstream Non-insurance Holding Companies

The Company does not have investments in downstream non-insurance holding companies.

M. All SCA Investments

The Company has no SCA Investments.

N. Investment in Insurance SCAs

The Company does not have investments in Insurance SCAs.

O. SCA or SSAP 48 Entity Loss Tracking

The Company does not have losses on investments in Insurance SCAs and/or joint ventures, partnerships or LLCs.

11. Debt

A. Capital Notes and Other Debt

The Company had no capital notes or other debt outstanding at December 31, 2022 and 2021.

B. FHLB (Federal Home Loan Bank) Agreements

The Company had no FHLB agreements outstanding at December 31, 2022 and 2021.

C. All Other Debt

The Company had no other debt outstanding at December 31, 2022 and 2021.

12. Retirement Plans, Deferred Compensation, Postemployment Benefits and Compensated Absences and Other Postretirement Benefit Plans

A. Defined Benefit Plan

Not applicable - See Note 12G.

- **B.** Not applicable See Note 12G.
- C. Not applicable See Note 12G.
- **D.** Not applicable See Note 12G.

E. Defined Contribution Plans

Not applicable - See Note 12G.

F. Multiemployer Plans

The Company does not participate in a multiemployer plan.

G. Consolidated/Holding Company Plans

The Company participates in frozen non-contributory defined benefit pension plans sponsored by ATH Holding, covering most employees of Elevance Health and its subsidiaries. ATH Holding allocates a share of the total accumulated costs of the plans to the Company based on the number of allocated employees. The Company has no legal obligation for benefits under these plans.

The Company participates in a postretirement medical benefit plan, sponsored by ATH Holding, providing certain health, life, vision and dental benefits to eligible retirees. ATH Holding allocates a share of the total accumulated costs of this plan to the Company based on the number of allocated employees. The Company has no legal obligation for benefits under this plan.

The Company participates in a nonqualified deferred compensation plan sponsored by Elevance Health which covers certain employees once the participant reaches the maximum contribution amount for the Elevance Health 401(k) Plan (the "401(k) Plan"). The deferred amounts are payable according to the terms and subject to the conditions of the deferred compensation plan. Elevance Health allocates a share of the total accumulated costs of this plan to the Company based on the number of allocated employees subject to the deferred compensation plan. The Company has no legal obligation for benefits under this plan.

The Company participates in the 401(k) Plan, sponsored by ATH Holding and covering substantially all employees. Voluntary employee contributions are matched by ATH Holding subject to certain limitations. ATH Holding allocates a share of the total accumulated costs of this plan to the Company based on the number of allocated employees. The Company has no legal obligation for benefits under this plan.

The Company participates in a stock incentive compensation plan, sponsored by Elevance Health, providing incentive awards to non-employee directors and employees, consisting of Elevance Health stock options, restricted stock, restricted stock units, stock appreciation rights, performance shares, and performance units. Elevance Health allocates a share of the total share-based compensation expense of this plan to the Company based on the number of allocated employees. The Company has no legal obligation for benefits under this plan.

During 2022 and 2021, the Company was allocated the following costs or (credits) for these retirement benefits:

	 2022	2021		
Defined benefit pension plan	\$ (109,266) \$	(139,094)		
Postretirement medical benefit plan	(68,034)	(83,456)		
Deferred compensation plan	10,097	16,228		
Defined contribution plan	1,040,378	1,228,199		
Stock incentive compensation plan	1,159,762	1,473,859		

H. Post Employment Benefits and Compensated Absences

Not applicable.

I. Impact of Medicare Modernization Act on Postretirement Benefits (INT 04-17)

Not applicable.

13. Capital and Surplus, Shareholders' Dividend Restrictions and Quasi-Reorganizations

A. Outstanding Shares

As of December 31, 2022, the Company has 2,500 shares of \$1,000 par value common stock authorized, issued and outstanding.

B. Preferred Stock

The Company has no preferred stock outstanding.

C. Dividend Restrictions

Under Maine law, the Company is limited in the amount of dividends that can be declared without regulatory approval. The Superintendent of Insurance must approve any dividend that, together with all dividends declared during the preceding twelve months, exceeds the greater of the net gain from operations for the twelve-month period ending December 31 of the preceding year or 10% of the Company's surplus to policyholders as of December 31 of the preceding year as long as unassigned surplus is positive. Also, any dividend paid from other than unassigned funds will need the approval of the Superintendent of Insurance.

D. Dividends Paid

See Footnote 10B.

E. Maximum Ordinary Dividend During 2023

Within the limitations of (C) above, the Company may pay \$55,351,002 in ordinary dividends during 2023 without restrictions, other than state notification requirements.

F. Unassigned Surplus Restrictions

Unassigned surplus funds are not restricted at December 31, 2022.

G. Mutual Surplus Advances

Not applicable.

H. Company Stock Held for Special Purpose

There are no shares of stock held for special purposes at December 31, 2022.

I. Changes in Special Surplus Funds

The change in balances of special surplus funds from the prior year are due to changes in the amounts segregated for the deferred gain on the Company's sale-leaseback transaction.

J. Changes in Unassigned Funds

There was no portion of unassigned funds represented by cumulative unrealized investment gains and losses at December 31, 2022.

K. Surplus Notes

The Company has not issued any surplus notes or debentures or similar obligations.

L. Restatement due to Prior Quasi-reorganizations

The Company had no restatements due to prior quasi-reorganizations.

M. Quasi-reorganizations over Prior 10 Years

The Company has not been involved in a quasi-reorganization during the past 10 years.

14. Liabilities, Contingencies and Assessments

A. Contingent Commitments

The Company had no contingent commitments at December 31, 2022 or 2021.

B. Assessments

(1) The Company is subject to guaranty fund and other assessments by the state in which it writes business. Guaranty fund assessments are accrued at the time of insolvencies. Other assessments are accrued either at the time of the assessment or at the time the losses are incurred.

(2) Guaranty Fund Assets Recognized Reconciliation

a. Guaranty fund assets recognized from paid and accrued premium tax offsets and policy surcharges prior year-end \$

120,194

b. Decreases current year:

Policy surcharges collected —
Policy surcharges charged off —
Promises to a first anglied —

Premium tax offset applied 33,429

c. Increases current year:

Policy surcharges recognized —
Premium tax offset recognized —

d. Guaranty fund assets recognized from paid and accrued premium tax offsets and policy surcharges current year-end

\$ 86,765

(3) Guaranty Fund Liabilities and Assets Related to Insolvencies of Entities That Wrote Long-Term Care Contracts

a. Discount Rate Applied

3.5%

b. The Undiscounted and Discounted Amount of the Guaranty Fund Assessments and Related Assets by Insolvency:

	Guaranty Fu	nd Assessment	Related Assets			
Name of the Insolvency	Undiscounted	Discounted	Undiscounted	Discounted		
Penn Treaty Network America Insurance Company and its subsidiary, American Network Insurance Company (collectively "Penn Treaty")	\$ 272,124	\$ 189,026	\$ 133,550	\$ 86,765		

c. Number of Jurisdictions, Ranges of Years Used to Discount and Weighted Average Number of Years of the Discounting Time Period for Payables and Recoverables by Insolvency:

	Payables			Recoverables			
Name of the Insolvency	Number of Jurisdictions			Number of Jurisdictions		Weighted Average Number of Years	
Penn Treaty	1	1 - 16	8.5	1	1 - 22	7.9	

C. Gain Contingencies

The Company has no gain contingencies at December 31, 2022 or 2021.

D. Claims-Related Extra Contractual Obligation and the Bad Faith Losses Stemming From Lawsuits

Not applicable.

E. Joint and Several Liabilities

Not applicable.

F. All Other Contingencies

Guaranty fund assessments

The National Organization of Life & Health Insurance Guaranty Associations, or NOLHGA, is a voluntary organization consisting of the state life and health insurance guaranty associations located throughout the U.S. Such associations, working together with NOLHGA, provide a safety net for their state's policyholders, ensuring that they continue to receive coverage, subject to state maximum limits, even if their insurer is declared insolvent. Under insolvency or guaranty association laws, insurance companies can be assessed for amounts paid by guaranty funds for policyholder losses incurred when an insurance company becomes insolvent. State insolvency or guaranty association laws currently provide for assessments based upon the amount of premiums received on insurance underwritten within such state (with a minimum amount payable even if no premium is received). Under these guaranty association laws, assessments are made retrospectively.

In March 2017, long term care insurance writers Penn Treaty Network America Insurance Company and its subsidiary American Network Insurance Company, (collectively "Penn Treaty"), were ordered to be liquidated by the Pennsylvania state court, which had jurisdiction over the Penn Treaty rehabilitation proceeding. The Company and other insurers have paid state guaranty association assessments and may be obligated to pay additional assessments to cover Penn Treaty policyholder claims. Payment of these assessments are largely recovered through premium tax credits over future years.

Litigation and regulatory proceedings

Blue Cross Blue Shield Antitrust Litigation

Elevance Health, Inc. (f/k/a Anthem, Inc.) is a defendant in multiple lawsuits that were initially filed in 2012 against the BCBSA and Blue Cross and/or Blue Shield licensees (the "Blue plans") across the country. Cases filed in twenty-eight states were consolidated into a single, multi-district proceeding captioned *In re Blue Cross Blue Shield Antitrust Litigation* that is pending in the U.S. District Court for the Northern District of Alabama (the "Court"). Generally, the suits allege that the BCBSA and the Blue plans have conspired to horizontally allocate geographic markets through license agreements, best efforts rules that limit the percentage of non-Blue revenue of each plan, restrictions on acquisitions, rules governing the BlueCard® and National Accounts programs and other arrangements in violation of the Sherman Antitrust Act ("Sherman Act") and related state laws. The cases were brought by two putative nationwide classes of plaintiffs, health plan subscribers and providers.

In April 2018, the Court issued an order on the parties' cross motions for partial summary judgment, determining that the defendants' aggregation of geographic market allocations and output restrictions are to be analyzed under a per se standard of review, and the BlueCard® program and other alleged Section 1 Sherman Act violations are to be analyzed under the rule of reason standard of review. With respect to whether the defendants operate as a single entity with regard to the enforcement of the Blue Cross Blue Shield trademarks, the Court found that summary judgment was not appropriate due to the existence of genuine issues of material fact. In April 2019, the plaintiffs filed motions for class certification, which defendants opposed.

The BCBSA and Blue plans approved a settlement agreement and release with the subscriber plaintiffs (the "Subscriber Settlement Agreement"), which agreement required the Court's approval to become effective. The Subscriber Settlement Agreement requires the defendants to make a monetary settlement payment and contains certain terms imposing non- monetary obligations including (i) eliminating the "national best efforts" rule in the BCBSA license agreements (which rule limits the percentage of non-Blue

revenue permitted for each Blue plan) and (ii) allowing for some large national employers with self-funded benefit plans to request a bid for insurance coverage from a second Blue plan in addition to the local Blue plan.

In November 2020, the Court issued an order preliminarily approving the Subscriber Settlement Agreement, following which members of the subscriber class were provided notice of the Subscriber Settlement Agreement and an opportunity to opt out of the class. A small number of subscribers submitted valid opt-outs by the July 2021 opt-out deadline. A fairness hearing was held in October 2021 and the Court took the request for final approval under advisement. In February 2022, the Court ordered the issuance of a supplemental notice to self-funded account class members. The notice process was completed in March 2022.

In August 2022, the Court issued a final order approving the Subscriber Settlement Agreement (the "Final Approval Order"). The Court amended its Final Approval Order in September 2022, further clarifying the injunctive relief that may be available to subscribers who submitted valid opt-outs. In September 2022, an objector filed a motion to amend the Final Approval Order, which the Court denied. In compliance with the Subscriber Settlement Agreement, Elevance Health paid \$506,000,000 into an escrow account in September 2022, for an aggregate and full settlement payment by Elevance Health of \$596,000,000. The Company recorded its estimated portion of the Subscriber Settlement Agreement, net of third party insurance cover, in 2020 and paid its remaining portion of the Subscriber Settlement Agreement in 2022.

Four notices of appeal of the Final Approval Order were filed by the September 2022 appeal deadline. Those appeals are proceeding in the United States Court of Appeals for the Eleventh Circuit. In the event that all appellate rights are exhausted in a manner that affirms the Court's Final Approval Order, the defendants' payment and non-monetary obligations under the Subscriber Settlement Agreement will become effective and the funds held in escrow will be distributed in accordance with the Subscriber Settlement Agreement.

In October 2020, after the Court lifted the stay as to the provider litigation, provider plaintiffs filed a renewed motion for class certification, which defendants opposed. In March 2021, the Court issued an order terminating the pending motion for class certification until the Court determines the standard of review applicable to the providers' claims. In May 2021, the defendants and provider plaintiffs filed renewed standard of review motions. In June 2021, the parties filed summary judgment motions not critically dependent on class certification. In February 2022, the Court issued orders (i) granting certain defendants' motion for partial summary judgment against the provider plaintiffs who had previously released claims against such defendants, and (ii) granting the provider plaintiffs' motion for partial summary judgment, holding that *Ohio v. American* Express Co. does not affect the standard of review in this case. In August 2022, the Court issued orders (i) granting in part the defendants' motion regarding the antitrust standard of review, holding that for the period of time after the elimination of the "national best efforts" rule, the rule of reason applies to the provider plaintiffs' market allocation conspiracy claims, and (ii) denying the provider plaintiffs' motion for partial summary judgment on the standard of review, reaffirming its prior holding that the providers' group boycott claims are subject to the rule of reason. In November 2022, the Court issued an order requiring the parties to submit supplemental briefs on certain questions related to providers' renewed motion for class certification. Elevance Health intends to continue to vigorously defend the provider litigation, which they believe is without merit, however, its ultimate outcome cannot be presently determined.

A number of follow-on cases involving entities that opted out of the Subscriber Settlement Agreement have been filed. Those actions are: *Alaska Air Group, Inc., et al. v. Anthem, Inc., et al.*, No. 2:21-cv-01209-AMM (N.D. Ala.); *JetBlue Airways Corp., et al. v. Anthem, Inc., et al.*, No. 2:22-cv-00558-GMB (N.D. Ala.); *Metropolitan*

Transportation Authority v. Blue Cross and Blue Shield of Alabama et al., No. 2:22-cv-00265-RDP (N.D. Ala.); Bed Bath & Beyond Inc. v. Anthem, Inc., No. 2:22-cv-01256-SGC (N.D. Ala.); Hoover, et al. v. Blue Cross Blue Shield Association, et al., No. 2:22-cv-00261-RDP (N.D. Ala.); and VHS Liquidating Trust v. Blue Cross of California, et al., No. RG21106600 (Cal. Super.). Elevance Health intends to continue to vigorously defend these follow-on cases, which they believe are without merit; however, their ultimate outcome cannot be presently determined.

Express Scripts, Inc. Pharmacy Benefit Management Litigation

In March 2016, Elevance Health, Inc. (f/k/a Anthem, Inc.) filed a lawsuit against Express Scripts, Inc. ("Express Scripts"), their vendor at the time for PBM services, captioned *Anthem, Inc. v. Express Scripts, Inc.*, in the U.S. District Court for the Southern District of New York (the "District Court"). The lawsuit seeks to recover over \$14,800,000,000 in damages for pharmacy pricing that is higher than competitive benchmark pricing under the agreement between the parties (the "ESI PBM Agreement"), over \$158,000,000 in damages related to operational breaches, as well as various declarations under the ESI PBM Agreement, including that Express Scripts: (i) breached its obligation to negotiate in good faith and to agree in writing to new pricing terms; (ii) was required to provide competitive benchmark pricing to Elevance Health through the term of the ESI PBM Agreement; (iii) has breached the ESI PBM Agreement; and (iv) is required under the ESI PBM Agreement to provide post-termination services, at competitive benchmark pricing, for one year following any termination.

Express Scripts has disputed Elevance Health's contractual claims and is seeking declaratory judgments: (i) regarding the timing of the periodic pricing review under the ESI PBM Agreement, and (ii) that it has no obligation to ensure that Elevance Health receives any specific level of pricing, that Elevance Health has no contractual right to any change in pricing under the ESI PBM Agreement and that its sole obligation is to negotiate proposed pricing terms in good faith. In the alternative, Express Scripts claims that Elevance Health has been unjustly enriched by its payment of \$4,675,000,000 at the time they entered into the ESI PBM Agreement. In March 2017, the District Court granted Elevance Health's motion to dismiss Express Scripts' counterclaims for (i) breach of the implied covenant of good faith and fair dealing, and (ii) unjust enrichment with prejudice. After such ruling, Express Scripts' only remaining claims were for breach of contract and declaratory relief. In August 2021, Express Scripts filed a motion for summary judgment, which Elevance Health opposed. In March 2022, the District Court granted in part and denied in part Express Scripts' motion for summary judgment. The District Court dismissed Elevance Health's declaratory judgment claim, Elevance Health's breach of contract claim for failure to prove damages and most of Elevance Health's operational breach claims. As a result of the summary judgment decision, the only remaining claims as of the filing of this Annual Report on Form 10-K are (i) Elevance Health's operational breach claim based on Express Scripts' prior authorization processes and (ii) Express Scripts' counterclaim for breach of the market check provision of the ESI PBM Agreement. Express Scripts filed a second motion for summary judgment in June 2022, challenging Elevance Health's remaining operational breach claims, which Elevance Health opposed in July 2022. Elevance Health intends to appeal the earlier summary judgment decision at the appropriate time, vigorously pursue their claims and defend against counterclaims, which they believe are without merit; however, the ultimate outcome of this litigation cannot be presently determined.

Medicare Risk Adjustment Litigation

In March 2020, the U.S. Department of Justice ("DOJ") filed a civil lawsuit against Elevance Health, Inc. (f/k/a Anthem, Inc.) in the U.S. District Court for the Southern District of New York (the "New York District Court") in a case captioned *United States v. Anthem, Inc.* The DOJ's suit alleges, among other things, that Elevance Health falsely certified the accuracy of the diagnosis data they submitted to the Centers for Medicare

and Medicaid Services ("CMS") for risk-adjustment purposes under Medicare Part C and knowingly failed to delete inaccurate diagnosis codes. The DOJ further alleges that, as a result of these purported acts, Elevance Health caused CMS to calculate the risk-adjustment payments based on inaccurate diagnosis information, which enabled Elevance Health to obtain unspecified amounts of payments in Medicare funds in violation of the False Claims Act. The DOJ filed an amended complaint in July 2020, alleging the same causes of action but revising some of its factual allegations. In September 2020, Elevance Health filed a motion to transfer the lawsuit to the Southern District of Ohio, a motion to dismiss part of the lawsuit, and a motion to strike certain allegations in the amended complaint. In an opinion and order issued October 3, 2022, the New York District Court denied Elevance Health's motions, and the case will now proceed in that court. In November 2022, Elevance Health filed an answer. They intend to continue to vigorously defend this suit, which they believe is without merit; however, the ultimate outcome cannot be presently determined.

Other Contingencies

From time to time, the Company and certain of its subsidiaries are parties to various legal proceedings, many of which involve claims for coverage encountered in the ordinary course of business. The Company, like Health Maintenance Organizations ("HMOs") and health insurers generally, exclude certain healthcare and other services from coverage under their HMO, Preferred Provider Organizations and other plans. The Company is, in the ordinary course of business, subject to the claims of their enrollees arising out of decisions to restrict or deny reimbursement for uncovered services. The loss of even one such claim, if it results in a significant punitive damage award, could have a material adverse effect on the Company. In addition, the risk of potential liability under punitive damage theories may increase significantly the difficulty of obtaining reasonable reimbursement of coverage claims.

In addition to the lawsuits described above, the Company is also involved in other pending and threatened litigation of the character incidental to their business and is from time to time involved as a party in various governmental investigations, audits, reviews and administrative proceedings. These investigations, audits, reviews and administrative proceedings include routine and special inquiries by state insurance departments, state attorneys general, the U.S. Attorney General and subcommittees of the U.S. Congress. Such investigations, audits, reviews and administrative proceedings could result in the imposition of civil or criminal fines, penalties, other sanctions and additional rules, regulations or other restrictions on the Company's business operations. Any liability that may result from any one of these actions, or in the aggregate, could have a material adverse effect on the Company's consolidated financial position or results of operations.

The Company has no other known material contingencies.

Provisions for uncollectible amounts

At December 31, 2022 and 2021, the Company reported admitted assets of \$191,426,602 and \$155,445,117, respectively, in premium receivables and receivables due from uninsured plans. Based upon the Company's experience, any uncollectible receivables are not expected to exceed \$29,037,474 that was nonadmitted at December 31, 2022; therefore, no additional provision for uncollectible amounts has been recorded. The potential for any additional loss is not believed to be material to the Company's financial condition.

15. Leases

A. Lessee Operating Lease

(1) The Company leases office space, office equipment, EDP equipment, and software under various noncancelable operating leases Certain leases have the right to renew. There are no escalation clauses for any lease. Related lease expense for 2022 and 2021 was \$135,605 and \$1,323,977, respectively.

The Company reevaluated its future office space needs and determined that it would permanently cease use of space under certain operating leases. At December 31, 2022 and 2021, the Company has lease exit costs liabilities of \$7,695,044 and \$9,373,962, respectively, included in general expenses due or accrued on the balance sheet.

(2) At December 31, 2022, the minimum aggregate rental commitments are as follows:

	Year Ending December 31	Operating Leases				
1.	2023	\$	1,837,660			
2.	2024		1,837,660			
3.	2025		1,837,660			
4.	2026		1,837,660			
5.	2027		1,071,968			
6.	Thereafter		_			
7.	Total (sum of 1 through 6)	\$	8,422,608			

(3)

- a. During 2015, the Company entered into a sale-leaseback transaction with an unaffiliated entity to lease the South Portland, Maine building for 12 years.
- b. Not applicable.

B. Lessor Leases

- (1) The Company has not entered into any operating leases.
- (2) The Company has not entered into any leveraged leases.

16. Information About Financial Instruments With Off-Balance Sheet Risk and Financial Instruments With Concentrations of Credit Risk

The Company has no significant financial instruments with off-balance sheet risk.

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of investment securities. All investment securities are managed by professional investment managers within policies authorized by the board of directors. Such policies limit the amounts that may be invested in any one issuer and prescribe certain investee company criteria. As of December 31, 2022, there were no significant concentrations.

17. Sale, Transfer and Servicing of Financial Assets and Extinguishments of Liabilities

A. Transfers of Receivables Reported as Sales

Not applicable at December 31, 2022 and 2021.

B. Transfer and Servicing of Financial Assets

(1) The Company participates in a securities lending program whereby marketable securities in its investment portfolio are transferred to independent brokers or dealers.

At December 31, 2022 the fair value of securities loaned was \$15,333,151 and the carrying value of securities loaned was \$16,846,925.

(2) - (7) Not applicable.

C. Wash Sales

- (1) In the course of the Company's asset management, securities may be sold and reacquired within 30 days of the sale date to enhance the yield on the investments.
- (2) At December 31, 2022 and 2021, there were no wash sales involving securities with an NAIC designation of 3 or below or unrated.

18. Gain or Loss to the Reporting Entity from Uninsured Plans and the Uninsured Portion of Partially Insured Plans

A. Administrative Services Only ("ASO") Plans

The gain or (loss) from operations from ASO uninsured plans and the uninsured portion of partially insured plans during 2022 was:

		AS	O Uninsured Plans	U	ninsured Portion of Partially Insured Plans	Total ASO
a.	Net reimbursement for administrative expenses (including administrative fees) in excess of (less than) actual expenses	\$	159,080	\$	(870,102) \$	(711,022)
b.	Total net other income or expenses (including interest paid to or received from plans)		_		_	_
c.	Net gain or (loss) from operations	\$	159,080	\$	(870,102) \$	(711,022)
d.	Total claim payment volume	\$	22,387,582	\$	24,110,769 \$	46,498,351

B. Administrative Services Contract ("ASC") Plans

The gain or (loss) from operations from ASC uninsured plans and the uninsured portion of partially insured plans during 2022 was:

		AS	C Uninsured Plans	Uı	ninsured Portion of Partially Insured Plans	Total ASC
a.	Gross reimbursement for medical cost incurred	\$	580,422,112	\$	_ \$	580,422,112
b.	Gross administrative fees accrued		33,694,302		_	33,694,302
c.	Other income or expenses (including interest paid to or received from plans)		_		_	_
d.	Gross expenses incurred (claims and administrative)		609,992,099		_	609,992,099
e.	Total gain or (loss) from operations	\$	4,124,315	\$	— \$	4,124,315

C. Medicare or Other Similarly Structured Cost-Based Reimbursement Contract

(1) The Company does not record revenue explicitly attributable to the cost share and reinsurance components of administered Medicare products.

(2)

Receivable from	Related to	Related to			
Federal government	ACA and Medicare cost sharing and reinsurance programs	\$	5,175	\$	1,030,780
State government	ACA cost sharing and reinsurance programs, including Section 1332	\$	6,886,164	\$	55,672
Uninsured plans	Uninsured business, not including pharmaceutical rebate receivables	\$	109,194,789	\$	78,243,930

- (3) As no revenue is recorded in connection with the cost share and reinsurance components of the Company's Medicare and ACA products, the Company has recorded no allowances and reserves for the adjustment of recorded revenues and receivables.
- (4) The Company has made no adjustment to revenue resulting from the audit of cost-reimbursement receivables related to revenues recorded in the prior period.

19. Direct Premium Written/Produced by Managing General Agents/Third Party Administrators

No premiums were written by managing general agents or third party administrators during the years ended December 31, 2022 and 2021.

20. Fair Value Measurements

A.

- (1) There are no assets or liabilities measured at fair value as of December 31, 2022.
- (2) Fair Value Measurements in (Level 3) of the Fair Value Hierarchy

There are no investments in Level 3 as of December 31, 2022 and 2021.

- (3) The Company's policy is to recognize transfers between Levels, if any, as of the beginning of the reporting period.
- (4) Fair values of bonds are based on quoted market prices, where available. These fair values are obtained primarily from third party pricing services, which generally use Level 1 or Level 2 inputs, for the determination of fair value to facilitate fair value measurements and disclosures. Level 2 securities primarily include United States government securities, corporate securities, securities from states, municipalities and political subdivisions, mortgage-backed securities and certain other asset-backed securities. For securities not actively traded, the pricing services may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. Inputs that are often used in the valuation methodologies include, but are not limited to, broker quotes, benchmark yields, credit spreads, default rates and prepayment speeds. The Company has controls in place to review the pricing services' qualifications and procedures used to determine fair values. In addition, the Company periodically reviews the pricing services' pricing methodologies, data sources and pricing inputs to ensure the fair values obtained are reasonable.

Certain bonds, primarily corporate debt securities, are designated Level 3. For these securities, the valuation methodologies may incorporate broker quotes or discounted cash flow analyses using assumptions for inputs such as expected cash flows, benchmark yields, credit spreads, default rates and prepayment speeds that are not observable in the markets.

Cash equivalents primarily consist of highly rated money market funds or bonds with original maturities of three months or less. Due to the high ratings and short-term nature, these investments are designated as Level 1. The Company also holds bonds purchased with less than three months to maturity. Fair value of these bonds are based on quoted market prices obtained from third party pricing services which generally use Level 1 or Level 2 inputs.

There have been no significant changes in the valuation techniques during the current period.

B. Fair Value Measurements Under Other Accounting Pronouncements

Not applicable at December 31, 2022 and 2021.

C. Financial Instruments

Type of Financial Instrument	Aggregate Fair Value	Admitted Assets	(Level 1)	(Level 2)	(Level 3)	Net Asset Value (NAV)	Not Practicable (Carrying Value)
Bonds	\$349,842,505	\$389,337,511	\$ —	\$349,842,505	\$ —	\$ —	\$ —
Cash equivalents	2,979,258	2,978,649	_	2,979,258	_	_	_
Short-term investments	2,782,394	2,781,860	_	2,782,394	_	_	_
Securities lending collateral asset	15,667,709	15,664,442	_	15,667,709	_	_	_

D. Not Practicable to Estimate Fair Value

There are no financial instruments that were not practicable to estimate fair value.

E. Investments Measured at Net Asset Value

The Company has no investments measured at net asset value.

21. Other Items

A. Unusual or Infrequent Items

Not applicable at December 31, 2022 and 2021.

B. Troubled Debt Restructuring: Debtors

Not applicable at December 31, 2022 and 2021.

C. Other Disclosures

Land is recorded at cost and other real estate is recorded at cost less accumulated depreciation. Depreciation is computed primarily using the straight-line method over the estimated useful lives of the assets. Real estate was not adjusted to market value at the date of purchase.

Assets in the amount of \$830,197 and \$850,725 at December 31, 2022 and 2021, respectively, were on deposit with government authorities or trustees as required by law.

The Company participates in the Federal Employee Health Benefits Program ("FEHBP") with other Blue Cross Blue Shield Plans. This program includes a fully-insured experience-rated contract, commonly known as the FEP, between the OPM and BCBSA, which acts as an agent for the participating Blue Cross Blue Shield plans. In addition, each participating plan, including the Company, executes a contract with BCBSA which obligates each participating plan to underwrite FEP benefits in its service area.

FEP premium is earned when chargeable benefit costs, allowable expenses or retentions are incurred. Deferred premiums are recorded to offset the FEP liabilities for incurred claims but not reported and claims adjustment expenses that are due from the OPM, when the claims are ultimately paid. Premium rates are developed by BCBSA and negotiated with OPM annually. These rates determine the funds that will be available to the participating Blue Cross Blue Shield plans to provide insurance to Federal employees that enroll with the Blue Cross Blue Shield FEP. The excess of gross premiums for the life of the program over the charges for the life of the program on an accrual basis is accounted for as a rate stabilization reserve (commonly referred to as the special reserve), as required by the contract between OPM and BCBSA. Each year, OPM also allocates a portion of the premiums to a contingency reserve, which may be utilized by the participating plans in the event that annual premiums paid to the insurance carrier are insufficient or the rate stabilization reserve falls below certain levels prescribed by OPM. Premiums paid to the carrier and available to each participating Blue Cross Blue Shield plan, including the special reserve and the contingency reserve, are held at the U.S. Treasury, including amounts unused from prior periods. Any premiums that remain in the rate stabilization reserve upon termination of the BCBSA contract after the claims runout and reimbursement of allowable administrative expenses would be returned to OPM for the benefit of the FEHBP. The FEP contract renews automatically each year unless written notice of termination is given by either party.

In accordance with the FEP contract, premium funds that exceed daily operating needs are held on behalf of the Company in letter of credit accounts at the U.S. Treasury to provide funding for claims, administrative expenses, and other charges to the contract. The Company, along with other Blue Cross Blue Shield plans who participate in the FEHBP contract, have an unrestricted right to draw funds being held in the U.S. Treasury, other than those allocated to the contingency reserve, for any valid claim or expense. If the balance of the special reserve is exhausted or falls below certain prescribed levels, OPM will transfer funds from the contingency reserve to the special reserve to the extent that funds are available in the contingency reserve. Amounts incurred in excess of the total reserves held at the U.S. Treasury for the FEP would not be reimbursed to the Company.

The Company has recorded its allocable share of the special reserve funds held in the U.S. Treasury as an asset, with an equivalent amount recorded as a rate stabilization reserve. These amounts are \$55,438,580 and \$45,655,126 as of December 31, 2022 and 2021, respectively, and are included in aggregate write-ins for other than invested assets and in health policy reserves in the accompanying balance sheets.

FEP represented approximately 54.9% and 59.1% of premiums receivable as of December 31, 2022 and 2021, respectively. FEP represented approximately 21.3% and 20.5% of net premiums written for the years ended December 31, 2022 and 2021, respectively.

D. Business Interruption Insurance Recoveries

The Company has reported no recoveries for business interruption for the years ended December 31, 2022 and 2021.

E. State Transferable and Non-Transferable Tax Credits

The Company did not have state transferable or non-transferable tax credits at December 31, 2022 and 2021.

F. Subprime Mortgage-Related Risk Exposure

- (1) The Company's investment strategy of providing safety and preservation of capital, sufficient liquidity to meet cash flow requirements and the attainment of a competitive after-tax investment return is supported by a well diversified portfolio consisting of many different types of investments. The portion of the Company's investment portfolio with subprime mortgage-related risk exposure is relatively small in comparison to the overall investment portfolio, and consists mainly of investment grade securities with no exposure to collateralized debt obligations. All mortgage related investments are monitored closely as part of the quarterly investment review performed by the Elevance Health Investment Impairment Review Committee.
- (2) The Company did not carry investments in subprime mortgage loans in its portfolio at December 31, 2022 or 2021.
- (3) At December 31, 2022, the Company's subprime mortgage-related risk exposure is detailed below:

	Actual Cost	Book/ Adjusted Carrying Value (excluding interest)	Fair Value	Other-Than- Temporary Impairment Losses Recognized
a. Residential mortgage- backed securities	\$ —	\$ —	\$	\$ —
b. Commercial mortgage- backed securities		_	_	_
c. Collateralized debt obligations	_	_	_	_
d. Structured securities	2,055,320	2,050,680	1,877,686	_
e. Equity investments in SCAs	_	_	_	_
f. Other assets	_	_		_
g. Total	\$ 2,055,320	\$ 2,050,680	\$ 1,877,686	\$

(4) The Company did not underwrite Mortgage Guaranty or Financial Guaranty insurance coverage at December 31, 2022 or 2021.

G. Retained Assets

The Company does not have retained assets at December 31, 2022 and 2021.

H. Insurance-Linked Securities Contracts

Not applicable.

I. The Amount That Could Be Realized on Life Insurance Where the Reporting Entity is Owner and Beneficiary or Has Otherwise Obtained Rights to Control the Policy

Not applicable.

22. Events Subsequent

Subsequent events have been considered through February 27, 2023 for the statutory statement issued on February 28, 2023. There were no events occurring subsequent to December 31, 2022 requiring recognition or disclosure.

23. Reinsurance

A. Ceded Reinsurance Report

Section 1 - General Interrogatories

(1) Are any of the reinsurers that are listed in Schedule S as non-affiliated owned in excess of 10% or controlled, either directly or indirectly, by the Company or by any representative, officer, trustee, or director of the Company?

Yes () No (X)

If yes, give full details.

(2) Have any policies issued by the Company been reinsured with a company chartered in a country other than the United States (excluding U.S. Branches of such companies) that is owned in excess of 10% or controlled, directly or indirectly, by an insured, a beneficiary, a creditor or an insured or any other person not primarily engaged in the insurance business?

Yes () No (X)

If yes, give full details.

Section 2 - Ceded Reinsurance Report - Part A

(1) Does the Company have any reinsurance agreements in effect under which the reinsurer may unilaterally cancel any reinsurance for reasons other than for nonpayment of premium or other similar credits?

Yes () No (X)

If yes, give full details.

(2) Does the reporting entity have any reinsurance agreements in effect such that the amount of losses paid or accrued through the statement date may result in a payment to the reinsurer of amounts that, in aggregate and allowing for offset of mutual credits from other reinsurance agreements with the same reinsurer, exceed the total direct premium collected under the reinsured policies?

Yes () No (X)

If yes, give full details.

Section 3 - Ceded Reinsurance Report - Part B

(1) What is the estimated amount of the aggregate reduction in surplus, (for agreements other than those under which the reinsurer may unilaterally cancel for reasons other than for nonpayment of premium or other similar credits that are reflected in Section 2 above) of termination of ALL reinsurance agreements, by either party, as of the date of this statement? Where necessary, the Company may consider the current or anticipated experience of the business reinsured in making this estimate.

\$217,597

(2) Have any new agreements been executed or existing agreements amended, since January 1 of the year of this statement, to include policies or contracts that were in force or which had existing reserves established by the Company as of the effective date of the agreement?

Yes () No (X)

If yes, give full details.

B. Uncollectible Reinsurance

The Company has no uncollectible reinsurance at December 31, 2022 and 2021.

C. Commutation of Ceded Reinsurance

The Company has not commuted ceded reinsurance during 2022 and 2021.

D. Certified Reinsurer Rating Downgraded or Status Subject Revocation

The Company has no downgraded certified reinsurer ratings or status subject to revocations during 2022 and 2021.

E. Reinsurance Credit

(1) The Company has the following reinsurance contracts subject to Life and Health Reinsurance Agreements Model Regulation Appendix A-791 ("A-791") that includes a provision which limits the reinsurer's assumption of risks, such as a deductible, a loss ratio corridor, a loss cap, or an aggregate limit, as defined in A-791:

Name of Reinsurer	Number of contracts to which such provisions apply	Was Deposit Accounting Applied (Yes or No)
Maine Guaranteed Access Reinsurance Association	1	No

- (2) Not applicable.
- (3) Not applicable.
- (4) Not applicable.
- (5) Not applicable.

24. Retrospectively Rated Contracts & Contracts Subject to Redetermination

A. The Company sells accident and health policies for which the premiums vary based on loss experience. The Company estimates retrospective premium adjustments through the

review of each retrospectively rated account, comparing the claim development with that anticipated in the policy contracts.

- **B.** The Company records accrued retrospective premium as an adjustment to earned premium.
- C. The amount of net premiums written by the Company at December 31, 2022 and 2021 that were subject to retrospective rating features was \$1,120,363,138 and \$1,039,515,195, respectively, which represented 92.8% and 91.9%, respectively, of the total net premiums written.
- **D.** In accordance with the NAIC SAP, medical loss ratio rebates in accordance with the Federal 2010 Patient Protection and Affordable Care Act and Public Health Service Act ("ACA Act" or "ACA"), are to be reported in accordance with SSAP No. 66 *Retrospectively Rated Contracts* ("SSAP No. 66"). A retrospectively rated contract is one that has the final policy premium calculated based on the loss experience of the insured during the term of the policy (including loss development after the term of the policy) and the stipulated formula set forth in the policy, or in the case of medical loss ratio rebates, a formula required by law. The Company based the incurred and unpaid liability amounts reported below based on its underwriting experience; actuarial, tax, and accounting estimates and assumptions at the financial statement date; as well as regulations and guidance available that is not final and subject to change prior to settlement. Accordingly, the Company's use of estimates and assumptions in the preparation of the statutory based financial statements and related footnote disclosures may differ from actual results. Hence, the amounts reported herein are for financial reporting purposes solely and not intended to be used for settlement purposes.

Medical loss ratio rebates accrued pursuant to the ACA Act are as follows:

	Individual	Small Group Employer	Large Group Employer	Other Categories with Rebates	Total
Prior Year Reporting:					
(1) Medical loss ratio rebates incurred	\$11,897,160	\$5,842,286	\$ —	\$ —	\$17,739,446
(2) Medical loss ratio rebates paid	16,013,403	4,116,729		_	20,130,132
(3) Medical loss ratio rebates unpaid	7,821,403	3,789,730		_	11,611,133
(4) Plus reinsurance assumed amounts	XXX	XXX	XXX	XXX	_
(5) Less reinsurance ceded amounts	XXX	XXX	XXX	XXX	_
(6) Rebates unpaid net of reinsurance	XXX	XXX	XXX	XXX	11,611,133
Current Reporting Year-to-Date					
(7) Medical loss ratio rebates incurred	\$ 4,090,205	\$ (170,793)	\$ —	\$ —	\$ 3,919,412
(8) Medical loss ratio rebates paid	8,374,926	3,618,937	_	_	11,993,863
(9) Medical loss ratio rebates unpaid	3,536,682	_	_	_	3,536,682
(10) Plus reinsurance assumed amounts	XXX	XXX	XXX	XXX	_
(11) Less reinsurance ceded amounts	XXX	XXX	XXX	XXX	_
(12) Rebates unpaid net of reinsurance	XXX	XXX	XXX	XXX	\$ 3,536,682

E. Risk-Sharing Provisions of the ACA

(1)		the reporting entity write accident and health insurance premium that is subject to Affordable Care Act risk-sharing provisions (YES/NO)?		Yes
(2)		pact of Risk-Sharing Provisions of the Affordable Care Act on Admitted Assets, bilities and Revenue for the Current Year		
	a.	Permanent ACA Risk Adjustment Program		
		Assets		
		Premium adjustments receivable due to ACA Risk Adjustment (including high risk pool payments) Liabilities	\$	2,376,747
		2. Risk adjustment user fees payable for ACA Risk Adjustment	\$	119,689
		3. Premium adjustments payable due to ACA Risk Adjustment (including high	Ψ	117,007
		risk pool premiums)	\$	13,432,070
		Operations (Revenue & Expense)		
		4. Reported as revenue in premium for accident and health contracts (written/collected) due to ACA Risk Adjustment	\$	(7,286,224)
		5. Reported in expenses as ACA risk adjustment user fees (incurred/paid)	\$	120,546
	b.	Transitional ACA Reinsurance Program		
		Assets		
		1. Amounts recoverable for claims paid due to ACA Reinsurance	\$	
		Amounts recoverable for claims unpaid due to ACA Reinsurance (contra liability)	\$	
		3. Amounts receivable relating to uninsured plans for contributions for ACA Reinsurance	\$	
		Liabilities		
		4. Liabilities for contributions payable due to ACA Reinsurance - not reported as ceded premium	\$	
		5. Ceded reinsurance premiums payable due to ACA Reinsurance	\$	
		6. Liability for amounts held under uninsured plans contributions for ACA Reinsurance	\$	
		Operations (Revenue & Expense)		
		7. Ceded reinsurance premiums due to ACA Reinsurance	\$	
		8. Reinsurance recoveries (income statement) due to ACA Reinsurance payments or expected payments	\$	
		9. ACA Reinsurance contributions - not reported as ceded premium	\$	
	c.	Temporary ACA Risk Corridors Program		
		Assets		
		1. Accrued retrospective premium due to ACA Risk Corridors Liabilities	\$	
		Reserve for rate credits or policy experience rating refunds due to ACA Risk Corridors	\$	
		Operations (Revenue & Expense)		
		3. Effect of ACA Risk Corridors on net premium income (paid/received)	\$	_
		4. Effect of ACA Risk Corridors on change in reserves for rate credits	\$	

Line items where the amount is zero is due to no balance and/or no activity as of the reporting date.

(3) Roll-forward of prior year ACA risk-sharing provisions for the following asset (gross of any nonadmission) and liability balances, along with the reasons for adjustments to prior year balance.

			Prior Yea	During the	the Curr	or Paid as of ent Year on	Differ	ences	Ad	justments			alances as of rting Date
			December	en Before 31 of the Prio Year	r December 3	ritten Before 31 of the Prior Tear	Prior Year Accrued Less Payments (Col 1-3)	Prior Year Accrued Less Payments (Col 2-4)	To Prior Year Balances	To Prior Year Balances		Cumulative Balance from Prior Years (Col 1-3+7)	Cumulative Balance from Prior Years (Col 2-4+8)
			1	2	3	4	5	6	7	8		9	10
			Receivable	(Payable)	Receivable	(Payable)	Receivable	(Payable)	Receivable	(Payable)	Ref	Receivable	(Payable)
a.		nanent ACA Risk ustment Program											
	1.	Premium adjustments receivable (including high risk pool payments)	\$ 1,180,51	4 \$ -	- \$ 4,253,872	s –	\$(3,073,358)	s —	\$ 3,073,358	s –	A	s —	s –
	2.	Premium adjustments (payable) (including high risk pool premiums)	s –	- \$17,562,58	2 \$ —	\$15,903,174	s –	\$ 1,659,408	s —	\$ (1,659,408)	В	s –	s –
	3.	Subtotal ACA Permanent Risk Adjustment Program	\$ 1.180.51	4 \$17.562.58	2 \$ 4,253,872	\$15,903 174	\$(3.073 358)	\$ 1.659 408	\$ 3,073 358	\$ (1.659 408)		s –	s –
b.		nsitional ACA Reinsurance	,0,01	,002,00	,200,012	V,- VU,1 1 T	. (=,=,5,550)	,,130	. 2,273,330	. (-,2,100)		-	-
	1.	Amounts recoverable for claims paid	s –	- \$ -	- \$ —	s –	s —	s –	s –	s –	С	s –	s —
	2.	Amounts recoverable for claims unpaid (contra liability)	s –	- \$ -	- \$ —	· s —	s –	s –	s –	s –	D	s –	s –
	3.	Amounts receivable relating to uninsured plans	s –	- \$ -	- \$ -	s —	s –	s –	s –	s –	E	s –	s –
	4.	Liabilities for contributions payable due to ACA Reinsurance - not reported as ceded											
	5.	Premium Ceded reinsurance	\$ -	- \$ -	- \$ _	<u> </u>	\$ <u> </u>	<u>s</u> –	<u> </u>	<u>s — </u>	F	<u>s</u> –	<u> </u>
		premiums payable	s –	- \$ -	- \$	s _	s –	s –	s –	s <u> </u>	G	s –	s —
	6.	Liability for amounts held under uninsured plans	s –	- \$ -	- s <u> </u>	s —	s –	s —	s –	s <u> </u>	Н	s –	s <u> </u>
	7.	Subtotal ACA Transitional Reinsurance Program	\$ -	- \$ -	- \$ —	· s —	s –	s –	s –	s –		s –	s –
c.	Con	nporary ACA Risk ridors Program											
	1.	Accrued retrospective premium	s –	- \$ -	- s	s —	s –	s –	s –	s –	I	s –	s –
	2.	Reserve for rate credits or policy experience rating refunds	s –	- \$ -	- \$ -	· s —	s –	s –	s –	s –	J	s –	s –
	3.	Subtotal ACA Risk Corridors Program	s –	- \$ -	- \$ —	s —	s –	s –	s –	s –	-	s –	s –
d.		al for ACA Risk Sharing			2 \$ 4,253,872							s —	
Even	·lone+	ione of A divetments											
EXP	A	Adjustments were made to Benefit Year."	reflect the er	nding balance i	n the Centers fo	r Medicare & N	Medicaid Servic	es "Summary l	Report on Pern	nanent Risk Adju	ıstme	ent Transfers fo	or the 2021

- Adjustments were made to reflect the ending balance in the Centers for Medicare & Medicaid Services "Summary Report on Permanent Risk Adjustment Transfers for the 2021 Benefit Year."
- C Not applicable.
- D Not applicable.
- E Not applicable.
- Not applicable.
- H Not applicable.
- I Not applicable.
- J Not applicable.
- (4) Not applicable.
- (5) Not applicable.

25. Change in Incurred Claims and Claim Adjustment Expenses

A. The estimated cost of claims and claim adjustment expense attributable to insured events of prior years decreased by \$14,687,009 during 2022. This is approximately 8.1% of unpaid claims and claim adjustment expenses of \$181,629,537 as of December 31, 2021. The redundancy reflects the decreases in estimated claims and claims adjustment expenses as a result of claims payment during the year, and as additional information is received regarding claims incurred prior to 2022. Recent claim development trends are

also taken into account in evaluating the overall adequacy of unpaid claims and unpaid claim adjustment expense.

B. There were no significant changes in methodologies and assumptions used in calculating the liability for unpaid losses and loss adjustment expenses.

26. Intercompany Pooling Arrangements

Not applicable at December 31, 2022 and 2021.

27. Structured Settlements

Not applicable at December 31, 2022 and 2021.

28. Health Care Receivables

A. Pharmaceutical Rebate Receivables

Quarter	Estimated Pharmacy Rebates as Reported on Financial Statements	Pharmacy Rebates as Billed or Otherwise Confirmed	Actual Rebates Received Within 90 Days of Billing	Actual Rebates Received Within 91 to 180 Days of Billing	Actual Rebates Received More Than 180 Days After Billing
12/31/2022	\$ 6,412,710	\$ 15,164,704	\$ 8,751,994	\$ —	
9/30/2022	5,680,222	14,471,827	13,243,187	_	
6/30/2022	5,520,503	14,738,163	13,341,188	1,396,975	
3/31/2022	6,101,461	13,712,502	12,487,769	1,224,733	
12/31/2021	4,847,291	12,559,751	11,579,479	980,272	
9/30/2021	4,658,006	11,930,081	10,740,071	1,190,010	
6/30/2021	4,498,943	8,267,932	7,661,773	606,159	
3/31/2021	5,786,448	12,447,077	11,395,030	1,052,047	
12/31/2020	5,551,777	10,061,404	9,541,031	520,373	
9/30/2020	8,192,911	9,655,749	8,520,125	1,135,623	
6/30/2020	9,099,251	18,711,100	16,609,934	2,101,165	
3/31/2020	15,768,522	19,236,921	18,495,878	741,043	

B. Risk Sharing Receivables

Not applicable at December 31, 2022 and 2021.

29. Participating Policies

Not applicable at December 31, 2022 and 2021.

30. Premium Deficiency Reserves

The Company had no liabilities related to premium deficiency reserves as of December 31, 2022 and 2021.

31. Anticipated Salvage and Subrogation

The Company took into account estimated anticipated subrogation and other recoveries in its determination of the liability for unpaid claims and reduced the liability by \$1,029,000 and \$707,000 at December 31, 2022 and 2021, respectively.

GENERAL INTERROGATORIES

PART 1 - COMMON INTERROGATORIES GENERAL

1.1	Is the reporting entity a member of an Insurance Holding Company System consisting of two or more affiliated persons, one of is an insurer?		Yes [X] No []
	If yes, complete Schedule Y, Parts 1, 1A, 2 and 3.		.00 [//	1 1
1.2	If yes, did the reporting entity register and file with its domiciliary State Insurance Commissioner, Director or Superintendent o such regulatory official of the state of domicile of the principal insurer in the Holding Company System, a registration statemer providing disclosure substantially similar to the standards adopted by the National Association of Insurance Commissioners (I its Model Insurance Holding Company System Regulatory Act and model regulations pertaining thereto, or is the reporting ensubject to standards and disclosure requirements substantially similar to those required by such Act and regulations?	nt NAIC) in tity] No [] N/A []
1.3	State Regulating?		Main	e
1.4	Is the reporting entity publicly traded or a member of a publicly traded group?		Yes [X] No []
1.5	If the response to 1.4 is yes, provide the CIK (Central Index Key) code issued by the SEC for the entity/group		0001156	039
2.1	Has any change been made during the year of this statement in the charter, by-laws, articles of incorporation, or deed of settle reporting entity?		Yes [] No [X]
2.2	If yes, date of change:			
3.1	State as of what date the latest financial examination of the reporting entity was made or is being made.		12/31/2	022
3.2	State the as of date that the latest financial examination report became available from either the state of domicile or the report entity. This date should be the date of the examined balance sheet and not the date the report was completed or released		12/31/2	017
3.3	State as of what date the latest financial examination report became available to other states or the public from either the stat domicile or the reporting entity. This is the release date or completion date of the examination report and not the date of the examination (balance sheet date).		10/23/2	019
3.4	By what department or departments? State of Maine Bureau of Insurance			
3.5	Have all financial statement adjustments within the latest financial examination report been accounted for in a subsequent financial examination report been accounted for in a subsequent financial examination report been accounted for in a subsequent financial examination report been accounted for in a subsequent financial examination report been accounted for in a subsequent financial examination report been accounted for in a subsequent financial examination report been accounted for in a subsequent financial examination report been accounted for in a subsequent financial examination report been accounted for in a subsequent financial examination report been accounted for in a subsequent financial examination report been accounted for in a subsequent financial examination report been accounted for in a subsequent financial examination report been accounted for in a subsequent financial examination report been accounted for in a subsequent financial examination report been accounted for in a subsequent financial examination report been accounted for in a subsequent financial examination for the subsequent financial examinatio] No [] N/A [X]
3.6	Have all of the recommendations within the latest financial examination report been complied with?	Yes [X] No [] N/A []
4.1	During the period covered by this statement, did any agent, broker, sales representative, non-affiliated sales/service organizar combination thereof under common control (other than salaried employees of the reporting entity), receive credit or commission a substantial part (more than 20 percent of any major line of business measured on direct premiums) of: 4.11 sales of new business?	ons for or control] No [X]
4.2	4.12 renewals? During the period covered by this statement, did any sales/service organization owned in whole or in part by the reporting entireceive credit or commissions for or control a substantial part (more than 20 percent of any major line of business measured opermiums) of:	ity or an affiliate,	Yes [] No [X]
	4.21 sales of new business?		_] No [X]] No [X]
5.1	Has the reporting entity been a party to a merger or consolidation during the period covered by this statement?		Yes [] No [X]
5.2	If yes, provide the name of the entity, NAIC Company Code, and state of domicile (use two letter state abbreviation) for any exceased to exist as a result of the merger or consolidation.	ntity that has		
	1 Name of Entity NAIC Company Code State of Dom			
6.1	Has the reporting entity had any Certificates of Authority, licenses or registrations (including corporate registration, if applicable revoked by any governmental entity during the reporting period?		Yes [] No [X]
6.2	If yes, give full information:			
7.1	Does any foreign (non-United States) person or entity directly or indirectly control 10% or more of the reporting entity?		Yes [] No [X]
7.2	If yes, 7.21 State the percentage of foreign control;			%
	1 2 Nationality Type of Entity			

8.1 8.2	Is the company a subsidiary of a depository institution holding company of the response to 8.1 is yes, please identify the name of the DIHC.	y (DIHC) or a DIHC itself, regulated by the Federal	Reserv	e Board	?	Yes []	No	[X]	
8.3 8.4	Is the company affiliated with one or more banks, thrifts or securities fir If response to 8.3 is yes, please provide below the names and location regulatory services agency [i.e. the Federal Reserve Board (FRB), the Insurance Corporation (FDIC) and the Securities Exchange Commission	(city and state of the main office) of any affiliates r Office of the Comptroller of the Currency (OCC), tl	egulate	d by a fe	deral	Yes []	No	[X]	
	1	2	3	4	5	6	1			
	Affiliate Name	Location (City, State)	FRB	OCC	FDIC	SEC	_			
۰.				•						
8.5	Is the reporting entity a depository institution holding company with sign Federal Reserve System or a subsidiary of the depository institution ho	olding company?				Yes []	No	[X]	
8.6	If response to 8.5 is no, is the reporting entity a company or subsidiary Federal Reserve Board's capital rule?				V _Φ ς [] No [Y 1	N/	λ Γ	1
9.	What is the name and address of the independent certified public acco				103 [] 140 [ν]	147	n [1
	Ernst & Young LLP, 111 Monument Circle, Suite 4000, Indianapolis, IN									
10.1	Has the insurer been granted any exemptions to the prohibited non-aur requirements as allowed in Section 7H of the Annual Financial Reporting or regulation?	ng Model Regulation (Model Audit Rule), or substa	intially s	imilar sta	ate	Yes [1	No '	[X]	
10.2	If the response to 10.1 is yes, provide information related to this exemp	otion:					•			
10.3 10.4	Has the insurer been granted any exemptions related to the other requallowed for in Section 18A of the Model Regulation, or substantially sin If the response to 10.3 is yes, provide information related to this exemp	nilar state law or regulation?	Regulat	ion as		Yes []	No	[X]	
10.5 10.6	Has the reporting entity established an Audit Committee in compliance If the response to 10.5 is no or n/a, please explain	with the domiciliary state insurance laws?] No []	N/	A []
11.	What is the name, address and affiliation (officer/employee of the repofirm) of the individual providing the statement of actuarial opinion/certifichristine Valdez, FSA, MAAA, Director & Actuary III (employee), 20458	rting entity or actuary/consultant associated with a ication?	n actuar	ial consu	ılting					
12.1	Does the reporting entity own any securities of a real estate holding con					Yes []	No	[X]	
	12.11 Name of real e	estate holding company								
	•	cels involved								
12.2	12.13 Total book/adjullf, yes provide explanation:	usted carrying value				\$				
12.2										
13.	FOR UNITED STATES BRANCHES OF ALIEN REPORTING ENTITIE	ES ONLY:								
13.1	What changes have been made during the year in the United States m	anager or the United States trustees of the reporti	ng entity	/?						
13.2	Does this statement contain all business transacted for the reporting er	ntity through its United States Branch on risks whe	rever lo	cated?		Yes [1	No I	[]	
13.3	Have there been any changes made to any of the trust indentures durin					Yes []	No I	[]	
13.4	If answer to (13.3) is yes, has the domiciliary or entry state approved the] No []	N/	Α[]
14.1	Are the senior officers (principal executive officer, principal financial off similar functions) of the reporting entity subject to a code of ethics, whi a. Honest and ethical conduct, including the ethical handling of actual or relationships:	ch includes the following standards?				Yes [X]	No I	[]	
	b. Full, fair, accurate, timely and understandable disclosure in the period. Compliance with applicable governmental laws, rules and regulation		ity;							
	d. The prompt internal reporting of violations to an appropriate person of									
14.11	e. Accountability for adherence to the code. If the response to 14.1 is No, please explain:									
14.2	Has the code of ethics for senior managers been amended?					Yes [X	. 1	No	[]	
	If the response to 14.2 is yes, provide information related to amendment	nt(s).				[//	•		. ,	
44.0	Code amended to reflect name change from Anthem to Elevance Heal					., .			, v -	
14.3 14.31	Have any provisions of the code of ethics been waived for any of the split the response to 14.3 is yes, provide the nature of any waiver(s).	pecified officers?				Yes []	No I	[X]	
	in the response to 14.0 is yes, provide the nature of any warrends.									

American			3	4	ł
Bankers Association ABA) Routing					
	g or Confirming Bank Name	Circumstances	That Can Trigger the Letter of Credit	Amo	ount
			_		
	estments of the reporting entity passe		of directors or a subordinate committee	Yes [X] No [
oes the reporting entity keep a ereof?	complete permanent record of the pr	oceedings of its board of dir	rectors and all subordinate committees	Yes [X	
art of any of its officers, director	s, trustees or responsible employees	that is in conflict or is likely	es of any material interest or affiliation on the to conflict with the official duties of such	Yes [X] No [
				-	
		FINANCIAL			
as this statement been prepare	d using a basis of accounting other the	han Statutory Accounting Pr	rinciples (e.g., Generally Accepted	Yes [1 No [
otal amount loaned during the	ear (inclusive of Separate Accounts,	exclusive of policy loans):	20.11 To directors or other officers	\$] 110 [
			20.12 To stockholders not officers		
			20.13 Trustees, supreme or grand		
			(Fraternal Only)	. \$	
	g at the end of year (inclusive of Sep	arate Accounts, exclusive of	of	œ.	
olicy loans):			20.21 To directors or other officers		
			20.22 To stockholders not officers 20.23 Trustees, supreme or grand	\$	
			(Fraternal Only)	s	
oligation being reported in the s	tatement?	oligation to transfer to anoth	er party without the liability for such	Yes [] No [
yes, state the amount thereof a	t December 31 of the current year:		21.21 Rented from others		
			21.22 Borrowed from others		
			21.23 Leased from others		
			21.24 Other	\$	
uaranty association assessmen	nents for assessments as described ts?		structions other than guaranty fund or	Yes [] No [
answer is yes:			2.21 Amount paid as losses or risk adjustment		
			2.22 Amount paid as expenses		
and the reporting entity report a	uny amounta dua fram parant, subaidi		2.23 Other amounts paid		
		_	or this statement?	-	-
oes the insurer utilize third part	ies to pay agent commissions in whic	ch the amounts advanced by	v the third parties are not settled in full within	Ψ Yes [
	entify the third-party that pays the age			-	
		Is the			
		Third-Party Ag a Related Par			
Na	me of Third-Party	(Yes/No)	.,		
			<u></u>		

25.02	If no, give full and complete information relating thereto			
25.03	whether collateral is carried on or off-balance sheet. (an alterna	ogram including value for collateral and amount of loaned securities, and tive is to reference Note 17 where this information is also provided)		
25.04	For the reporting entity's securities lending program, report and Instructions.	ount of collateral for conforming programs as outlined in the Risk-Based Capital	\$ 15,664	4,44
25.05	For the reporting entity's securities lending program, report amo	ount of collateral for other programs.	\$	
25.06	Does your securities lending program require 102% (domestic outset of the contract?	X] No [] N/A	[
25.07	Does the reporting entity non-admit when the collateral received	d from the counterparty falls below 100%? Yes [X] No [] N/A]
25.08	Does the reporting entity or the reporting entity 's securities lend conduct securities lending?	ding agent utilize the Master Securities lending Agreement (MSLA) to Yes [X] No [] N/A]
25.09	For the reporting entity's securities lending program state the ar	mount of the following as of December 31 of the current year:		
	25.092 Total book adjusted/carrying value of re	assets reported on Schedule DL, Parts 1 and 2einvested collateral assets reported on Schedule DL, Parts 1 and 2orted on the liability page.	\$ 15,664	4,44
26.1	control of the reporting entity or has the reporting entity sold or	entity owned at December 31 of the current year not exclusively under the transferred any assets subject to a put option contract that is currently in 03).	Yes [X] No []
26.2	If yes, state the amount thereof at December 31 of the current y	26.21 Subject to repurchase agreements	. \$	
		excluding FRLB Capital Stock 26.27 FHLB Capital Stock 26.28 On deposit with states 26.29 On deposit with other regulatory bodies 26.30 Pledged as collateral - excluding collateral pledged t an FHLB 26.31 Pledged as collateral to FHLB - including assets backing funding agreements 26.32 Other	\$	30 , 19
26.3	For category (26.26) provide the following:	2	3	7
26.3		Description	Amount	
26.3	1 Nature of Restriction	Description	Amount	
26.3	Nature of Restriction	Description	Amount	
	Nature of Restriction Does the reporting entity have any hedging transactions reported	Description	Amount Yes [] No []	х]
27.1 27.2	Nature of Restriction Does the reporting entity have any hedging transactions reporter lif yes, has a comprehensive description of the hedging program	Description and on Schedule DB?	Amount Yes [] No []	х]
27.1 27.2	Nature of Restriction Does the reporting entity have any hedging transactions reported life yes, has a comprehensive description of the hedging program of no, attach a description with this statement. Toes the reporting entity utilize derivatives to hedge variable and the statement of the statement of the statement.	Description and on Schedule DB?	Amount Yes [] No []] X] [
27.1 27.2 INES 2	Nature of Restriction Nature of Restriction Does the reporting entity have any hedging transactions reporter If yes, has a comprehensive description of the hedging program If no, attach a description with this statement. 7.3 through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITY Does the reporting entity utilize derivatives to hedge variable are If the response to 27.3 is YES, does the reporting entity utilize:	Description and on Schedule DB?	Yes [] No []] X] [
27.1 27.2 INES 2 27.3	Nature of Restriction Nature of Restriction Does the reporting entity have any hedging transactions reported lifyes, has a comprehensive description of the hedging program of no, attach a description with this statement. Through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITY Does the reporting entity utilize derivatives to hedge variable and of the response to 27.3 is YES, does the reporting entity utilize: By responding YES to 27.41 regarding utilizing the special accordiolowing: The reporting entity has obtained explicit approval from the Hedging strategy subject to the special accounting pro Actuarial certification has been obtained which indicate reserves and provides the impact of the hedging strates. Financial Officer Certification has been obtained which	Description and on Schedule DB?	Yes [] No []] X] [
27.1 27.2 INES 2 27.3 27.4	Nature of Restriction Nature of Restriction Does the reporting entity have any hedging transactions reported for year, has a comprehensive description of the hedging program of no, attach a description with this statement. Through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITY Does the reporting entity utilize derivatives to hedge variable and of the response to 27.3 is YES, does the reporting entity utilize: The response to 27.41 regarding utilizing the special accordiolowing: The reporting entity has obtained explicit approval from the Hedging strategy subject to the special according program of the hedging strategy entity that the hedging strategy entity that the hedging strategy within VM-21 and that the Clearly Derits actual day-to-day risk mitigation efforts. Were any preferred stocks or bonds owned as of December 31	Description and on Schedule DB?	Yes [] No [] Yes [] No [Yes [Yes [] No [Yes [Yes [] No [Yes [X] [X]]
27.1 27.2 INES 2 27.3 27.4	Nature of Restriction Nature of Restriction Does the reporting entity have any hedging transactions reported for the nedging program of the nedging entity utilize of the reporting entity utilize of the reporting entity utilize. By responding YES to 27.41 regarding utilizing the special according of the nedging strategy subject to the special accounting pro Actuarial certification has been obtained which indicate reserves and provides the impact of the hedging strategy in the nedging strategy within VM-21 and that the Clearly De its actual day-to-day risk mitigation efforts. Were any preferred stocks or bonds owned as of December 31 issuer, convertible into equity?	Description and on Schedule DB?	Yes [] No []	X] [X]]
27.1 27.2 INES 2 27.3 27.4 27.5	Nature of Restriction If yes, has a comprehensive description of the hedging program of no, attach a description with this statement. Nature of Restrictions reported If yes, has a comprehensive description of the hedging program of no, attach a description with this statement. Nature of Restrictions reported If yes, has a comprehensive description of the hedging program of the reporting entity utilize derivatives to hedge variable are of the response to 27.3 is YES, does the reporting entity utilize: Nature of Restrictions reported If yes program of the reporting entity derivatives to hedge variable are of the response to 27.3 is YES, does the reporting entity utilize: Nature of Restrictions reported If the response to 27.5: FOR LIFE/FRATERNAL REPORTING ENTITY The reporting entity utilize derivatives to hedge variable are of the reporting entity utilize: Nature of Restrictions reported If the response to 27.3: YES, does the reporting entity utilize: Nature of Restrictions reported The redording tension of the program of the reporting entity utilize: Nature of Restriction of the hedging program of the reporting entity utilize: Nature of Restriction of the hedging program of the reporting entity utilize: Nature of Restriction of the hedging program of the reporting entity utilize: Nature of Restriction of the hedging program of the reporting entity utilize: Nature of Restriction of the hedging program of the reporting entity utilize: Nature of Restriction of the hedging program of the reporting entity utilize: Nature of Restriction of the hedging strate of the reporting entity utilize: Nature of Restriction of the hedging strate of the hedg	Description and on Schedule DB?	Yes [] No []	x] [X]]
27.1 27.2 INES 2 27.3 27.4 27.5	Nature of Restriction Does the reporting entity have any hedging transactions reported for yes, has a comprehensive description of the hedging program of no, attach a description with this statement. Through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITY Does the reporting entity utilize derivatives to hedge variable and of the response to 27.3 is YES, does the reporting entity utilize: 27. By responding YES to 27.41 regarding utilizing the special accordiolowing: • The reporting entity has obtained explicit approval from the Hedging strategy subject to the special accounting promatical entities and provides the impact of the hedging strate of Financial Officer Certification has been obtained which Hedging Strategy within VM-21 and that the Clearly Defits actual day-to-day risk mitigation efforts. Were any preferred stocks or bonds owned as of December 31 issuer, convertible into equity? If yes, state the amount thereof at December 31 of the current years of the special Deposits, real offices, vaults or safety deposit boxes, were all stocks, bonds a custodial agreement with a qualified bank or trust company in a Outsourcing of Critical Functions, Custodial or Safekeeping Aging the special Deposits, real offices, vaults or safety deposit boxes, were all stocks, bonds a custodial agreement with a qualified bank or trust company in a Outsourcing of Critical Functions, Custodial or Safekeeping Aging the special Deposits, real offices, vaults or safety deposit boxes, were all stocks, bonds a custodial agreement with a qualified bank or trust company in a Outsourcing of Critical Functions, Custodial or Safekeeping Aging the special Deposits, real offices, vaults or safety deposit boxes, were all stocks, bonds a custodial agreement with a qualified bank or trust company in a coutsourcing of Critical Functions, Custodial or Safekeeping Aging the special Deposits, real offices, vaults or Safekeeping Aging the special Deposits, real offices, vaults or Safekeeping Aging the special Deposits, real offices, vaults or Safe	Description and on Schedule DB?	Yes [] No []	X] [X]] X]
27.1 27.2 INES 2 27.3 27.4 27.5	Nature of Restriction Nature of Restriction Does the reporting entity have any hedging transactions reported for yes, has a comprehensive description of the hedging program of no, attach a description with this statement. Through 27.5: FOR LIFE/FRATERNAL REPORTING ENTITY Does the reporting entity utilize derivatives to hedge variable and of the response to 27.3 is YES, does the reporting entity utilize: The response to 27.41 regarding utilizing the special accordiologistic following: The reporting entity has obtained explicit approval from the Hedging strategy subject to the special accounting promen in the following of the hedging strates. Financial Officer Certification has been obtained which hedging Strategy within VM-21 and that the Clearly Degree its actual day-to-day risk mitigation efforts. Were any preferred stocks or bonds owned as of December 31 issuer, convertible into equity? Excluding items in Schedule E - Part 3 - Special Deposits, real offices, vaults or safety deposit boxes, were all stocks, bonds a custodial agreement with a qualified bank or trust company in a Outsourcing of Critical Functions, Custodial or Safekeeping Agreements that comply with the requirements of the NAIC	Description and on Schedule DB?	Yes [] No []	X] [X]] X]

GENERAL INTERROGATORIES

29.02	For all agreements that do not comply with the requirements of the NAIC Financial Condition Examiners Handbook, provide the name, location
	and a complete explanation:

1	2	3
Name(s)	Location(s)	Complete Explanation(s)

29.03	Have there been any changes, including name changes, in the custodian(s) identified in 29.01 during the current year?	Yes []	No	[X]]
29.04	If yes, give full and complete information relating thereto:					

1	2	3	4
Old Custodian	New Custodian	Date of Change	Reason

29.05 Investment management – Identify all investment advisors, investment managers, broker/dealers, including individuals that have the authority to make investment decisions on behalf of the reporting entity. For assets that are managed internally by employees of the reporting entity, note as such. ["...that have access to the investment accounts"; "...handle securities"]

1 Name of Firm or Individual	2 Affiliation
Elevance Health, Inc	T U
Pacific Investment Management Company	U

29.06 For those firms or individuals listed in the table for 29.05 with an affiliation code of "A" (affiliated) or "U" (unaffiliated), provide the information for the table below.

1	2	3	4	5
				Investment
				Management
Central Registration				Agreement
Depository Number	Name of Firm or Individual	Legal Entity Identifier (LEI)	Registered With	(IMA) Filed
			Securities Exchange	
105377	Loomis, Sayles & Company, LP	JIZPN2RX3UMN0YIDI313	Commission	NO
			Securities Exchange	
104559	Pacific Investment Management Company		Commission	N0

30.1	Does the reporting entity have any diversified mutual funds reported in Schedule D, Part 2 (diversified according to the Securities and				
	Exchange Commission (SEC) in the Investment Company Act of 1940 [Section 5(b)(1)])?	Yes []	No	[X]

30.2 If yes, complete the following schedule:

1	2	3
		Book/Adjusted
CUSIP#	Name of Mutual Fund	Carrying Value
30.2999 - Total		0

30.3 For each mutual fund listed in the table above, complete the following schedule:

1	2	3	4
		Amount of Mutual	
		Fund's Book/Adjusted	
		Carrying Value	
	Name of Significant Holding of the	Attributable to the	Date of
Name of Mutual Fund (from above table)	Mutual Fund	Holding	Valuation

GENERAL INTERROGATORIES

31. Provide the following information for all short-term and long-term bonds and all preferred stocks. Do not substitute amortized value or statement value for fair value.

	1	2	3
			Excess of Statement
			over Fair Value (-), or
	Statement (Admitted)		Fair Value over
	Value	Fair Value	Statement (+)
31.1 Bonds	395,098,019	355,604,153	(39,493,866)
31.2 Preferred stocks	0		0
31.3 Totals	395,098,019	355,604,153	(39,493,866)

31.4	Describe the sources or methods utilized in determining the fair values: Fair values were obtained from third-party pricing sources. If a security was not priced by a third-party pricing source, internal analytical systems or broker quotes were utilized.					
32.1	Was the rate used to calculate fair value determined by a broker or custodian for any of the securities in Schedule D?	Ye	es []	No [Х]
32.2	If the answer to 32.1 is yes, does the reporting entity have a copy of the broker's or custodian's pricing policy (hard copy or electronic copy) for all brokers or custodians used as a pricing source?	Ye	es []	No []
32.3	If the answer to 32.2 is no, describe the reporting entity's process for determining a reliable pricing source for purposes of disclosure of fair value for Schedule D:					
33.1 33.2	Have all the filing requirements of the Purposes and Procedures Manual of the NAIC Investment Analysis Office been followed?	Ye	es [Х]	No []
34.	By self-designating 5GI securities, the reporting entity is certifying the following elements of each self-designated 5GI security: a. Documentation necessary to permit a full credit analysis of the security does not exist or an NAIC CRP credit rating for an FE or PL security is not available. b. Issuer or obligor is current on all contracted interest and principal payments. c. The insurer has an actual expectation of ultimate payment of all contracted interest and principal. Has the reporting entity self-designated 5GI securities?	Yı	es []	No [X]
35.	By self-designating PLGI securities, the reporting entity is certifying the following elements of each self-designated PLGI security: a. The security was purchased prior to January 1, 2018. b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security. c. The NAIC Designation was derived from the credit rating assigned by an NAIC CRP in its legal capacity as a NRSRO which is shown on a current private letter rating held by the insurer and available for examination by state insurance regulators. d. The reporting entity is not permitted to share this credit rating of the PL security with the SVO. Has the reporting entity self-designated PLGI securities?	Yı	es []	No [X]
36.	By assigning FE to a Schedule BA non-registered private fund, the reporting entity is certifying the following elements of each self-designated FE fund: a. The shares were purchased prior to January 1, 2019. b. The reporting entity is holding capital commensurate with the NAIC Designation reported for the security. c. The security had a public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO prior to January 1, 2019. d. The fund only or predominantly holds bonds in its portfolio. e. The current reported NAIC Designation was derived from the public credit rating(s) with annual surveillance assigned by an NAIC CRP in its legal capacity as an NRSRO. f. The public credit rating(s) with annual surveillance assigned by an NAIC CRP has not lapsed. Has the reporting entity assigned FE to Schedule BA non-registered private funds that complied with the above criteria?	Yı	es []	No [Х]
37.	By rolling/renewing short-term or cash equivalent investments with continued reporting on Schedule DA, Part 1 or Schedule E Part 2 (identified through a code (%) in those investment schedules), the reporting entity is certifying to the following: a. The investment is a liquid asset that can be terminated by the reporting entity on the current maturity date. b. If the investment is with a nonrelated party or nonaffiliate, then it reflects an arms-length transaction with renewal completed at the discretion of all involved parties. c. If the investment is with a related party or affiliate, then the reporting entity has completed robust re-underwriting of the transaction for which documentation is available for regulator review. d. Short-term and cash equivalent investments that have been renewed/rolled from the prior period that do not meet the criteria in 37.a - 37.c are reported as long-term investments. Has the reporting entity rolled/renewed short-term or cash equivalent investments in accordance with these criteria?]	No [X]	N/A	[

38.1	Does the reporting entity directly hold cryptocurrencies?			Yes []	No [X	(]
38.2	If the response to 38.1 is yes, on what schedule are they reported?						
39.1	Does the reporting entity directly or indirectly accept cryptocurrencies as payments for	premiums on policies?		Yes []	No [X	(]
39.2		liately converted to U.S. dollars?]	No []
39.3	If the response to 38.1 or 39.1 is yes, list all cryptocurrencies accepted for payments of			ies [1	NO [J
	1 Name of Cryptocurrency	2 Immediately Converted to USD, Directly Held, or Both	3 Accepted for Payment of Premiums				
	OTHER	<u> </u>		<u>l</u>			
40.1 40.2	Amount of payments to trade associations, service organizations and statistical or rational content of the organization and the amount paid if any such payment represented service organizations and statistical or rating bureaus during the period covered by this	ed 25% or more of the total paymer				194	4,945
	1 Name		2 nt Paid				
	Blue Cross Blue Shield Association						
41.1	Amount of payments for legal expenses, if any?			\$		68 [.]	1,852
41.2	List the name of the firm and the amount paid if any such payment represented 25% of during the period covered by this statement.	or more of the total payments for leg	gal expenses				
	1 Name		2 nt Paid				
	Roach Ruprecht Sanchez & Bischoff, PC						
42.1	Amount of payments for expenditures in connection with matters before legislative boo	dies, officers or departments of gov	ernment, if any?	\$		57	7, 124
42.2	List the name of the firm and the amount paid if any such payment represented 25% connection with matters before legislative bodies, officers, or departments of governments.						
	1 Name		2 nt Paid				
	Preti Flaherty Beliveau Pachios LLP		52,859				

Lobbying expenses disclosed reflect amounts reported in the Lobbyist Disclosure Reports filed with the Secretary of State as well as the cost of external contractors who provided lobbying services to the Company. The amount may include expenses that may have been paid by an affiliate on behalf of the Company and, as a result, may not be included in the Underwriting Gain reported on page 4 of the 2022 Annual Statement.

GENERAL INTERROGATORIES

PART 2 - HEALTH INTERROGATORIES

	the reporting entity have any direct Medicare Supplement Insurance in for indicate premium earned on U.S. business only.		\$\$ 58,565,9
	portion of Item (1.2) is not reported on the Medicare Supplement Insuranc Reason for excluding	e Experience Exhibit?	
Indica	te amount of earned premium attributable to Canadian and/or Other Alien	not included in Item (1.2) above	\$
	te total incurred claims on all Medicare Supplement Insurance		
Individ	dual policies:	Most current three years:	
	·	1.61 Total premium earned	\$ 16,748,9
		1.62 Total incurred claims	
		1.63 Number of covered lives	
		All years prior to most current three years	
		1.64 Total premium earned	
		1.65 Total incurred claims 1.66 Number of covered lives	
		1.00 ((ambo) of 0000100 (1000	
Group	policies:	Most current three years:	
		1.71 Total premium earned	
		1.72 Total incurred claims	\$
		1.73 Number of covered lives	
		All years prior to most current three years	:
		1.74 Total premium earned	
		1.75 Total incurred claims	
		1.76 Number of covered lives	
Health	Test:		
		1 2 Current Year Prior Year	
2.4	Premium Numerator		
2.1			
	Premium Denominator		
2.3	Premium Ratio (2.1/2.2)		
2.4	Reserve Numerator		
2.5	Reserve Denominator		
2.6	Reserve Ratio (2.4/2.5)	1.0001.000	
eturn	ne reporting entity received any endowment or gift from contracting hospitated when, as and if the earnings of the reporting entity permits?give particulars:		Yes [] No [X]
return If yes,	ed when, as and if the earnings of the reporting entity permits?give particulars:		Yes [] No [X]
If yes,	ed when, as and if the earnings of the reporting entity permits?	cians', and dentists' care offered to subscribers and	
If yes, Have deper	ed when, as and if the earnings of the reporting entity permits?give particulars:	cians', and dentists' care offered to subscribers and	 . Yes [X] No []
If yes, Have deper	ed when, as and if the earnings of the reporting entity permits?	cians', and dentists' care offered to subscribers and see agreements include additional benefits offered?	Yes [X] No [] Yes [] No []
return If yes, Have deper If not Does If no,	give particulars: copies of all agreements stating the period and nature of hospitals', physical dents been filed with the appropriate regulatory agency? previously filed, furnish herewith a copy(ies) of such agreement(s). Do the	cians', and dentists' care offered to subscribers and see agreements include additional benefits offered?	Yes [X] No [] Yes [] No [] . Yes [] No [X]
If yes, Have deper If not Does If no, Eleva	give particulars: copies of all agreements stating the period and nature of hospitals', physical dents been filed with the appropriate regulatory agency? previously filed, furnish herewith a copy(ies) of such agreement(s). Do the the reporting entity have stop-loss reinsurance?	cians', and dentists' care offered to subscribers and see agreements include additional benefits offered?	Yes [X] No [] Yes [] No [] . Yes [] No [X]
If yes, Have deper If not Does If no, Eleva	give particulars: copies of all agreements stating the period and nature of hospitals', physicidents been filed with the appropriate regulatory agency? previously filed, furnish herewith a copy(ies) of such agreement(s). Do the the reporting entity have stop-loss reinsurance? explain: nce Health, Inc. has financial reserves available to cover catastrophic loss	cians', and dentists' care offered to subscribers and see agreements include additional benefits offered?	Yes [X] No [] Yes [] No [] . Yes [] No [X]
If yes, Have deper If not Does If no, Eleva	give particulars: copies of all agreements stating the period and nature of hospitals', physicidents been filed with the appropriate regulatory agency? previously filed, furnish herewith a copy(ies) of such agreement(s). Do the the reporting entity have stop-loss reinsurance? explain: nce Health, Inc. has financial reserves available to cover catastrophic loss	cians', and dentists' care offered to subscribers and see agreements include additional benefits offered?	Yes [X] No [] Yes [] No [] . Yes [] No [X]
return If yes, Have deper If not Does If no, Eleva	give particulars: copies of all agreements stating the period and nature of hospitals', physicidents been filed with the appropriate regulatory agency? previously filed, furnish herewith a copy(ies) of such agreement(s). Do the the reporting entity have stop-loss reinsurance? explain: nce Health, Inc. has financial reserves available to cover catastrophic loss	cians', and dentists' care offered to subscribers and see agreements include additional benefits offered?	Yes [X] No [] Yes [] No [] . Yes [] No [X]
return If yes, Have deper If not Does If no, Eleva	give particulars: copies of all agreements stating the period and nature of hospitals', physicidents been filed with the appropriate regulatory agency? previously filed, furnish herewith a copy(ies) of such agreement(s). Do the the reporting entity have stop-loss reinsurance? explain: nce Health, Inc. has financial reserves available to cover catastrophic loss	cians', and dentists' care offered to subscribers and see agreements include additional benefits offered?	Yes [X] No [] Yes [] No [] . Yes [] No [X]
If yes, Have deper If not Does If no, Eleva	give particulars: copies of all agreements stating the period and nature of hospitals', physicidents been filed with the appropriate regulatory agency? previously filed, furnish herewith a copy(ies) of such agreement(s). Do the the reporting entity have stop-loss reinsurance? explain: nce Health, Inc. has financial reserves available to cover catastrophic loss	cians', and dentists' care offered to subscribers and se agreements include additional benefits offered? ses. Also see the response to question 6 below. 5.31 Comprehensive Medical 5.32 Medical Only 5.33 Medicare Supplement 5.34 Dental & Vision 5.35 Other Limited Benefit Plan	Yes [X] No [] Yes [] No [] . Yes [] No [X]
If yes, Have deper If not Does If no, Eleva Maxin	give particulars: copies of all agreements stating the period and nature of hospitals', physicidents been filed with the appropriate regulatory agency? previously filed, furnish herewith a copy(ies) of such agreement(s). Do the the reporting entity have stop-loss reinsurance? explain: nce Health, Inc. has financial reserves available to cover catastrophic loss num retained risk (see instructions)	cians', and dentists' care offered to subscribers and se agreements include additional benefits offered? ses. Also see the response to question 6 below. 5.31 Comprehensive Medical 5.32 Medical Only 5.33 Medicare Supplement 5.34 Dental & Vision 5.35 Other Limited Benefit Plan 5.36 Other	Yes [X] No [] Yes [] No [] . Yes [] No [X]
return If yes, Have deper If not Does If no, Eleva Maxin Descr hadre If the obliga	give particulars: copies of all agreements stating the period and nature of hospitals', physicidents been filed with the appropriate regulatory agency? previously filed, furnish herewith a copy(ies) of such agreement(s). Do the the reporting entity have stop-loss reinsurance? explain: nce Health, Inc. has financial reserves available to cover catastrophic loss num retained risk (see instructions)	cians', and dentists' care offered to subscribers and se agreements include additional benefits offered? ses. Also see the response to question 6 below. 5.31 Comprehensive Medical 5.32 Medical Only 5.33 Medicare Supplement 5.34 Dental & Vision 5.35 Other Limited Benefit Plan 5.36 Other s and their dependents against the risk of insolvency includin with providers to continue rendering services, and any other extent of its assets, to assume all contractual and financial ated the Insolvency Agreement with Anthem Insurance	Yes [X] No [] Yes [] No [X] Yes [] No [X]
If yes, Have deper If not Does If no, Eleva Maxin Describold hagree If the comp	give particulars: copies of all agreements stating the period and nature of hospitals', physicidents been filed with the appropriate regulatory agency? previously filed, furnish herewith a copy(ies) of such agreement(s). Do the the reporting entity have stop-loss reinsurance? explain: nce Health, Inc. has financial reserves available to cover catastrophic loss num retained risk (see instructions) iibe arrangement which the reporting entity may have to protect subscriber that agreements are provisions, conversion privileges with other carriers, agreements ments: company becomes insolvent, Elevance Health, Inc. had agreed to the full tions of the Company. Effective November 30, 2018, the Company termin	cians', and dentists' care offered to subscribers and se agreements include additional benefits offered? ses. Also see the response to question 6 below. 5.31 Comprehensive Medical 5.32 Medical Only 5.33 Medicare Supplement 5.34 Dental & Vision 5.35 Other Limited Benefit Plan 5.36 Other se and their dependents against the risk of insolvency includin with providers to continue rendering services, and any other extent of its assets, to assume all contractual and financial atted the Insolvency Agreement with Anthem Insurance di Harmless provisions.	Yes [X] No [] Yes [] No [X] Yes [] No [X]
return If yes, Have deper If not Does If no, Eleva Maxin Descr hadr hagree If the obliga Comp	give particulars: copies of all agreements stating the period and nature of hospitals', physical indents been filed with the appropriate regulatory agency? previously filed, furnish herewith a copy(ies) of such agreement(s). Do the the reporting entity have stop-loss reinsurance? explain: nce Health, Inc. has financial reserves available to cover catastrophic loss num retained risk (see instructions) iibe arrangement which the reporting entity may have to protect subscriber larmless provisions, conversion privileges with other carriers, agreements ments: company becomes insolvent, Elevance Health, Inc. had agreed to the full tions of the Company. Effective November 30, 2018, the Company termin vanies, Inc. The majority of provider and professional contracts include Holizanies, Inc. The majority of provider and professional contracts include Holizanies, Inc. The majority of provider and professional contracts include Holizanies.	cians', and dentists' care offered to subscribers and se agreements include additional benefits offered? ses. Also see the response to question 6 below. 5.31 Comprehensive Medical 5.32 Medical Only 5.33 Medicare Supplement 5.34 Dental & Vision 5.35 Other Limited Benefit Plan 5.36 Other se and their dependents against the risk of insolvency includin with providers to continue rendering services, and any other extent of its assets, to assume all contractual and financial atted the Insolvency Agreement with Anthem Insurance di Harmless provisions.	Yes [X] No [] Yes [] No [X] Yes [] No [X]
return If yes, Have deper If not Does If no, Eleva Maxin Descrhold harder If the deper If no, If yes, If	give particulars: copies of all agreements stating the period and nature of hospitals', physical dents been filed with the appropriate regulatory agency? previously filed, furnish herewith a copy(ies) of such agreement(s). Do the the reporting entity have stop-loss reinsurance? explain: nce Health, Inc. has financial reserves available to cover catastrophic loss num retained risk (see instructions) iibe arrangement which the reporting entity may have to protect subscriber tearmless provisions, conversion privileges with other carriers, agreements ments: company becomes insolvent, Elevance Health, Inc. had agreed to the full tions of the Company. Effective November 30, 2018, the Company terminanies, Inc. The majority of provider and professional contracts include Holther reporting entity set up its claim liability for provider services on a service.	cians', and dentists' care offered to subscribers and se agreements include additional benefits offered? ses. Also see the response to question 6 below. 5.31 Comprehensive Medical 5.32 Medical Only 5.33 Medicare Supplement 5.34 Dental & Vision 5.35 Other Limited Benefit Plan 5.36 Other se and their dependents against the risk of insolvency includin with providers to continue rendering services, and any other extent of its assets, to assume all contractual and financial atted the Insolvency Agreement with Anthem Insurance di Harmless provisions.	Yes [X] No [] Yes [] No [X] Yes [] No [X] S
return If yes, Have deper If not Does If no, Eleva Maxin Describold hagree If the obliga Comp Does If no,	give particulars: copies of all agreements stating the period and nature of hospitals', physicial previously filed, furnish herewith a copy(ies) of such agreement(s). Do the the reporting entity have stop-loss reinsurance? explain: nce Health, Inc. has financial reserves available to cover catastrophic loss num retained risk (see instructions) iibe arrangement which the reporting entity may have to protect subscriber narmless provisions, conversion privileges with other carriers, agreements ments: company becomes insolvent, Elevance Health, Inc. had agreed to the full tions of the Company. Effective November 30, 2018, the Company terminaries, Inc. The majority of provider and professional contracts include Hold the reporting entity set up its claim liability for provider services on a service give details	cians', and dentists' care offered to subscribers and se agreements include additional benefits offered? ses. Also see the response to question 6 below. 5.31 Comprehensive Medical 5.32 Medical Only 5.33 Medicare Supplement 5.34 Dental & Vision 5.35 Other Limited Benefit Plan 5.36 Other s and their dependents against the risk of insolvency includin with providers to continue rendering services, and any other extent of its assets, to assume all contractual and financial ated the Insolvency Agreement with Anthem Insurance d Harmless provisions. 8.1 Number of providers at start of reporting ye 8.2 Number of providers at end of reporting ye	Yes [X] No [] Yes [] No [X] Yes [] No [X] S

10.1	Does the reporting entity have Incentive Pool, Withhold or Bonus Arrangements in its provider contracts?						Yes [X]] No [[]
10.2	If yes:		1(1)	0.22 Amount actua 0.23 Maximum am	ount payable bonus ally paid for year bor ount payable withh ally paid for year wit	nuses olds	\$	7,	170,494
11.1	Is the reporting entity organized as:			11.13 An Indivi	al Group/Staff Mode dual Practice Assoc Model (combination	ciation (IPA), or,] No] No] No	[]
11.2 11.3 11.4	If yes, show the name of the state requiring such minimum capital and surplus.						\$	55,8	Maine 890,893
11.5 11.6	Is this amount included as part of a contingency rese If the amount is calculated, show the calculation 250% of Health Risk-Based Capital Authorized Cont						Yes [No [[X]
12.	List service areas in which reporting entity is license	d to operate:							
	Name of Service Area State of Maine								
13.1	Do you act as a custodian for health savings accoun	ts?					Yes [] No [[X]
13.2	If yes, please provide the amount of custodial funds	held as of the re	porting date				\$		
13.3	Do you act as an administrator for health savings ac	counts?					Yes [] No [[X]
13.4	If yes, please provide the balance of funds administe	ered as of the re	porting date				\$		
14.1 14.2	Are any of the captive affiliates reported on Schedule If the answer to 14.1 is yes, please provide the follow		orized reinsurers?			Yes [] No [] N,	/A [X]
	1	2	3	4		Supporting Reserve			
	Company Name	NAIC Company Code	Domiciliary Jurisdiction	Reserve Credit	5 Letters of Credit	6 Trust Agreements	7 Other		
15.	Provide the following for individual ordinary life insur ceded):	ance* policies (l	J.S. business only	,	ar (prior to reinsura		\$		
	15.2 Total Incurred Claims						•		
	*Ordinary Life Insurance Includes								
	Term(whether full underwriting, limited underwriting, jet issue, "short form app") Whole Life (whether full underwriting, limited underwriting, jet issue, "short form app") Variable Life (with or without secondary gurarantee)								
	Universal Life (with or without secondary gurarantee) Variable Universal Life (with or without secondary gurarantee)								
16.	Is the reporting entity licensed or chartered, registere			·	o states?		Yes [] N	No [X	1
16.1	If no, does the reporting entity assume reinsurance to domicile of the reporting entity?	ousiness that co	vers risks residing	in at least one sta	te other than the sta	ate of		No [X	

ANNUAL STATEMENT FOR THE YEAR 2022 OF THE Anthem Health Plans of Maine, Inc.

FIVE-YEAR HISTORICAL DATA

		1 2022	2 2021	3 2020	4 2019	5 2018
	Balance Sheet (Pages 2 and 3)				=5.15	
1.	Total admitted assets (Page 2, Line 28)	740.507.952	683.378.987	619.182.017	499.695.483	493,935,763
2.	Total liabilities (Page 3, Line 24)					
3.	Statutory minimum capital and surplus requirement .					
4.	Total capital and surplus (Page 3, Line 33)					
	Income Statement (Page 4)		,,	,		, , , , , , , , , , , , , , , , , , , ,
5.	Total revenues (Line 8)	1.202.014.061	1.166.425.411	1.109.882.018	1.169.038.959	991.739.739
6.	Total medical and hospital expenses (Line 18)					
7.	Claims adjustment expenses (Line 20)					
8.	Total administrative expenses (Line 21)					
9.	Net underwriting gain (loss) (Line 24)					
10.	Net investment gain (loss) (Line 27)					
11.	Total other income (Lines 28 plus 29)					
12.	Net income or (loss) (Line 32)					
12.	Cash Flow (Page 6)				1,000,720	
13.	Net cash from operations (Line 11)	(66 198 638)	115 093 727	139 929 170	120 768 229	(57 605 836
10.	Risk-Based Capital Analysis	(00, 100,000)	110,000,727		120,700,220	(07,000,000
14.	Total adjusted capital	153 627 228	146 289 952	155 707 822	178 725 531	120 058 373
15.	Authorized control level risk-based capital					
10.	Enrollment (Exhibit 1)		22,012,404	10,200,440	20,002,010	21,070,704
16.	Total members at end of period (Column 5, Line 7)	369 894	407 540	393 293	393 941	361 759
17.	Total members months (Column 6, Line 7)		4,864,236			
.,.	Operating Percentage (Page 4) (Item divided by Page 4, sum of Lines 2, 3 and 5) x 100.0	4,010,004	4,004,200	4,707,000		7,012,002
18.	Premiums earned plus risk revenue (Line 2 plus Lines 3 and 5)	100.0	100.0	100.0	100.0	100.0
19.	Total hospital and medical plus other non-health (Lines 18 plus Line 19)	87.7	87.9	81.9	84.4	85.9
20.	Cost containment expenses					
21.	Other claims adjustment expenses	1.5	1.5	1.8	1.2	1.1
22.	Total underwriting deductions (Line 23)	96.4	96.8	94.7	92.8	95.4
23.	Total underwriting gain (loss) (Line 24)	3.6	3.2	5.3	7.2	4.6
	Unpaid Claims Analysis (U&I Exhibit, Part 2B)					
24.	Total claims incurred for prior years (Line 17, Col. 5)	160,888,657	114,006,120	95,802,582	72,913,114	129,908,137
25.	Estimated liability of unpaid claims-[prior year (Line 17, Col. 6)]	178, 103, 948	125,527,599	100,370,821	84,863,772	146,533,692
	Investments In Parent, Subsidiaries and Affiliates					
26.	Affiliated bonds (Sch. D Summary, Line 12, Col. 1)					
27.	Affiliated preferred stocks (Sch. D Summary, Line 18, Col. 1)		0	0	0	
28.	Affiliated common stocks (Sch. D Summary, Line 24, Col. 1)		0	0	0	
29.	Affiliated short-term investments (subtotal included in Schedule DA Verification, Col. 5, Line 10)	0	0	0	0	0
30.	Affiliated mortgage loans on real estate					
31.	All other affiliated					
32.	Total of above Lines 26 to 31	0	0	0	0	0
33.	Total investment in parent included in Lines 26 to 31 above.					


NOTE: If a party to a merger, have the two most recent years of this exhibit been restated due to a merger in compliance with the disclosure				
requirements of SSAP No. 3, Accounting Changes and Correction of Errors?	Yes [] N	No []
If no, please explain:				


SCHEDULE T PREMIUMS AND OTHER CONSIDERATIONS


Allocated by States and Territories


1	Allocated by States and Territories 1 Direct Business Only											
			Active	2 Accident and	3	4	5	6 Federal Employees Health Benefits	7 Life and Annuity Premiums &	8 Property/	9 Total	10
	States, etc.		Status (a)	Health Premiums	Medicare Title XVIII	Medicaid Title XIX	CHIP Title XXI	Program Premiums	Other Considerations	Casualty Premiums	Columns 2 Through 8	Deposit-Type Contracts
1.	Alabama		N								0	
2. 3.	Alaska	AK AZ	N N								0	
			N								0	
5.	California	CA	N								0	
6.	Colorado		N								0	
7.	Connecticut		N								0	
8.	Delaware	DE	N								0	
	District of Columbia	DC	N								0	
10.	Florida	FL	N								0	
11.	Georgia	GA	N								0	
12.	Hawaii	HI	N								0	
13.	Idaho	ID	N								0	
14.	Illinois	IL	N								0	
15.	Indiana	IN	N								0	
16.	lowa	IA	N								0	
	Kansas	-	N								0	
	Kentucky		N								0	
	Louisiana		N								0	
	Maine		L	951,710,245	(94,289)			257,584,948			1,209,200,904	
	Maryland	MD	N								0	
	Massachusetts	MA	N								0	
	Michigan	MI	N								0	
	Minnesota	MN	N								0	
	Mississippi		N N								0	
	Missouri Montana	MO MT	N								0	
	Nebraska	MT NE	N N								0	
		NE NV	N								0	
	New Hampshire		N			•••••				•	0	
	New Jersey		N							•••••	0	
	New Mexico		N								0	
	New York		N								0	
	North Carolina		N								0	
		-	N								0	
	Ohio		N								0	
	Oklahoma	-	N								0	
	Oregon	OR	N								0	
	Pennsylvania		N								0	
40.	Rhode Island	RI	N								0	
41.	South Carolina	SC	N								0	
42.	South Dakota	SD	N								0	
43.	Tennessee	TN	N								0	
44.	Texas	TX	N								0	
_	Utah	UT	N								0	
	Vermont		N								0	
	Virginia		N								0	
	-		N								0	
	West Virginia		N								0	
	Wisconsin		N								0	
	Wyoming	WY	N								0	
	American Samoa		N								0	
	Guam Puerto Rico	GU	N								0	
	U.S. Virgin Islands		N N								0	
	Northern Mariana	VI	IV								J	
30.	Islands	MP	N								0	
57.	Canada		N								0	
	Aggregate Other					, i]			1	
_	Aliens		XXX	0	0	0	0	0	0	0	0	0
	Subtotal Reporting Entity Contributions for En	nployee	XXX	951,710,245	(94,289)	0	0	257,584,948	0	0	1,209,200,904	0
	Benefit Plans		XXX	054 740 045	/04 000			057 504 045			0	-
61.	Totals (Direct Busine	,	XXX	951,710,245	(94,289)	0	0	257,584,948	0	0	1,209,200,904	0
E0004	DETAILS OF WRITE		1001									
58001. 58002.			XXX									
58002.			XXX									
	Summary of remainir		^^							•		
	write-ins for Line 58 f		V///	_	_	^	_	_	_	^	_	^
58999.	overflow page Totals (Lines 58001 t 58003 plus 58998)(L		XXX	0	0	0	0	0	0	0	0	0
	above) Status Counts:		XXX	0	0	0	0	0	0	0	0	0

1-1	•	. 0	_	0	1 . 1	_	_		
(a)	Α	CI	ve	S	tat	นร	C	oun	IS:
(/									










 $^{^3}$ Anthem Workers' Compensation, LLC is owned 75% by Anthem Blue Cross Life and Health Insurance Company and 25% by HealthLink, Inc.




⁴ HealthKeepers, Inc. is owned 92.51% by Anthem Southeast, Inc. and 7.49% by UNICARE National Services, Inc.


BCBSA Licensee

Regulated Insurance Company


Regulated BCBSA Licensee

ALL SUBSIDIARIES 100% OWNED AND LLC'S ARE CONTROLLED BY MEMBERS UNLESS OTHERWISE NOTED






⁵ Amerigroup Corporation holds a 2% interest in Highland Investor Holdings, LLC, and ATH Holding Company, LLC holds the remaining 98% interest.



BCBSA Licensee
Regulated Insurance Company
Regulated BCBSA Licensee

ALL SUBSIDIARIES 100% OWNED AND LLC'S ARE CONTROLLED BY MEMBERS UNLESS OTHERWISE NOTED



7 Community Care Health Plan of Louisiana, Inc. is a joint venture 75% owned by Anthem Partnership Holding Company, LLC and 25% owned by Louisiana Health Service & Indemnity Company d/b/a Blue Cross and Blue Shield of Louisiana (non-affiliate)

8 CCHA, LLC is a joint venture 50% owned by Anthem Partnership Holding Company, LLC and 50% owned by Colorado Community Health Alliance, LLC (non-affiliate)

⁹ AMH Health, LLC is a joint venture 50% owned by MaineHealth (non-affiliate) and 50% owned by Anthem Partnership Holding Company, LLC


Momentum Health Partners, LLC is a joint venture 50% owned by Anthem Partnership Holding Company, LLC and 50% owned by Blue Cross and Blue Shield of North Carolina (non-affiliate)

¹¹ GR Health Solutions, LLC is a joint venture 50% owned by Anthem Partnership Holding Company, LLC and 50% owned by Independence Blue Cross, LLC (nonaffiliate)

¹² Community Care Health Plan of Nebraska, Inc. is a joint venture 95% owned by Anthem Partnership Holding Company, LLC and 5% owned by Blue Cross and Blue Shield of Nebraska, Inc. (non-affiliate).

¹³ APC PASSE, LLC (regulated entity) is a joint venture 49% owned by Anthem Partnership Holding Company, LLC and 51% owned by Arkansas Provider Coalition, LLC (non-affiliate).

¹⁴ Community Care Health Plan of Kansas, Inc. is a joint venture 90% owned by Anthem Partnership Holding Company, LLC, 5% owned by Blue Cross and Blue Shield of Kansas (non-affiliate) and 5% owned by Blue Cross and Blue Shield of Kansas City (non-affiliate).



ANNUAL STATEMENT FOR THE YEAR 2022 OF THE Anthem Health Plans of Maine, Inc.

OVERFLOW PAGE FOR WRITE-INS

Additional Write-ins for Assets Line 25

Additional Write-ins for Assets Line 25									
			Current Year						
		1	2	3	4				
				Net Admitted Assets	Net Admitted				
		Assets	Nonadmitted Assets	(Cols. 1 - 2)	Assets				
2504.	Prepaid expenses	1,747,510	1,747,510	0	0				
2597.	Summary of remaining write-ins for Line 25 from overflow page	1,747,510	1,747,510	0	0				

Additional	Write-ins t	for Liabilities	Line 23
Auditional	WILLE-ILIS I	IUI LIADIIILIES	LIIIE 23

			Current Year					
		1	2	3	4			
		Covered	Uncovered	Total	Total			
2304.	Performance guarantee liability	513,295		513,295	900,217			
2305.	Federal Employee Program special advance			0	7,504,060			
2306.	Blue Card liabilities			0	4,336			
2397.	Summary of remaining write-ins for Line 23 from overflow page	513,295	0	513,295	8,408,613			